NZ615735B2 - Cd37-binding molecules and immunoconjugates thereof - Google Patents
Cd37-binding molecules and immunoconjugates thereof Download PDFInfo
- Publication number
- NZ615735B2 NZ615735B2 NZ615735A NZ61573512A NZ615735B2 NZ 615735 B2 NZ615735 B2 NZ 615735B2 NZ 615735 A NZ615735 A NZ 615735A NZ 61573512 A NZ61573512 A NZ 61573512A NZ 615735 B2 NZ615735 B2 NZ 615735B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- antibody
- use according
- polypeptide
- antigen
- Prior art date
Links
- 101700044364 CD37 Proteins 0.000 title claims abstract description 246
- 230000027455 binding Effects 0.000 title claims abstract description 139
- 108010027440 Immunoconjugates Proteins 0.000 title claims description 67
- 102000018748 Immunoconjugates Human genes 0.000 title claims description 67
- 102000004965 antibodies Human genes 0.000 claims abstract description 530
- 108090001123 antibodies Proteins 0.000 claims abstract description 530
- 102100016530 CD37 Human genes 0.000 claims abstract description 245
- 239000000427 antigen Substances 0.000 claims abstract description 111
- 108091007172 antigens Proteins 0.000 claims abstract description 111
- 102000038129 antigens Human genes 0.000 claims abstract description 111
- 239000003814 drug Substances 0.000 claims abstract description 65
- 206010003816 Autoimmune disease Diseases 0.000 claims abstract description 39
- 238000000338 in vitro Methods 0.000 claims abstract description 33
- 200000000018 inflammatory disease Diseases 0.000 claims abstract description 29
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims abstract description 24
- 108091006028 chimera Proteins 0.000 claims abstract description 18
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 17
- 206010059512 Apoptosis Diseases 0.000 claims abstract description 15
- 230000006907 apoptotic process Effects 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 210000004027 cells Anatomy 0.000 claims description 254
- 229920001184 polypeptide Polymers 0.000 claims description 187
- 210000003719 B-Lymphocytes Anatomy 0.000 claims description 150
- 241000282414 Homo sapiens Species 0.000 claims description 95
- 201000010099 disease Diseases 0.000 claims description 64
- 239000003795 chemical substances by application Substances 0.000 claims description 56
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 31
- 239000002254 cytotoxic agent Substances 0.000 claims description 29
- 229920001223 polyethylene glycol Polymers 0.000 claims description 27
- -1 N- succinimidyl(iodoacetyl)-aminobenzoate Chemical compound 0.000 claims description 24
- 230000000779 depleting Effects 0.000 claims description 24
- 230000001939 inductive effect Effects 0.000 claims description 20
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 18
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 15
- 150000002500 ions Chemical class 0.000 claims description 15
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 15
- 230000035693 Fab Effects 0.000 claims description 14
- 210000004408 Hybridomas Anatomy 0.000 claims description 14
- 230000001363 autoimmune Effects 0.000 claims description 14
- 206010003246 Arthritis Diseases 0.000 claims description 13
- 201000010874 syndrome Diseases 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 12
- 230000001419 dependent Effects 0.000 claims description 10
- 201000001981 dermatomyositis Diseases 0.000 claims description 8
- 201000006417 multiple sclerosis Diseases 0.000 claims description 8
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 8
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 claims description 7
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 claims description 7
- 241000282553 Macaca Species 0.000 claims description 7
- 206010063344 Microscopic polyangiitis Diseases 0.000 claims description 7
- 206010028417 Myasthenia gravis Diseases 0.000 claims description 7
- 206010047115 Vasculitis Diseases 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 229940002612 prodrugs Drugs 0.000 claims description 7
- 201000004624 dermatitis Diseases 0.000 claims description 6
- 150000002019 disulfides Chemical class 0.000 claims description 6
- 230000001404 mediated Effects 0.000 claims description 6
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims description 5
- AMRJKAQTDDKMCE-UHFFFAOYSA-N Dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 5
- 208000007475 Hemolytic Anemia Diseases 0.000 claims description 5
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims description 5
- 208000005987 Polymyositis Diseases 0.000 claims description 5
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims description 5
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims description 5
- 229940035295 Ting Drugs 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
- 230000001154 acute Effects 0.000 claims description 5
- 201000003542 factor VIII deficiency Diseases 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 230000002757 inflammatory Effects 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 208000000594 Bullous Pemphigoid Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 229960004679 Doxorubicin Drugs 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 claims description 4
- 206010018651 Graft versus host disease Diseases 0.000 claims description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 claims description 4
- 206010034277 Pemphigoid Diseases 0.000 claims description 4
- 241000721454 Pemphigus Species 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 230000001684 chronic Effects 0.000 claims description 4
- 210000000056 organs Anatomy 0.000 claims description 4
- 201000009594 systemic scleroderma Diseases 0.000 claims description 4
- SLMVEZKWNOGJPD-UHFFFAOYSA-M 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound [O-]C(=O)CCCSSC1=CC=CC=N1 SLMVEZKWNOGJPD-UHFFFAOYSA-M 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 206010009887 Colitis Diseases 0.000 claims description 3
- 206010011401 Crohn's disease Diseases 0.000 claims description 3
- VQNATVDKACXKTF-XELLLNAOSA-N Duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 3
- 208000005679 Eczema Diseases 0.000 claims description 3
- 206010014599 Encephalitis Diseases 0.000 claims description 3
- 102100000368 F8 Human genes 0.000 claims description 3
- 101700070229 F8 Proteins 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 201000004779 Graves' disease Diseases 0.000 claims description 3
- 208000009292 Hemophilia A Diseases 0.000 claims description 3
- YACHGFWEQXFSBS-RJXCBBHPSA-N Leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 claims description 3
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims description 3
- 208000004358 Polyneuropathy Diseases 0.000 claims description 3
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 claims description 3
- 208000002574 Reactive Arthritis Diseases 0.000 claims description 3
- 206010038294 Reiter's syndrome Diseases 0.000 claims description 3
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 230000001058 adult Effects 0.000 claims description 3
- 201000001320 atherosclerosis Diseases 0.000 claims description 3
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 3
- NZNMSOFKMUBTKW-UHFFFAOYSA-M cyclohexanecarboxylate Chemical compound [O-]C(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-M 0.000 claims description 3
- 231100000406 dermatitis Toxicity 0.000 claims description 3
- 231100001003 eczema Toxicity 0.000 claims description 3
- 201000002481 myositis Diseases 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 201000004681 psoriasis Diseases 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (6R,6aS,8E)-8-ethylidene-3-hydroxy-2,6-dimethoxy-6,6a,7,9-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical class CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 claims description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 2
- 206010048594 Allergic granulomatous angiitis Diseases 0.000 claims description 2
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 claims description 2
- 206010003230 Arteritis Diseases 0.000 claims description 2
- 208000006673 Asthma Diseases 0.000 claims description 2
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims description 2
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 2
- 208000009863 Chronic Kidney Failure Diseases 0.000 claims description 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 206010018620 Goodpasture's syndrome Diseases 0.000 claims description 2
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 208000010159 IGA Glomerulonephritis Diseases 0.000 claims description 2
- 206010021263 IgA nephropathy Diseases 0.000 claims description 2
- 208000006897 Interstitial Lung Disease Diseases 0.000 claims description 2
- 201000007313 Kawasaki disease Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000008795 Neuromyelitis Optica Diseases 0.000 claims description 2
- 201000007142 Omenn syndrome Diseases 0.000 claims description 2
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 claims description 2
- 208000003782 Raynaud Disease Diseases 0.000 claims description 2
- 206010037912 Raynaud's phenomenon Diseases 0.000 claims description 2
- 206010038444 Renal failure chronic Diseases 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims description 2
- 206010043554 Thrombocytopenia Diseases 0.000 claims description 2
- 206010052568 Urticaria chronic Diseases 0.000 claims description 2
- OOUPHXWHXYLQBK-UHFFFAOYSA-M [O-]C(=O)CCC(C)SSC1=CC=CC=N1 Chemical compound [O-]C(=O)CCC(C)SSC1=CC=CC=N1 OOUPHXWHXYLQBK-UHFFFAOYSA-M 0.000 claims description 2
- 201000010411 adult dermatomyositis Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims description 2
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 claims description 2
- 201000006747 infectious mononucleosis Diseases 0.000 claims description 2
- 201000001779 leukocyte adhesion deficiency Diseases 0.000 claims description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 2
- 201000001263 psoriatic arthritis Diseases 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 108010022043 Antineutrophil Cytoplasmic Antibodies Proteins 0.000 claims 2
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- NNPUPCNWEHWRPW-UHFFFAOYSA-M OS(=O)(=O)C(C([O-])=O)CCSSC1=CC=CC=N1 Chemical compound OS(=O)(=O)C(C([O-])=O)CCSSC1=CC=CC=N1 NNPUPCNWEHWRPW-UHFFFAOYSA-M 0.000 claims 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 230000000241 respiratory Effects 0.000 claims 1
- 230000003582 thrombocytopenic Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 description 93
- 125000005647 linker group Chemical group 0.000 description 56
- 230000014509 gene expression Effects 0.000 description 51
- 239000000203 mixture Substances 0.000 description 50
- 229940079593 drugs Drugs 0.000 description 49
- 235000001014 amino acid Nutrition 0.000 description 47
- 239000000562 conjugate Substances 0.000 description 45
- 230000000694 effects Effects 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 41
- 150000001413 amino acids Chemical class 0.000 description 40
- 229920000023 polynucleotide Polymers 0.000 description 40
- 239000002157 polynucleotide Substances 0.000 description 40
- 230000001225 therapeutic Effects 0.000 description 33
- 210000001744 T-Lymphocytes Anatomy 0.000 description 30
- 125000003275 alpha amino acid group Chemical group 0.000 description 30
- 210000004369 Blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 239000000523 sample Substances 0.000 description 26
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 24
- 239000002202 Polyethylene glycol Substances 0.000 description 23
- 238000004166 bioassay Methods 0.000 description 22
- 238000006467 substitution reaction Methods 0.000 description 22
- 102000018358 Immunoglobulins Human genes 0.000 description 21
- 108060003951 Immunoglobulins Proteins 0.000 description 21
- 102100000165 MS4A1 Human genes 0.000 description 21
- 101710010909 MS4A1 Proteins 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 21
- 239000004698 Polyethylene (PE) Substances 0.000 description 20
- 239000011324 bead Substances 0.000 description 20
- 238000010186 staining Methods 0.000 description 20
- 108010045030 monoclonal antibodies Proteins 0.000 description 19
- 102000005614 monoclonal antibodies Human genes 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 210000001616 Monocytes Anatomy 0.000 description 16
- URRBLVUOXIGNQR-HXUWFJFHSA-N [(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate Chemical compound C1([C@@H](C)OC(=O)N(CCN)CC=2C=C(C(=CC=2)OCC=2C=CC=CC=2)OC)=CC=CC=C1 URRBLVUOXIGNQR-HXUWFJFHSA-N 0.000 description 16
- 201000002491 encephalomyelitis Diseases 0.000 description 16
- 210000001519 tissues Anatomy 0.000 description 15
- 108010001645 Rituximab Proteins 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000006011 modification reaction Methods 0.000 description 13
- 239000011886 peripheral blood Substances 0.000 description 13
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 229960004641 rituximab Drugs 0.000 description 12
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 11
- 230000000295 complement Effects 0.000 description 11
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 11
- 230000001965 increased Effects 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 229920001850 Nucleic acid sequence Polymers 0.000 description 10
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 229960000060 monoclonal antibodies Drugs 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 108090001095 Immunoglobulin G Proteins 0.000 description 9
- 102000004851 Immunoglobulin G Human genes 0.000 description 9
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 9
- 108020004459 Small Interfering RNA Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000306 component Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 150000003573 thiols Chemical class 0.000 description 9
- 239000004971 Cross linker Substances 0.000 description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- 210000002966 Serum Anatomy 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 229960000485 methotrexate Drugs 0.000 description 8
- 239000002924 silencing RNA Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 7
- 108010090838 Alemtuzumab Proteins 0.000 description 7
- 210000000601 Blood Cells Anatomy 0.000 description 7
- 229920001405 Coding region Polymers 0.000 description 7
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 7
- 210000004698 Lymphocytes Anatomy 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 206010025310 Other lymphomas Diseases 0.000 description 7
- 210000002381 Plasma Anatomy 0.000 description 7
- 210000003324 RBC Anatomy 0.000 description 7
- 108010033725 Recombinant Proteins Proteins 0.000 description 7
- 102000007312 Recombinant Proteins Human genes 0.000 description 7
- 241000219061 Rheum Species 0.000 description 7
- 229960000548 alemtuzumab Drugs 0.000 description 7
- 108010004469 allophycocyanin Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 230000002934 lysing Effects 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 230000002829 reduced Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 229920002395 Aptamer Polymers 0.000 description 6
- 108010071919 Bispecific Antibodies Proteins 0.000 description 6
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 6
- 210000003743 Erythrocytes Anatomy 0.000 description 6
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 6
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 6
- 102100007544 NCAM1 Human genes 0.000 description 6
- 101700077124 NCAM1 Proteins 0.000 description 6
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 6
- 239000000611 antibody drug conjugate Substances 0.000 description 6
- 108091008116 antibody drug conjugates Proteins 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 230000001580 bacterial Effects 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000003247 decreasing Effects 0.000 description 6
- 201000003444 follicular lymphoma Diseases 0.000 description 6
- 230000003211 malignant Effects 0.000 description 6
- 239000002609 media Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000001105 regulatory Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 210000004881 tumor cells Anatomy 0.000 description 6
- 102100005826 CD19 Human genes 0.000 description 5
- 101700087100 CD19 Proteins 0.000 description 5
- 210000003169 Central Nervous System Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 230000036499 Half live Effects 0.000 description 5
- 239000012593 Hanks’ Balanced Salt Solution Substances 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 229920000272 Oligonucleotide Polymers 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 108010071892 TRU 016 Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001588 bifunctional Effects 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 229960005188 collagen Drugs 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000036961 partial Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 230000002103 transcriptional Effects 0.000 description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 208000007502 Anemia Diseases 0.000 description 4
- 101700044948 CD38 Proteins 0.000 description 4
- 102100003279 CD38 Human genes 0.000 description 4
- 229920002676 Complementary DNA Polymers 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 210000002683 Foot Anatomy 0.000 description 4
- 210000003714 Granulocytes Anatomy 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 210000000987 Immune System Anatomy 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 241000229754 Iva xanthiifolia Species 0.000 description 4
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 4
- 210000000952 Spleen Anatomy 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 4
- 230000001594 aberrant Effects 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000240 adjuvant Effects 0.000 description 4
- 230000003042 antagnostic Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000000890 antigenic Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- 231100000588 tumorigenic Toxicity 0.000 description 4
- 230000000381 tumorigenic Effects 0.000 description 4
- 101700027111 3SA0 Proteins 0.000 description 3
- 101700033362 CD28 Proteins 0.000 description 3
- 102100019461 CD28 Human genes 0.000 description 3
- 102000013135 CD52 Antigen Human genes 0.000 description 3
- 108010065524 CD52 Antigen Proteins 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 230000036947 Dissociation constant Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000000999 Encephalomyelitis, Autoimmune, Experimental Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- 210000000265 Leukocytes Anatomy 0.000 description 3
- 210000003141 Lower Extremity Anatomy 0.000 description 3
- 206010025135 Lupus erythematosus Diseases 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 3
- 229960004452 Methionine Drugs 0.000 description 3
- 108091005771 Peptidases Proteins 0.000 description 3
- 102000035443 Peptidases Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 241000907335 Sal Vieja virus Species 0.000 description 3
- 101710043164 Segment-4 Proteins 0.000 description 3
- 101700038759 VP1 Proteins 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 230000002378 acidificating Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 239000012503 blood component Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 101700067609 ctx Proteins 0.000 description 3
- 239000002619 cytotoxin Substances 0.000 description 3
- 230000002354 daily Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000001809 detectable Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 230000002349 favourable Effects 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 101700005460 hemA Proteins 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 210000003519 mature B lymphocyte Anatomy 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000002093 peripheral Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920000406 phosphotungstic acid polymer Polymers 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000717 retained Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000002269 spontaneous Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 230000002195 synergetic Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- 101710027066 ALB Proteins 0.000 description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 229960001230 Asparagine Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 102100003268 CD14 Human genes 0.000 description 2
- 101700027514 CD14 Proteins 0.000 description 2
- 101700020617 CD22 Proteins 0.000 description 2
- 102100000189 CD22 Human genes 0.000 description 2
- 101700017647 CD33 Proteins 0.000 description 2
- 102100016493 CD33 Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- 101000229600 CD37 Proteins 0.000 description 2
- 101710040446 CD40 Proteins 0.000 description 2
- 102100013137 CD40 Human genes 0.000 description 2
- 101700078950 CD44 Proteins 0.000 description 2
- 102100003735 CD44 Human genes 0.000 description 2
- 102100013391 CD55 Human genes 0.000 description 2
- 101710006195 CD55 Proteins 0.000 description 2
- 102100003281 CD59 Human genes 0.000 description 2
- 101700073334 CD59 Proteins 0.000 description 2
- 102100005830 CD70 Human genes 0.000 description 2
- 101700017377 CD70 Proteins 0.000 description 2
- 102100019451 CD80 Human genes 0.000 description 2
- 101700080477 CD80 Proteins 0.000 description 2
- 102100006400 CSF2 Human genes 0.000 description 2
- 229940112129 Campath Drugs 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 210000004436 Chromosomes, Artificial, Bacterial Anatomy 0.000 description 2
- 229920000453 Consensus sequence Polymers 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 210000004443 Dendritic Cells Anatomy 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N Fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 208000006572 Human Influenza Diseases 0.000 description 2
- 102100006815 IL2RA Human genes 0.000 description 2
- 101700082799 IL2RA Proteins 0.000 description 2
- 101700015336 ISG20 Proteins 0.000 description 2
- 229960000310 ISOLEUCINE Drugs 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 206010022000 Influenza Diseases 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 family Proteins 0.000 description 2
- 108090000171 Interleukin-18 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000008968 Lymphoma, Large-Cell, Anaplastic Diseases 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- 206010026798 Mantle cell lymphomas Diseases 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- 206010027926 Monoplegia Diseases 0.000 description 2
- 210000000066 Myeloid Cells Anatomy 0.000 description 2
- 210000000440 Neutrophils Anatomy 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- 241000577979 Peromyscus spicilegus Species 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 229960005190 Phenylalanine Drugs 0.000 description 2
- 210000004011 Plasma Cells Anatomy 0.000 description 2
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N Psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 206010072736 Rheumatic disease Diseases 0.000 description 2
- 102000035266 SCARB3 Human genes 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 210000000278 Spinal Cord Anatomy 0.000 description 2
- 241000702287 Sugarcane streak virus Species 0.000 description 2
- 108091008153 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100009534 TNF Human genes 0.000 description 2
- 101710040533 TNFRSF8 Proteins 0.000 description 2
- 102100009538 TNFRSF8 Human genes 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 102000009332 Tetraspanins Human genes 0.000 description 2
- 108050000196 Tetraspanins Proteins 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 210000001364 Upper Extremity Anatomy 0.000 description 2
- SRBFZHDQGSBBOR-SQOUGZDYSA-N Xylose Natural products O[C@@H]1CO[C@@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-SQOUGZDYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000001064 anti-interferon Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 230000000973 chemotherapeutic Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 125000002228 disulfide group Chemical group 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000038101 human CD37 protein Human genes 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000000366 juvenile Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000009906 meningitis Diseases 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- 230000000813 microbial Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000002797 proteolythic Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000002285 radioactive Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000003248 secreting Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 125000000101 thioether group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 230000003442 weekly Effects 0.000 description 2
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 description 1
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 description 1
- LZMSXDHGHZKXJD-WPOPZESYSA-O (2S)-2-azaniumyl-5-[[(4R)-4-[[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino]-5,8,19,22-tetraoxo-1,2-dithia-6,9,18,21-tetraza-13-azoniacyclotetracos-23-yl]amino]-5-oxopentanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC(=O)NC1CSSC[C@H](NC(=O)CC[C@H]([NH3+])C([O-])=O)C(=O)NCC(=O)NCCC[NH2+]CCCCNC(=O)CNC1=O LZMSXDHGHZKXJD-WPOPZESYSA-O 0.000 description 1
- UFHJEZDFEHUYCR-YUMQZZPRSA-N (2S,3S)-2,3-bis(2,2-dimethylpropanoyloxy)butanedioic acid Chemical compound CC(C)(C)C(=O)O[C@H](C(O)=O)[C@@H](C(O)=O)OC(=O)C(C)(C)C UFHJEZDFEHUYCR-YUMQZZPRSA-N 0.000 description 1
- SJSYJHLLBBSLIH-SDNWHVSQSA-N (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoic acid Chemical class COC1=CC=CC=C1\C=C(\C(O)=O)C1=CC=CC=C1 SJSYJHLLBBSLIH-SDNWHVSQSA-N 0.000 description 1
- KSEZPRJUTHMFGZ-UHFFFAOYSA-N 1-(3-ethyl-5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)ethanone Chemical compound CC1(C)CCC(C)(C)C2=C1C=C(C(C)=O)C(CC)=C2 KSEZPRJUTHMFGZ-UHFFFAOYSA-N 0.000 description 1
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-Naphthaleneacetic acid Chemical class C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1H-indol-2-yl)acetic acid Chemical class C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AQIXEPGDORPWBJ-UHFFFAOYSA-N 3-Pentanol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 1
- AGAYQLZJBWFZQV-UHFFFAOYSA-N 3-acetyloxolane-2,5-dione Chemical compound CC(=O)C1CC(=O)OC1=O AGAYQLZJBWFZQV-UHFFFAOYSA-N 0.000 description 1
- PQYGLZAKNWQTCV-HNNXBMFYSA-N 4-[N'-(2-hydroxyethyl)thioureido]-L-benzyl EDTA Chemical compound OCCNC(=S)NC1=CC=C(C[C@@H](CN(CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 PQYGLZAKNWQTCV-HNNXBMFYSA-N 0.000 description 1
- 101710026914 AAG Proteins 0.000 description 1
- 102100009254 ACOT1 Human genes 0.000 description 1
- 101700030167 ACOT1 Proteins 0.000 description 1
- 102100000358 ADIG Human genes 0.000 description 1
- 101700032935 ADIG Proteins 0.000 description 1
- 101710028272 ALATS Proteins 0.000 description 1
- 229940033495 ANTIMALARIALS Drugs 0.000 description 1
- 101710034857 ATIC Proteins 0.000 description 1
- 206010049460 Abasia Diseases 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N Acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 201000004304 Addison's disease Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 240000000800 Allium ursinum Species 0.000 description 1
- 229940059260 Amidate Drugs 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N Anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 206010002967 Aplastic anaemia Diseases 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 108090000206 Autoantibodies Proteins 0.000 description 1
- 102000003852 Autoantibodies Human genes 0.000 description 1
- 208000006647 Autoimmune Polyendocrinopathy Diseases 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000009137 Behcet Syndrome Diseases 0.000 description 1
- 201000008335 Behcet's disease Diseases 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 229960001950 Benzethonium Chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 1
- 230000037177 Biodistribution Effects 0.000 description 1
- 108010007539 Blocking Antibodies Proteins 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 1
- 101700085877 CECC1 Proteins 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-L CHEBI:8154 Chemical group [O-]P([O-])=O ABLZXFCXXLZCGV-UHFFFAOYSA-L 0.000 description 1
- 102100012601 CNST Human genes 0.000 description 1
- 108060001684 CNST Proteins 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-M COP([O-])=O Chemical class COP([O-])=O QCMYYKRYFNMIEC-UHFFFAOYSA-M 0.000 description 1
- 229920002574 CR-39 Polymers 0.000 description 1
- OSNYMVWMPOZYSX-UHFFFAOYSA-M CSC(C([O-])=N)CC Chemical compound CSC(C([O-])=N)CC OSNYMVWMPOZYSX-UHFFFAOYSA-M 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N Chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960003677 Chloroquine Drugs 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 229920000062 Coding strand Polymers 0.000 description 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical class O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101700011961 DPOM Proteins 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 208000004275 Demyelinating Disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N Ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 101700053597 FCER2 Proteins 0.000 description 1
- 102100014608 FCER2 Human genes 0.000 description 1
- 101710003440 FCGR1A Proteins 0.000 description 1
- 102100015540 FCGR1A Human genes 0.000 description 1
- 101710044640 FCGR2A Proteins 0.000 description 1
- 101710044641 FCGR2B Proteins 0.000 description 1
- 101710044642 FCGR2C Proteins 0.000 description 1
- 102100015544 FCGR2C Human genes 0.000 description 1
- 102100015541 FCGR3A Human genes 0.000 description 1
- 101710044656 FCGR3A Proteins 0.000 description 1
- 101710044657 FCGR3B Proteins 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000218627 Garlic common latent virus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 208000007465 Giant Cell Arteritis Diseases 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 210000000585 Glomerular Basement Membrane Anatomy 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 102000005720 Glutathione Transferase family Human genes 0.000 description 1
- 108010070675 Glutathione Transferase family Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 241000586268 Henia Species 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000406221 Hypostomus robinii Species 0.000 description 1
- WDTLSHLXZWPLNU-UHFFFAOYSA-M ICC(=O)C=1C(=C(C(=O)[O-])C=CC1)N Chemical compound ICC(=O)C=1C(=C(C(=O)[O-])C=CC1)N WDTLSHLXZWPLNU-UHFFFAOYSA-M 0.000 description 1
- 101710039379 IL1RL1 Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 231100000608 Immunotoxin Toxicity 0.000 description 1
- 108010004484 Immunotoxins Proteins 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin resistance Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 229940100601 Interleukin-6 Drugs 0.000 description 1
- 210000004153 Islets of Langerhans Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101700021338 LEC Proteins 0.000 description 1
- 101700048515 LEC1 Proteins 0.000 description 1
- 101700046135 LEC2 Proteins 0.000 description 1
- 101700077545 LECC Proteins 0.000 description 1
- 101700028499 LECG Proteins 0.000 description 1
- 101700028593 LECH Proteins 0.000 description 1
- 101700063913 LECT Proteins 0.000 description 1
- 101700001674 LEVI Proteins 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 102000019298 Lipocalins Human genes 0.000 description 1
- 108050006654 Lipocalins Proteins 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- 208000003747 Lymphoid Leukemia Diseases 0.000 description 1
- 208000006557 Lymphoma, B-Cell, Marginal Zone Diseases 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229940041334 Meclofenamate Sodium Drugs 0.000 description 1
- 241000469204 Mellita Species 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000004841 Meum athamanticum Species 0.000 description 1
- 210000004688 Microtubules Anatomy 0.000 description 1
- 102000028664 Microtubules Human genes 0.000 description 1
- 108091022031 Microtubules Proteins 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101700001911 NO27 Proteins 0.000 description 1
- 101700064921 NO93 Proteins 0.000 description 1
- 101710024861 NRT2.2 Proteins 0.000 description 1
- 229920002957 Naked DNA Polymers 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 210000004248 Oligodendroglia Anatomy 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710034340 Os04g0173800 Proteins 0.000 description 1
- 101700061424 POLB Proteins 0.000 description 1
- 101700031953 PTMA Proteins 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 206010034695 Pernicious anaemia Diseases 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- LLKYUHGUYSLMPA-UHFFFAOYSA-N Phosphoramidite Chemical compound NP([O-])[O-] LLKYUHGUYSLMPA-UHFFFAOYSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000002151 Pleural Effusion Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010051358 Post transplant lymphoproliferative disease Diseases 0.000 description 1
- 229960002429 Proline Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 101700054624 RF1 Proteins 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 229920001914 Ribonucleotide Polymers 0.000 description 1
- 229940003641 Rituxan Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010060243 SMIP-016 Proteins 0.000 description 1
- 101700058207 SPP1 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- 206010040767 Sjogren's syndrome Diseases 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M Stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 206010072148 Stiff person syndrome Diseases 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 241000282890 Sus Species 0.000 description 1
- 108060008105 TCTA Proteins 0.000 description 1
- JVHROZDXPAUZFK-UHFFFAOYSA-N TETA Chemical compound OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CCCN(CC(O)=O)CC1 JVHROZDXPAUZFK-UHFFFAOYSA-N 0.000 description 1
- 229960003080 Taurine Drugs 0.000 description 1
- 206010043207 Temporal arteritis Diseases 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 206010043778 Thyroiditis Diseases 0.000 description 1
- 210000003371 Toes Anatomy 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000711508 Turkey coronavirus Species 0.000 description 1
- 102200012894 UGT2B7 H35A Human genes 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N Zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2S)-2-aminopentanedioic acid;(2S)-2-aminopropanoic acid;(2S)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000000078 anti-malarial Effects 0.000 description 1
- 230000000931 anti-neutrophil Effects 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000001479 arabinose derivatives Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000004339 autoimmune neuropathy Diseases 0.000 description 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000001488 breeding Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000005037 combinatorial chemistry Methods 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical class [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 description 1
- 125000005414 dithiopyridyl group Chemical group 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003118 drug derivative Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000037320 fibronectin Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000003260 fluorescence intensity Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 102000035362 glycosylated proteins Human genes 0.000 description 1
- 108091005600 glycosylated proteins Proteins 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 235000020021 gose Nutrition 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000003463 hyperproliferative Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 101700009932 ida-1 Proteins 0.000 description 1
- 238000002318 immunoblotting Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 101700036391 lecA Proteins 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 101700079891 lgg-2 Proteins 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000006439 lymphocytic leukemia Diseases 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 201000011152 pemphigus Diseases 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 230000003169 placental Effects 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- 230000003334 potential Effects 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 1
- 230000000861 pro-apoptotic Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 230000003947 protein internalization Effects 0.000 description 1
- 230000003161 proteinsynthetic Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 102220298347 rs201415443 Human genes 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Substances [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- OGPIIGMUPMPMNT-UHFFFAOYSA-M sodium;2-(2,6-dichloro-3-methylanilino)benzoate Chemical compound [Na+].CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl OGPIIGMUPMPMNT-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 108060005723 speA Proteins 0.000 description 1
- 230000003393 splenic Effects 0.000 description 1
- 201000002661 spondylitis Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004173 sunset yellow FCF Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001360 synchronised Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical class [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 108091005683 transmembrane proteins Proteins 0.000 description 1
- 102000035402 transmembrane proteins Human genes 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
Abstract
Discloses the use of a purified humanized antibody or antigen-binding fragment thereof that specifically binds to CD37 in the preparation of a medicament for treating a patient having an autoimmune or inflammatory disease, wherein said humanized antibody or fragment thereof retains the ability of at least its chimeric or murine parent antibody to induce apoptosis in vitro in the absence of a cross-linking agent. least its chimeric or murine parent antibody to induce apoptosis in vitro in the absence of a cross-linking agent.
Description
CD37-BINDING MOLECULES AND IMMUNOCONJUGATES THEREOF
Field of the Inventior’:
The field of the invention generally relates to dies, n-binding fragments f,
polypeptides, and immunoconjugates that bind to CD37, as well as to s of using such CD37—
binding molecules for the treatment of diseases, such as mune diseases and inflammatory diseases.
Background of the Invention
Leukocyte antigen CD37 ("CD37"), also known as GP52—40, tetraspanin—26, or TSPAN26, is
a transmembrane protein of the tetraspanin superfamily (Maecker et al., 1997 FASEB J. 112428-442). It is
a heavily glycosylated protein with four transmembrane domains that is expressed on B cells during the
pre-B to eral mature B-cell stages, but is reportedly absent on terminal differentiation to plasma
cells. (Link et al., 1987, J Pathol. —21). The CD37 antigen is only weakly expressed on T-cells,
myeloid cells, and granulocytes (Schwartz-Albiez et al. 1988, J. Immunol., 140(3)905-914). r,
CD37 is also expressed on malignant B-cells such as tleose founding non-Hodgkin’s lymphoma (NHL)
and chronic lymphoid leukemia (CLL) (Moore et al. 1986, J Immunol. 137(9):3013-8).
While the exact physiological role of CD37 is unclear, studies in eficient mice suggest
an immunoregulatory function. Although mice deficient in CD37 expression have normal development
(Knobeloch et al. 2000, Mol Cell Biol., 20(15):5363—9), in the C57/Bl6 background, CD'37-/- T cells are
hyper-proliferative (van Spriel et al., J Immunol. 172, 2953 (2004)), CD37-/- dendritic cells (DC) exhibit
an increased antigen presentation (Sheng et al., Eur J Immunol. 39, 50 (2009)), and CD3 7—/— macrophages
show increased -l—induced IL—6 production (Meyer-Wentrup et al., J Immunol. 178, 154 (2007)).
CD3 ient C57/Bl6 mice also contain significantly higher level of IgA than the wild—type mice (van
Spriel et al., PLoS Pathol. 5, e1000338 (2009) and Rops et al., Am J Pathol. 176, 2188 (2010)). All of
these results suggest a general regulatory role of CD37 in the immune system. Interestingly, crosslinking
of CD37 n by antibody on human T cells inhibits T cell proliferation induced by CD3 stimulation
(van Spriel eta1., J Immunol. 172, 2953 (2004)).
Antibodies are emerging as a promising method to treat human diseases ing
autoimmune diseases. Cureently, an anti-CD20 antibody called rituximab has been approved for
rheumatoid tis (RA) treatment (Edwards JC et al. 2006, Nat Rev Immunol. 6: 119), Rituximab is
used in the United States in combination with methotrexate (MTX) to reduce signs and symptoms in adult
ts with moderately— to severely-active RA who have had an inadequate response to at least one TNF
antagonist. Many studies address the use of rét’uximab in a variety of non—malignant autoimmune or
inflammatory disorders, including RA, in which B-cells and autoantibodies appear to play a role in
disease pathophysiology. Edwards et al., Biochem Soc. Trans. 30:824—828 (2002). Targeting of CD20
W0 2012/135740 PCT/U82012/031648
_ 2 _
using anti-CD20 antibody has been reported to potentially relieve signs and ms of a number of
autoimmune or inflammatory diseases including, for example, RA ro et al., Ann. Rheum. Dis.
61 88 (2002); Edwards et al., Arthritis Rheum, 46 (Suppl. 9): S46 (2002); Stahl et al., Ann. Rheum.
Dis., 62 (Suppl. 1): OP004 (2003); Emery et al., Arthritis Rheum. 48(9): S439 ), lupus (Eisenberg,
tis. Res. Ther. 5:157-159 (2003); Leandro et al. Arthritis Rheum. 46: 2673—2677 (2002); Goranan et
al., Lupus, 13: 312—316 (2004)), immune thrombocytopenic purpura (D'Arena et al., Leuk. Lymphoma
44:561-562 (2003); Stasi et al., Blood, 98: 952-957 (2001); Saleh et al., Semin. Oncol., 27 (Supp 12):99—
103 (2000); Zaja et al., Haematologica, 87:189-195 (2002); Ratanatharathom et al., Ann. Int. Med.,
133:275-279 (2000)), pure red cell aplasia (Auner et al., Br. J. Haematol, 116:725-728 (2002));
autoimmune anemia (Zaja et al., supra (erratum appears in Haematologica 87:3 36 (2002)), cold agglutinin
disease (Layios et al., Leukemia, 15:187—8 ; sen et al., Blood, 103: 2925-2928 ;
Berentsen et al., Br. J. Haematol., 115:79-83 (2001); Bauduer, Br. J. Haematol, 112:1083-1090 ;
Zaja et al., Br. J. Haematol, 115:232-233 (2001)), type B syndrome of severe insulin resistance (Coll et
al., N. Engl. J. Med., 350:310-311 (2004), mixed cryoglobulinerrnia (DeVita et al., Arthrétis Rheum. 46
Suppl. 91S206/S469 (2002)), myasthenia gravis (Zaja et al., Neurology, 55:1062-1063 (2000); Wylam et
al., J. r., 143:674—677 (2003)), Wegener’s granulomatosis s et al., Arthritis & Rheumatism
44:2836—2840 (2001)), microscopic polyangiitis (MPA), refractory pemphigus is (Dupuy et al.,
Arch Dermatol, 140:91—96 (2004)), dermatomyositis (Levine, Arthritis Rheum, 46 . 9)281299
(2002)), n's me (Somer et al., Arthritis & Rheumatism, 49:394—398 (2003)), active type-II
mixed cryoglobulinemia (Zaja et al., Blood, 101:3 827-3834 (2003)), pemphigus is (Dupay et al.,
Arch. Dermatol, —95 (2004)), autoimmune neuropathy (Pestronk et al., J. Neurol. Neurosurg.
Psychiatry 74:485-489 (2003)), paraneoplastic opsoclonus—myoclonus syndrome (Pranzatelli et al.
Neurology 60 (Suppl. 1) POS.128:A395 (2003)), and relapsing—remitting multiple sclerosis (RRMS).
Cross et a1. (abstract) "Preliminary Results from a Phase II Trial of Rituximab in MS” Eighth Annual
Meeting of the Americas Committees for Research and Treatment in Multiple Sclerosis, 20-21 (2003).
In animal models, B—cell depletion using antibodies against B—cell antigens such as CD20 has
been shown to inhibit or ameliorate several autoimmune diseases including systemic lupus erytléematosus
(SLE), experimental autoimmune encephalomyelitis (EAE; mouse model of multiple sclerosis), type-1
diabetes (TlD) and rheumatoid arthritis (RA). Rituximab has been shown to deplete both malignant and
normal B cells in vivo in animal models as well as patients {Malone}; DG et al, Blood.
l994;84(8):2457~66; Reff ME, et al. Blood. 3(2):435-45; Schroder C, et at. Transpl lmmunol.
2003;12(l):l9—28). It can aiso deplete nermal s from human peripheral blood rnononnclear celis
(PBMCS) in in with; experiments (Vugmeyster Y, et a1, Cytometry A. 2003;52(2):101—9; Vngmeyster Y
and Hewell Kint lmrntmopharmacol. 2004;4(8):l l l7~24).
W0 2012/135740 PCT/U82012/031648
_ 3 _
Campath-lH (alumtuzumab), an anti-CD52 chimeric IgGl, binds to the CD52 antigen, which
is highly expressed on all lymphocytes (Ginaldi L, et al,Leuk Res. 1998 (2):l85-91; Hale G, et al,
Tissue Antigens. 1990 Mar;35(3):l 1 8-27). It is used in patients to deplete malignant lymphocytes and is
approved for treating chronic lymphocytic leukemia. It has also shown efficacy in treating le
sclerosis and is currently in Phase III clinical testing (N Engl J Med 2008; 359:1786-1801;
ClinicalTrials.gov NCT00530348 & 48405). It has been shown to deplete normal lymphocytes
in vitro as well (Hale G, et al. Blood. 1983 Oct;62(4):873—82; nn H and Hale G Philos Trans R
Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1707-1l).
CD37-binding agents are also being tested as potential therapeutics for B-cell malignancies.
Emergent Biosolutions (formerly Trubion Pharmaceuticals) developed the CD37-binding agents SMIP-
016 and TRU-016 (Zhao et al., 2007, Blood, 110:2569—2577). SMIP—016 is a single chain polypeptide
that es variable regions from a hybridoma and ered human constant regions. TRU-016 is a
humanized version of the anti-CD37 SMIP n. See e.g. U.S. Published Application No.
2007/0059306. TRU—Ol6 is being tested clinically for the treatment of chronic lymphocytic leukemia
(CLL). Boehringer Ingelheim has also disclosed a CD37 binding agent in International Published
Application No. . r, no CDC activity has been described for any of these
binding agents and no in vitro pro-apoptotic activity has been described in the absence of cross-linking
agents.
immunotherapy (RIT) has been attempted using a radio—labeled anti-CD37 antibody
MB—l in two separate trials. Therapeutic doses of 131I-MB-l were administered to six relapsed NHL
patients (Press et al. 1989 J Clin Oncol. 7(8):1027—38; Press at el. 1993, N Engl J Med. 329(17):l2l9-24).
All six patients achieved a complete remission (CR) with a duration of four to thirty—one months. In
another trial, 131I-MB—l was administered to ten relapsed NHL patients (Kaminski et al. 1992 J Clin
Oncol. :l696-7ll). A total of four patients had a response ranging in duration from two to six
months, although only one CR was reported. r, not all patients could be treated due to an
unfavorable biodistribution of the radio—label which raised concern for radiation exposure of vital non-
target organs. Indeed, RIT related toxicities were observed in these trials ing severe
myelosupression and pulmonary toxicity. While these clinical data suggest that anti—CD37 radio-
immunoconjugates may be effective, these ies are cumbersome to administer, and at relapse post-
RIT patients cannot be retreated with RIT due to the risks ated with high doses of radiation.
To overcome the tions of RIT, antibody—cytotoxic agent conjugates (ACC), also called
antibody-drug conjugates (ADC), have been developed. These are immunoconjugates that include a
cytotoxic agent covalently linked to an antibody through a chemical linker which can allow for specific
delivery of cytotoxic drugs to cells expressing a protein ized by the antibody. However, proteins
that are poorly alized are not considered to be favorable targets for such therapeutics. CD37 is
W0 2012/135740 PCT/U82012/031648
_ 4 -
structurally similar to CD20 as both antigens contain four transmembrane domains, gh CD20 is not
part of the tetraspanin family (Tedder et a1. 1989, J. Immun. 142: 2560—2568). Antibodies against several
B-cell antigens including CD37 and CD20 have been studied for their ability to undergo tosis and
degradation (Press et al. 1989, Cancer Res. 49(17):4906—12, and Press et a1. 1994, Blood. 83(5):1390-7).
The anti-CD37 antibody MB-l was retained on the cell surface and alized slowly in Daudi
lymphoma cells in vitro. The MB—l dy also had a low rate of endocytosis and intracellular
metabolism in NHL patient cells in vitro. Similar results were obtained with the anti—CD20 antibody 1F5,
which was also retained mainly on the lymphoma cell surface and internalized poorly. ADCs of CD20
dies have been studied previously but have not trated cantly strong potency,
especially when non-disulfrde or acid stable linkers are used (see for example Polson et al., 2009, Cancer
Res, 69(6):2358-2364). In light of these observations, CD37 has not been considered a favorable target
for antibody-drug conjugates.
While their role in cancer treatment has been studied, the potential effect of CD37-directed
therapies such as antibodies, antibody tives or radio-immunoconjugates on cells involved in
autoimmune diseases, atory es or other disorders of the immune system is not well
understood. Furthermore, none of the compounds described above have been trated to induce
depletion of target cells involved in manifestation or progression of these types of diseases.
Therefore, there exists a need for CD37 binding agents including antibodies, antigen-binding
fragments thereof, and antibody-drug conjugates (immunoconjugates) as a means to treat autoimmune
diseases, inflammatory diseases, or other ers of the immune system. The t invention
addresses that need.
BRIEF SUMMARY OF THE INVENTION
[0012| In one aspect, the present disclosure es a method for depleting B-cells or treating a
disease associated with aberrant B-cell activity, comprising stering to a patient an ive amount
of a humanized CD37 targeting antibody or immunoconjugate provided herein. In some embodiments,
the B—cells are non-cancerous FEE-cells. In some embodiments, the B—cells do not overexpress CD37.
In certain embodiments, the disease associated with aberrant B-cell activity is a disease
associated with B-cell autoantibody production, and/or a disease associated with inappropriate T-cell
stimulation in connection with a B—cell pathway.
In certain embodiments, the disease characterized by autoantibody production is toid
arthritis, multiple sclerosis, type I diabetes mellitus, idiopathic inflammatory myopathy, systemic lupus
erythematosus (SLE), myasthenia gravis, Grave's disease, derrnatomyositis, polymyositis, or other
autoimmune diseases,
W0 2012/135740 PCT/U82012/031648
_ 5 _
In certain ments, the present disclosure provides a method for depleting a B—cell
comprising ting a B-cell (e.g., in a population of cells comprising a non-cancerous B—cell) with an
antibody or antigen binding fragment thereof that specifically binds to CD37, wherein the antibody or
fragment thereof is capable of inducing apoptosis in vitro in the absence of a cross—linking agent. In
certain embodiments, the present sure provides a method for treating a patient having an
autoimmune or atory disease comprising administering to the patient a therapeutically effective
amount of an antibody or antigen-binding nt f that specifically binds to CD37, wherein the
antibody or fragment thereof is capable of inducing apoptosis in vitro in the absence of a cross—linking
agent. In some embodiments, the antibody or antigen—binding fragment thereof is also capable of
inducing complement dependent cytotoxicity (CDC). In some embodiments, the antibody or antigen-
binding fragment thereof is also capable of inducing antibody dependent cell mediated cytotoxicity
(ADCC). In some embodiments, the antibody or antigen-binding fragment f has a long serum half-
life.
In certain embodiments, the present sure provides a method for depleting a B-cell
sing contacting a B-cell (e.g., in a population of cells comprising a non-cancerous B-cell)
with an antibody or antigen g fragment thereof that specifically binds to the same CD37
epitope as an antibody ed from the group consisting of: (a) an antibody comprising the
polypeptide of SEQ ID X0255 and the polypeptide of SEQ ID NO:72; (b) an antibody comprising the
polypeptide of SEQ ID NO:56 and the polypeptide of SEQ ID NO:73; (c) an antibody comprising the
polypeptide of SEQ ID \10257 and the polypeptide of SEQ ID NO:74; (d) an antibody comprising the
polypeptide of SEQ ID \O:58 and the polypeptide of SEQ ID NO:74; (e) an antibody comprising the
polypeptide of SEQ ID I\O:59 and the polypeptide of SEQ ID NO:75; (i) an antibody comprising the
polypeptide of SEQ ID \'O:60 and the polypeptide of SEQ ID NO:76; (g) an dy comprising the
polypeptide of SEQ ID N026] and the polypeptide of SEQ ID NO:77; (h) an antibody comprising the
polypeptide of SEQ ID \'O:62 and the ptide of SEQ ID NO:78; (i) an dy sing the
polypeptide of SEQ ID \IO:63 and the polypeptide of SEQ ID NO:79; (j) an antibody comprising the
polypeptide of SEQ ID \‘Oz64 and the polypeptide of SEQ ID NO:80; (k) an dy comprising the
polypeptide of SEQ ID XO:65 and the polypeptide of SEQ ID NO:81; (1) an antibody comprising the
polypeptide of SEQ ID ROz66 and the polypeptide of SEQ ID NO:82; (m) an antibody comprising the
ptide of SEQ ID V067 and the polypeptide of SEQ ID NO:83; (n) an antibody comprising the
polypeptide of SEQ ID NO:68 and the polypeptide of SEQ ID NOz84; (0) an antibody comprising the
polypeptide of SEQ ID N069 and the polypeptide of SEQ ID NO:85; (p) an antibody comprising the
polypeptide of SEQ ID I\O:70 and the polypeptide of SEQ ID N0286; (q) an antibody comprising the
polypeptide of SEQ ID NO:71 and the polypeptide of SEQ ID NO:87; and (r) an antibody sing the
polypeptide of SEQ ID NO:177 and the polypeptide of SEQ ID NO:l78,.
W0 35740 PCT/U82012/031648
_ 6 _
In certain embodiments, the present disclosure provides a method for treating a t
having an autoimmune or inflammatory disease comprising administering to the patient a therapeutically
effective amount of an antibody or antigen-binding fragment thereof that specifically binds to the same
CD37 e as an antibody selected from the group described above. In some embodiments, the
antibody or antigen-binding fragment thereof competitively inhibits an antibody selected from the group
described above.
In certain embodiments, the present disclosure es a method for depleting a B-cell
comprising contacting a B—cell (e.g., in a tion of cells comprising a non-cancerous B—cell) with an
antibody or antigen-binding fragment thereof that specifically binds to CD37 and specifically binds to the
polypeptide of SEQ ID NO: 184. In certain embodiments, the t disclosure provides a method for
treating a patient having an autoimmune or inflammatory disease comprising administering to the patient
a therapeutically effective amount of an antibody or antigen—binding fragment thereof that specifically
binds to CD37 and specifically binds to the polypeptide of SEQ ID NO: 184. In some embodiments, the
antibody or antigen-binding fragment thereof does not bind to the polypeptide of SEQ ID NO: 185.
In certain embodiments, the present disclosure provides a method for ing a B-cell
comprising ting a B—cell (e.g., in a population of cells comprising a ncerous B-cell) with an
antibody or antigen-binding fragment thereof that ically binds to CD37 and does not specifically
bind to the polypeptide of SEQ ID NO: 185. In certain embodiments, the present disclosure provides a
method for treating a patient having an autoimmune or inflammatory disease comprising administering to
the patient a therapeutically effective amount of an antibody or antigen-binding fragment thereof that
specifically binds to CD37 and does not ically bind to the polypeptide of SEQ ID NO: 185.
In certain embodiments, the present disclosure provides a method for depleting a B-cell
comprising contacting a B-cell (e.g., in a population of cells comprising a non-cancerous B-cell) with an
antibody or antigen-binding fragment thereof produced by a hybridoma selected from the group consisting
of ATCC Deposit ation PTA-10664, ted with the ATCC on February 18, 2010, ATCC
Deposit Designation PTA-10665, deposited with the ATCC on February 18, 2010, ATCC Deposit
Designation 666, deposited with the ATCC on February 18, 2010, ATCC Deposit Designation
PTA-10667, deposited with the ATCC on February 18, 2010, ATCC Deposit Designation PTA-10668,
deposited with the ATCC on ry 18, 2010, ATCC Deposit Designation PTA-10669, deposited with
the ATCC on February 18, 2010, and ATCC Deposit Designation PTA—10670, deposited with the ATCC
on February 18, 2010. In n embodiments, the t disclosure provides a method for ng a
patient having an autoimmune or inflammatory disease comprising administering to the patient a
therapeutically effective amount of an antibody or antigen-binding fragment thereof produced by a
hybridoma described above...
W0 2012/135740 PCT/U82012/031648
- 7 _
In certain embodiments, the present disclosure provides a method for depleting a B-cell
comprising contacting a B-cell (e.g., in a population of cells sing a non—cancerous B-cell) with an
dy or antigen—binding fragment thereof that specifically binds to CD37, wherein the antibody
comprises polypeptide sequences selected from the group consisting of: (a) SEQ ID NOs: 4, 5, and 6 and
SEQ ID NOS: 28, 29, and 30; (b) SEQ ID NOS: 7, 8, and 9 and SEQ ID NOS: 31, 32, and 33; (c) SEQ ID
NOS: 10, 11, and 12 and SEQ ID NOS: 34, 35, and 36; (d) SEQ ID NOS: 13, 14, and 15 and SEQ ID NOS:
37, 38, and 39; (e) SEQ ID NOS: 13, 14, and 15 and SEQ ID NOS: 37, 40, and 39; (f) SEQ ID NOS: 16,
17, and 18 and SEQ ID NOS: 41, 42, and 43; (g) SEQ ID N05: 19, 20, and 21 and SEQ ID NOS: 44, 45,
and 46; (h) SEQ ID NOS: 19, 20, and 21 and SEQ ID NOS: 44, 47, and 46; (i) SEQ ID NOS; 22, 23, and
24 and SEQ ID NOS: 48, 49, and 50; (j) SEQ ID NOS: 22, 23, and 24 and SEQ ID NOs: 48, 51, and 50;
(k) SEQ ID NOS: 25, 26, and 27 and SEQ ID NOS: 52, 53, and 54; (l) SEQ ID N05: 171, 172 or 181, and
173 and SEQ ID NOS: 174, 175, and 176; (m) variants of (a) to (1) comprising 1, 2, 3, or 4 vative
amino acid substitutions. In certain embodiments, the present disclosure provides a method for treating a
patient having an autoimmune or inflammatory disease comprising administering to the t a
therapeutically effective amount of an antibody or antigen-binding fragment thereof with an antibody or
antigen-binding fragment thereof that Specifically binds to CD37, wherein the antibody comprises
polypeptide sequences selected from the group described above. In some ments, the antibody or
antigen-binding fragment thereof comprises polypeptide sequences that are at least 90% identical to
ptide sequences described above. In some embodiments, the polypeptide sequences are at least
95% identical to the polypeptide sequences. In some embodiments, the polypeptide sequences are at least
99% identical to the polypeptide ces. In some embodiments, the antibody or antigen-binding
fragment thereof ses polypeptide sequences that are at least 90% identical, at least 95% identical, at
least 99% identical, or idential to the polypeptide sequences of SEQ ID NO: 57 and SEQ ID NO:74. In
some embodiments, the antibody or antigen—binding fragment thereof comprises polypeptide sequences
that are at least 90% identical, at least 95% identical, at least 99% identical, or idential to the polypeptide
sequences of SEQ ID NO: 58 and SEQ ID NO:74. In some embodiments, the antibody or n-binding
fragment thereof comprises polypeptide sequences that are at least 90% identical, at least 95% identical, at
least 99% identical, or idential to the polypeptide sequences of SEQ ID NO: 63 and SEQ ID NO:79. In
some embodiments, the antibody or antigen-binding fragment thereof ses polypeptide ces
that are at least 90% identical, at least 95% identical, at least 99% identical, or idential to the polypeptide
sequences of SEQ ID NO: 65 and SEQ ID NO:81.
In some ments, the antibody or n binding fragment thereof is murine, non-
human, humanized, chimeric, resurfaced, or human.
In some embodiments, the dy or dy fragment is capable of inducing apoptosis of
a cell expressing CD37 in vitro in the absence of cross-linking agents. In some embodiments, the antibody
W0 2012/135740 2012/031648
_ g _
or antigen binding fragment is capable of inducing complement dependent xicity (CDC). In some
embodiments, the antibody is capable of inducing antibody dependent cell mediated cytotoxicity (ADCC).
In certain embodiments, the present disclosure provides a method for depleting a B-cell
sing contacting a B-cell (e.g., in a population of cells comprising a non-cancerous B-cell) with a
human or zed antibody or antigen binding fragment thereof that specifically binds to CD37,
wherein the antibody or fragment thereof is capable of inducing apoptosis of a cell expressing CD37 in
vitro in the absence of cross—linking agents. In n embodiments, the present disclosure es a
method for treating a t having an autoimmune or inflammatory disease comprising stering to
the patient a therapeutically effective amount of a human or humanized antibody or antigen binding
fragment thereof that specifically binds to CD37, wherein the antibody or fragment thereof is capable of
inducing apoptosis of a cell expressing CD37 in vitro in the absence of cross-linking agents. In some
embodiments, the human or humanized dy or antigen binding fragment thereof is also capable of
inducing complement dependent cytotoxicity (CDC). In some embodiments, the human or humanized
antibody or antigen binding fragment f is also capable of inducing antibody dependent cell mediated
cytotoxicity (ADCC).
In some embodiments, the antibody or antigen-binding fragment binds to human CD37 and
macaque CD37.
In some embodiments, the antibody is a full length dy. In some embodiments, an
antigen-binding fragment is used. In some ments, the antibody or antigen—binding fragment
thereof comprises a Fab, Fab', F(ab')2, F(1, single chain Fv or scFv, disulfide linked Fv, V-NAR domain,
IgNar, intrabody, IgGACHZ, minibody, F(ab')3, ody, triabody, diabody, -domain antibody,
DVD—lg, Fcab, mAb2, (scFv)2, or c.
In some embodiments, the antibody or antigen-binding fragment f is linked via a linker
(L) to a cytotoxic agent (C) to form an immunoconjugate.
In certain embodiments, the present disclosure provides a method for depleting a B—cell
comprising contacting a B-cell (e.g., in a population of cells comprising a non-cancerous B-cell) with a
composition comprising an immunoconjugate having the formula (A) - (L)
- (C), wherein: (A) is an
antibody or antigen binding fragment that specifically binds to CD37; (L) is a non-cleavable linker; and
(C) is a cytotoxic agent; and wherein the linker (L) links (A) to (C). In certain embodiments, the t
disclosure provides a method for treating a patient having an mune or inflammatory disease
comprising administering to the patient a therapeutically effective amount of a composition comprising an
immunoconjugate having the formula (A) — (L) - (C), n: (A) is an antibody or antigen binding
fragment that specifically binds to CD37; (L) is a non-cleavable linker; and (C) is a cytotoxic agent; and
wherein the linker (L) links (A) to (C). In some ments, the immunoconjugate has a serum half—life
that is comparable to that of the naked antibody,
W0 2012/135740 PCT/U82012/031648
In certain embodiments, the present disclosure provides a method for depleting a B-cell
sing contacting a B-cell (e.g., in a population of cells comprising a non-cancerous B-cell) with a
composition comprising an immunoconjugate having the formula (A) - (L)
— (C), wherein: (A) is an
antibody or antigen binding fragment that specifically binds to CD37; (L) is a linker; and (C) is a
maytansinoid; and wherein the linker (L) links (A) to (C). In certain embodiments, the present disclosure
provides a method for treating a patient having an autoimmune or inflammatory disease comprising
administering to the patient a therapeutically effective amount of a composition comprising an
immunoconjugate having the formula (A) - (L) - (C), wherein: (A) is an antibody or antigen binding
fragment that specifically binds to CD37; (L) is a linker; and (C) is a maytansinoid; and wherein the linker
(L) links (A) to (C).
In some embodiments, the linker is a non-cleavable linker. In some embodiments, the
immunoconjugate further comprises a second (C). In some ments, the immunoconjugate further
ses a third (C). In some embodiments, the immunoconjugate further comprises a fourth (C). In
some embodiments, the immunoconjugate comprises 2—6 (C). In some embodiments, the
immunoconjugate comprises 3-4 (C).
In some ments, the linker is selected from the group consisting of a ble , a
non—cleavable linker, a hilic linker, and a dicarboxylic acid based linker. In some embodiments,
the linker is selected from the group consisting of: N—succinimidyl 4-(2—pyridyldithio)pentanoate (SPP);
N—succinimidyl 4-(2—pyridyldithio)butanoate (SPDB) or N-succinimidyl 4-(2-pyridyldithio)—2-
utanoate (sulfo-SPDB); N-succinimidyl 4—(maleirnidomethyl) cyclohexanecarboxylate (SMCC); N-
sulfosuccinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (sulfoSMCC); N—succinimidyl
(iodoacetyl)—aminobenzoate (SIAB); and N—succinimidyl—[(N-maleimidopropionamido)—
tetraethyleneglycol] ester (NHS-PEG4-maleimide). In some ments, the linker is N—succinimidyl—
[(N-maleimidopropionamido)—tetraethyleneglycol] ester (NHS-PEG4-maleimide).
In some embodiments, the cytotoxic agent is selected from the group consisting of a
maytansinoid, maytansinoid analog, doxornbicin, a modified bicin, benzodiazepine, taxoid, CC—
1065, CC-lO65 analog, znycin, duocarznycin analog, calicheamicin, dolastatin, dolastatin analog,
aristatin, ycin derivative, and leptomycin derivative or a prodrug of the agent. In some
embodiments, the cytotoxic agent is a maytansinoid. In some embodiments, the cytotoxic agent is N(2')—
deacetyl-N(2')-(3-mercapto—l-oxopropyl)—maytansine (DMl) or deacetyl-N2—(4-mercapto—4-methyl—
l-oxopentyl)—maytansine (DM4).
In some embodiments, the composition sing an immunoconjugate comprises multiple
cytotoxic agents (C) with an average of about 3 to about 4 (C) per (A). In some embodiments, the
unoeonjugates have an average of about 3.5 (C) per (A). In some embodiments, the
immunoccnjugates have an average ofabout 3.5 i 0.5 (C) per (A).
_ 10 -.
In some embodiments, the composition comprising an conjugate comprises an
antibody comprising SEQ ID NO:57 and SEQ ID NO:74 or SEQ ID NO:58 and SEQ ID NO:74, an
SMCC linker, and DM1. In some embodiments, the composition sing an immunoconjugate
comprises an antibody sing SEQ ID NO:63 and SEQ ID NO:79, an SMCC linker, and DM1. In
some ments, the composition comprising an immunoconjugate comprises an antibody comprising
SEQ ID NO:65 and SEQ ID NO:81, an SMCC linker, and DM1.
In some embodiments, the antibody or antigen-binding fragment is capable of depleting B-
cells. In some embodiments, the antibody or antigen—binding fragment is capable of inhibiting T-cell
responses.
In some embodiments, the B-cell is in a composition further comprising a T-cell. In some
embodiments, the B—cell is in a ition sing peripheral blood mononuclear cells. In some
embodiments, the peripheral blood mononuclear cells were obtained from a human. In some
embodiments, the B—cell is in whole blood. In some embodiments, the whole blood was obtained from a
human. In some embodiments, the B—cell is in an sm. In some embodiments, the B-cell is in a
patient having an mune or inflammatory disease.
In some embodiments, the B-cell is an autoreactive B—cell.
In some embodiments, at least about 30% of B-cells are depleted. In some embodiments, less
than about 5% of T-cells are depleted.
In some embodiments, a second eutic agent is administered. In some embodiments, the
second therapeutic is selected from the group consisting of methotrexate, an anti—CD20 therapeutic, an
anti-IL-6 receptor therapeutic, ar anti-1L—12/23p40 therapeutic, a chemotherapeutic, an
suppressant, an anti-Interferon beta-1a therapeutic, glatiramer acetate, an L4—integrin
therapeutic, fingolimod, an anti-BLys therapeutic, c, or an anti-TNF therapeutic. In some
embodiments, the second therapeutic is an antibody ed against an antigen selected from a group
consisting of CD3, CD14, CD19, CD20, CD22, CD25, CD28, CD30, CD33, CD36, CD3 8, CD40, CD44,
CD52, CD55, CD59, CD56, CD70, CD79, CD80, CD103, CD134, CD137, CD138, and CD152. In some
embodiments, the second therapeutic is an antibody directed against an antigen selected from the group
consisting of 1L-2, IL—6, IL—12, 1L-23, IL—12/23 p40, IL—17, IFNy, TNFoc, IFNOL, IL—15, IL-21, IL—Ia, 1L-
lb, IL—18, IL-8, IL—4, GM—CSF, IL—3, and IL—5.
In some embodiments, the mune or inflammatory disease is selected from the group
consisting of rheumatoid arthritis, multiple sclerosis, type I diabetes mellitas, idiopathic inflammatory
myopathy, systemic lupus erythematosus (SLE), myasthenia gravis, Grave's disease, dermatomyositis,
polymyositis, Crohn’s diasease, ulcerative colitis, gastritis, Hashimoto’s thyroiditis, , psoriasis,
psoriatic arthritis, dertmatitis, ic sclerodema and sclerosis, inflammatory bowel disease (IBD),
respiratory distress syndrome, meningitis, encephalitis, uveitis, glmerulonephritis, eczema,
atherosclerosis, leukocyte adhesion deficiency, Raynaud’s syndrome, Sjögren’s syndrome, Reiter’s
disease, Beheet’s disease,immune complex nephritis, IgA nephropathy, IgM polyneuropathies,
immune-mediated thrombocytopenias, acute thic thrombocytopenic purpura, chronic
thic thrombocytopenic purpura, hemolytic anemia, myasthenia gravis, lupus nephritis, atopic
dermatitis, pemphigus vulgaris, opsoclonus-myoclonus syndrome, pure red cell aplasia, mixed
cryoglobulinemia, sing spondylitis, hepatitis C-associated cryoglobulinemic vasculitis,
chronic focal alitis, bullous pemphigoid, ilia A, membranoproliferative
glomerulonephritis, adult and juvenile dermatomyositis, adult polymyositis, chronic urticaria,
primary biliary cirrhosis, neuromyelitis optica, Graves’ dysthyroid disease, bullous pemphigoid,
membranoproliferative glomerulonephritis, Churg-Strauss syndrome, juvenile onset diabetes,
hemolytic anemia, atopic dermatitis, systemic sclerosis, Sjögren’s syndrome and
glomerulonephritis, dermatomyositis, anti-neutrophil cytoplasmic dy (ANCA), aplastic
anemia, autoimmune tic anemia , factor VIII deficiency, hemophilia A, autoimmune
neutropenia, Castleman's syndrome, Goodpasture's syndrome, solid organ transplant rejection, graft
versus host disease (GVHD), mune hepatitis, lymphoid interstitial pneumonitis, HIV,
iolitis obliterans ransplant), Guillain-Barre Syndrome, large vessel vasculitis, giant
cell (Takayasu's) arteritis, medium vessel vasculitis, Kawasaki's Disease, polyarteritis nodosa,
Wegener’s granulomatosis, microscopic polyangiitis (MPA), Omenn’s syndrome, chronic renal
failure, acute infectious mononucleosis, HIV and herpes virus associated diseases.
[0039a] Definitions of the specific embodiments of the invention as claimed herein follow.
[0039b] According to a first embodiment of the invention, there is ed use of a ed
humanized dy or antigen-binding nt thereof that specifically binds to CD37 in the
preparation of a medicament for treating a patient having an autoimmune or inflammatory disease,
n said humanized antibody or fragment thereof retains the ability of at least its chimeric or
murine parent antibody to induce apoptosis in vitro in the absence of a linking agent.
[0039c] According to a second embodiment of the invention, there is provided use of a
purified humanized antibody or antigen-binding fragment f that specifically binds to CD37 in
the preparation of a medicament for depleting a B-cell in a population of cells comprising a noncancerous
B-cell, wherein said humanized antibody or fragment thereof retains the ability of at
least its chimeric or murine parent antibody to induce sis in vitro in the absence of a crosslinking
agent. .
- 11a -
[0039d] According to a third embodiment of the invention, there is provided use of a
purified zed antibody or n-binding fragment thereof that specifically binds to CD37 in
the preparation of a medicament for treating a patient having an autoimmune or inflammatory
disease, wherein the antibody or antigen-binding fragment thereof comprises ptide
sequences selected from the group consisting of:
(a) SEQ ID NO:57 and SEQ ID NO:74;
(b) SEQ ID NO:58 and SEQ ID NO:74;
(c) SEQ ID NO:63 and SEQ ID NO:79;
(d) SEQ ID NO:65 and SEQ ID NO:81;
(e) SEQ ID NO:67 and SEQ ID NO:83;
(f) SEQ ID NO:69 and SEQ ID NO:85; and
(g) SEQ ID NO:71 and SEQ ID NO:87.
[0039e] According to a fourth embodiment of the invention, there is provided use of a
ed humanized antibody or antigen-binding fragment thereof that specifically binds to CD37 in
the ation of a medicament for depleting a B-cell in a population of cells comprising a cerous
B-cell, wherein the antibody or antigen-binding fragment thereof comprises polypeptide
sequences selected from the group ting of:
(a) SEQ ID NO:57 and SEQ ID NO:74;
(b) SEQ ID NO:58 and SEQ ID NO:74;
(c) SEQ ID NO:63 and SEQ ID NO:79;
(d) SEQ ID NO:65 and SEQ ID NO:81;
(e) SEQ ID NO:67 and SEQ ID NO:83;
(f) SEQ ID NO:69 and SEQ ID NO:85; and
(g) SEQ ID NO:71 and SEQ ID NO:87.
BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES
Figure 1 depicts an FL2-H (PE) histogram overlay for a flow cytometry experiment
with human B-cells. The following conditions are shown: antibody control (dark filled), isotype
control stain (light filled), anti-CD37 stain (thick black line), and anti-CD20 stain (dashed line) for
- 11b -
CD19+ B-cells.
Figure 2 depicts the results of in vitro depletion experiments using purified human
PBMC samples treated with 10 μg/mL of huCD37-3, SMCC-DM1, huCD37-50,
huCD37SMCC-DM1, rituximab, 6, or alemtuzumab. Results from two different
donors are shown in panel A and B.
Figure 3 depicts the results of in vitro depletion experiments using purified human
PBMC samples treated with varying concentrations of huCD37SMCC-DM1. Results from two
different donors are shown in panels A and B. Figure 3 (C) shows the results using -3,
huCD37-38, huCD37-50 and huCD37-56.
Figure 4 depicts the results of in vitro depletion experiments using unpurified whole
human blood samples treated with 10 μg/mL of huCD37-3, huCD37SMCC-DM1, huCD37-50,
huCD37SMCC-DM1, mab, TRU-016, or alemtuzumab.
[TEXT CONTINUES ON PAGE 12]
{new Figure 5 depicts the results of in vine depletion experiments using fied whole human
blood samples treated with vaming concentrations of (A) hnCDB 7-3, huClIXW—B—Sl‘vfiiCC~li)lVll, and
ritnxiinab and (B) huCDBY-IB, huCDW—lSMCC-DMI , huCD37«50, and ritnximab,
EQMSE Figure 6 depicts release of lFN--y feron), "l‘NF~€x (Tumor Necrosis ) and Ibo
(lnterleukimé) measured by ELlSpot as number of spots per leGEZS peripheral blood mononuclear cells
(PBMCS) from one healthy human donor incubated for ill—20 hours with compounds at a concentration of
2,5 rig/ml;- to 25$ gig/nil...
{0046} Figure ‘7 depicts release of 119wa (Interferon), TNF~«:L {Tumor Necrosis Factor) and lire
(interleukineé) measured by ELlSpot as mimber of spots per 5x“? peripheral blood mononuclear cells
(PBMCs) from a second healthy human donor incubated for 18-20 hours with compounds at a
concentration of 2.5 ng/mL to 250' ug/mL.
Figure 8 depicts the g curve of anti-muCD37 monoclonal antibody clone 252—3.
Figure 9 shows the activity of the 252—3 antibody in depleting peripheral blood B cells (A)
and in inhibiting EAE (B) in C57B1/6 mice. In (A), each symbol represent one mouse; to compare the B
cell level in control vs. experimental mice, B cell level was normalized with T cell level and ratio of B/T
cell in control mice was considered 100%. In (B), open and closed symbols represent mean of EAE score
in control group (n=10) and 252—3 dy treated group (n=10), respectively; arrow indicates day of
antibody injection.
Figure 10 shows the activity of the 252-3 antibody in depleting peripheral blood B cells (A)
and in inhibiting TlD (B) in NOD mice. In (A), each symbol represent one mouse; to compare the B cell
level in l vs. experimental mice, B cell level was normalized with T cell level and ratio of B/T cell
in l mice was considered 100%. In (B), open and closed symbols represent the diabetes incidence in
control group (n36) and 252—3 antibody treated group (n=6), respectively.
Figure 11 shows the activity of the 252-3 antibody in depleting peripheral blood B cells (A)
and in inhibiting CIA (B) in DBA/l mice. In (A), each symbol ent one mouse; to compare the B cell
level in control vs. mental mice, B cell level was normalized with T cell level and ratio of B/T cell
in control mice was considered 100%. In (B), open and closed symbols represents mean of CIA score in
control group (n=l2) and 252-3 antibody treated group (n:12), respectively; arrow indicates day of
antibody ion.
DETAILED DESCRIPTION OF THE INVENTION
{GoSE} The present ion provides methods of depleting B~cells and of treating diseases
associated with aberrant Bucell activity and/or aberrant 'l‘~cell stimulation in tion with a B~cell
y using (2937 binding molecules.
_ 13 _
I. Definitions
To facilitate an understanding of the present invention, a number of terms and phrases are
defined below.
The term CD37 as used herein, refers to any native CD37, unless otherwise indicated. CD37
is also referred to as GP52-40, leukocyte antigen CD37, and Tetraspanin—26. The term "CD37"
encompasses "full-length," unprocessed CD37 as well as any form of CD37 that results from processing
in the cell. The term also encompasses naturally occurring variants of CD37, e.g., splice variants, c
variants, and isoforms. The CD37 polypeptides described herein can be isolated from a variety of sources,
such as from human tissue types or from another source, or prepared by recombinant or synthetic
methods.
The term "antibody" means an globulin molecule that recognizes and specifically
binds to a target, such as a protein, polypeptide, peptide, ydrate, polynucleotide, lipid, or
combinations of the ing h at least one n recognition site within the variable region of
the immunoglobulin molecule. As used herein, the term "antibody" encompasses intact polyclonal
dies, intact monoclonal antibodies, antibody fragments (such as Fab, Fab’, F(ab')2, and Fv
fragments), single chain Fv (scFv) mutants, multispecific antibodies such as bispecific antibodies
generated frorre at least two intact antibodies, chimeric antibodies, humanized antibodies, human
antibodies, fusion proteins comprising an antigen determination portion of an antibody, and any other
modified immunoglobulin molecule comprising an antigen recognition site so long as the antibodies
exhibit the desired biological activity. An antibody can be of any the five major classes of
immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) thereof (e.g. lgGl, lgG2, IgGE,
IgG4, lgAl and IgAZ), based on the ty of their heavy-chain constant domains referred to as alpha,
delta, epsilon, gamma, and mu, respectively. The different classes of immunoglobulins have different and
well known subunit ures and three-dimensional configurations. Antibodies can be naked or
conjugated to other molecules such as , radioisotopes, etc.
A "blocking" antibody or an ”antagonist" antibody is one which inhibits or reduces biological
activity of the antigen it binds, such as CD37. in some embodiments, blocking antibodies or antagonist
antibodies substantially or completely inhibit the biological ty of the antigen. The biological activity
can be reduced by 10%, 20%, 30%, 50%, 70%, 80%, 90%, 95%, or even 100%.
The term "anti-CD37 antibody" or "an antibody that binds to CD3 7" refers to an dy that
is capable of binding CD37 with ent affinity such that the dy is useful as a diagnostic and/or
eutic agent in targeting CD37. The extent of binding of an anti-CD37 antibody to an unrelated, non-
CD37 protein can be less than about 10% of the binding of the antibody to CD37 as measured, e.g., by a
radioimmunoassay (RIA). In n embodiments, an antibody that binds to CD37 has a dissociation
constant (Kd) of :1 nM, £100 nM, 510 nM, 51 nM, or 30.1 nM.
W0 2012/135740
_ 14 _
The term "antibody nt" refers to a portion of an intact antibody and refers to the
antigenic determining variable regions of an intact antibody. Examples of dy fragments include, but
are not limited to Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, single chain antibodies, and
multispecific antibodies formed from antibody fragments.
A "monoclonal antibody" refers to a neous antibody population involved in the highly
specific recognition and binding of a single antigenic determinant, or epitope. This is in contrast to
polyclonal antibodies that lly include ent antibodies directed against ent antigenic
determinants. The term “monoclonal dy” encompasses both intact and full—length monoclonal
antibodies as well as antibody fragments (such as Fab, Fab', F(ab')2, Fv), single chain (scFv) mutants,
fusion proteins comprising an antibody portion, and any other modified immunoglobulin molecule
comprising an antigen recognition site. Furthermore, “monoclonal antibody” refers to such dies
made in any number of manners including but not limited to by hybridoma, phage selection, recombinant
expression, and transgenic animals.
The term "humanized antibody" refers to forms of non—human (e.g. murine) antibodies that
are specific immunoglobulin chains, chimeric immunoglobulins, or fragments thereof that n
l non-human (e.g., murine) sequences. Typically, humanized antibodies are human
immunoglobulins in which residues from the complementary determining region (CDR) are replaced by
residues from the CDR of a non-human species (e.g. mouse, rat, , hamster) that have the d
specificity, affinity, and capability (Jones et al., 1986, , 321:522-525; Riechmann et al., 1988,
, 332:323-327; Verhoeyen et al., 1988, Science, 239:1534-1536). In some instances, the Fv
framework region (FR) residues of a human immunoglobulin are replaced with the corresponding residues
in an antibody from a non-human species that has the desired specificity, y, and capability. The
humanized antibody can be further modified by the substitution of additional residues either in the Fv
framework region and/or within the replaced non-human residues to refine and optimize antibody
specificity, affinity, and/or capability. In l, the humanized antibody will comprise substantially all
of at least one, and typically two or three, variable domains containing all or substantially all of the CDR
regions that correspond to the non-human immunoglobulin whereas all or ntially all of the FR
regions are those of a human immunoglobulin consensus sequence. The humanized antibody can also
comprise at least a portion of an globulin constant region or domain (Fc), typically that of a
human immunoglobulin. Examples of methods used to generate humanized antibodies are described in
US. Pat. 5,225,539.
{0060} A "variabie region" oft-1n antibody refers tn the variable regien of the antibody Eight. chain or
the variable region of the antibody heavy chain, either aicne er in combination. The variable regions of
the heavy and Eight chain each consist at" four framework s (FR) cnnnected by three
complementarity determining regions {CDRs} also knnwn as hypervariabie regicns. The CDRs in each
_ 15 _
chain are held together in close proximity by the FRs and, with the CDRs from the other chain, bute
to the formation of the antigen—binding site of antibodies. There are at least two techniques for
determining CDRs: (1) an approach based on cross—species sequence variability (i.e., Kabat et al.
Sequences of Proteins of Immunological Interest, (5th ed., 1991, National Institutes of Health, Bethesda
Md.)); and (2) an approach based on crystallographic studies of antigen-antibody complexes (Al-lazikani
et a1 (1997) J. Molec. Biol. 7-948)). In addition, combinations of these two approaches are
sometimes used in the art to determine CDRs.
The Kabat ing system is lly used when referring to a residue in the variable
domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) (e.g,
Kabat et al., Sequences of Immunological Interest. 5th Ed. Public Health Service, al Institutes of
Health, Bethesda, Md. (1991)).
The amino acid position numbering as in Kabat, refers to the numbering system used for
heavy chain variable domains or light chain variable s of the compilation of antibodies in Kabat et
al., ces of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of
Health, Bethesda, Md. (1991). Using this numbering system, the actual linear amino acid sequence can
contain fewer or additional amino acids corresponding to a ning of, or insertion into, a FR or CDR
of the variable domain. For example, a heavy chain variable domain can include a single amino acid insert
(residue 52a according to Kabat) after residue 52 of H2 and inserted residues (e.g. residues 82a, 82b, and
82c, etc according to Kabat) after heavy chain FR residue 82. The Kabat numbering of residues can be
determined for a given antibody by alignment at regions of homology of the sequence of the antibody
with a "standard" Kabat numbered sequence. a refers instead to the location of the structural loops
(Chothia and Lesk J. Mol. Biol. 1962901-917 (1987)). The end of the Chothia CDR—HI loop when
numbered using the Kabat ing tion varies between H32 and H34 depending on the length of
the loop (this is because the Kabat numbering scheme places the insertions at H35A and H3 5B; if neither
35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and
35B are present, the loop ends at 34). The AbM hypervariable regions represent a mise between
the Kabat CDRs and Chothia ural loops, and are used by Oxford Molecular's AbM antibody
modeling software.
W0 2012/135740 PCT/U82012/031648
_ 16 _
Loop Kabat AbM a
LE L24FL34 L24—L34 L24—L34
LE. 1450-1456 LEO-L56 L50—L56
L3 7 L89—L97 L89—L97
H1 BBL-H358 H26—H3SB H26—H32..34
(Kabat Numbering)
H1 1131-1135 1126—1135 H26-H32
ia Numbering)
H2 ESQ-H65 1150—1158 HS2-1156
H3 11931-1102 11954-1132 1195—11102
The term "human antibody" means an antibody produced by a human or an dy having
an amino acid sequence corresponding to an dy produced by a human made using any technique
known in the art. This definition of a human antibody includes intact or full—length antibodies, fragments
thereof, and/or antibodies comprising at least one human heavy and/or light chain polypeptide such as, for
example, an antibody comprising murine light chain and human heavy chain polypeptides.
The term "chimeric dies" refers to antibodies wherein the amino acid sequence of the
immunoglobulin molecule is d from two or more species. Typically, the variable region of both
light and heavy chains ponds to the variable region of antibodies derived from one species of
mammals (e.g. mouse, rat, rabbit, etc) with the desired specificity, affinity, and capability while the
constant regions are homologous to the sequences in antibodies derived from r ly human) to
avoid eliciting an immune response in that species.
The term "epitope" or "antigenic determinant" are used interchangeably herein and refer to
that portion of an antigen capable of being recognized and specifically bound by a particular antibody.
When the antigen is a polypeptide, epitopes can be formed both from contiguous amino acids and
noncontiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes foréned from contiguous
amino acids are typically retained upon protein denaturing, s epitopes formed by tertiary folding
are typically lost upon protein denaturing. An epitope typically includes at least 3, and more usually, at
least 5 or 8-10 amino acids in a unique spatial conformation.
"Binding affinity" generally refers to the strength of the sum total of noncovalent interactions
n a single binding site of a le (e.g., an antibody) arzd its binding partner (e.g., an antigen).
Unless indicated otherwise, as used herein, ng affinity" refers to intrinsic binding affinity which
reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a
molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can
be measured by common methods known in the art, including those described herein. Low-affinity
antibodies generally bind n slowly and tend to dissociate readily, s high—affinity antibodies
W0 2012/135740 PCT/U82012/031648
-17_
generally bind n faster and tend to remain bound longer. A variety of methods of measuring binding
affinity are known in the art, any of which can be used for purposes of the present invention. Specific
illustrative embodiments are described in the following.
"Or better" when used herein to refer to binding affinity refers to a er binding between a
molecule and its binding partner. "Or better" when used herein refers to a stronger binding, represented by
a smaller numerical Kd value. For example, an antibody which has an affinity for an antigen of "0.6 nM or
better", the antibody's affinity for the antigen is <0.6 nM, i.e. 0.59 nM, 0.58 nM, 0.57 nM etc. or any value
less than 0.6 HM.
By ”specifically binds," it is generally meant that an antibody binds to an epitope via its
antigen binding domain, and that the bindirgg entails some mentarity between the antigen g
domain and the epitope. According to this definition, an antibody is said to "specifically bind" to an
epitope when it binds to that epitope, via its antigen binding domain more y than it would bind to a
random, unrelated epitope. The term "specificity" is used herein to qualify the relative affinity by which a
certain antibody binds to a n epitope. For example, antibody "A" may be deemed to have a higher
specificity for a given epitope than antibody "B," or antibody "A" may be said to bind to epitope "C" with
a higher city than it has for related epitope "D."
By "preferentially binds," it is meant that the antibody specifically binds to an epitope more
readily than it would bind to a related, similar, gous, or analogous epitope. Thus, an antibody
which "preferentially binds" to a given epitope would more likely bind to that epitope than to a related
epitope, even though such an antibody may cross-react with the related e.
An antibody is said to "competitively inhibit" binding of a reference antibody to a given
epitope if it preferentially binds to that e to the extent that it blocks, to some degree, binding of the
reference antibody to the epitope. Competitive inhibition may be determined by any method known in the
art, for example, competition ELISA assays. An antibody may be said to competitively inhibit g of
the reference antibody to a given epitope by at least 90%, at least 80%, at least 70%, at least 60%, or at
least 50%.
The phrase "substantially r," or "substantially the same", as used herein, denotes a
sufficiently high degree of similarity between two numeric values (generally one associated with an
dy of the invention and the other associated with a reference/comparator dy) such that one of
skill in the art would consider the difference between the two values to be of little or no ical and/or
statistical significance within the context of the biological characteristic ed by said values (e.g., Kd
values). The difference between said two values can be less than about 50%, less than about 40%, less
than about 30%, less than about 20%, or less than about 10% as a function of the value for the
reference/comparator antibody.
PCT/U82012/031648
_ 18 _
A ptide, antibody, polynucleotide, vector, cell, or composition which is "isolated" is a
polypeptide, antibody, polynucleotide, vector, cell, or composition which is in a form not found in nature.
Isolated polypeptides, antibodies, polynucleotides, vectors, cell or compositions e those which have
been d to a degree that they are no longer in a form in which they are found in nature. In some
ments, an antibody, polynucleotide, vector, cell, or composition which is isolated is substantially
pure.
As used herein, "substantially pure" refers to material which is at least 50% pure (i.e., free
from contaminants), at least 90% pure, at least 95% pure, at least 98% pure, or at least 99% pure.
The term "immunoconjugate" or "conjugate" as used herein refers to a nd or a
derivative thereof that is linked to a cell binding agent (i.e., an anti—CD37 antibody or fragment thereof)
and is defined by a generic formula: C—L-A, wherein C — cytotoxin, L = linker, and A = cell binding agent
or anti-CD37 antibody or antibody fragment. Immunoconjugates can also be defined by the generic
formula in reverse order: A-L-C.
A "linker" is any chemical moiety that is e of linking a compound, usually a drug, such
thereof in a ,
as a maytansinoid, to a cell-binding agent such as an anti CD37 antibody or a fragment
covalent manner. s can be susceptible to or be substantially resistant to acid—induced cleavage,
light—induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond
cleavage, at conditions under which the compound or the antibody remains . Suitable linkers are
well known in the art and include, for example, ide groups, thioether groups, acid labile groups,
photolabile , peptidase labile groups and esterase labile . Linkers also include charged
linkers, and hydrophilic forms thereof as described herein and know in the art.
The terms r" and "cancerous" refer to or describe the physiological condition in
mammals in which a tion of cells are characterized by unregulated cell growth. Examples of cancer
include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. "Tumor" and
"neoplasm" refer to one or more cells that result from ive cell growth or proliferation, either benign
(noncancerous) or malignant (cancerous) including pre-cancerous s. Examples of "cancer" or
"tumorigenic" diseases which can be treated and/or prevented include B-cell lymphomas including NHL,
B-cell neoplasms, such as B-cell chronic
precursor B—cell lymphoblastic leukemia/lymphoma and mature
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), B-cell phocytic leukemia,
lymphoplasmacytic lymphoma, mantle cell lymphoma (MCL), follicular lymphoma (FL), including low—
grade, intermediate—grade and high-grade FL, cutaneous follicle center lymphoma, marginal zone B-cell
lymphoma (MALT type, nodal and splenic type), hairy cell leukemia, e large B-cell ma,
Burkitt's lymphoma, plasmacytoma, plasma cell myeloma, post-transplant lymphoproliferative disorder,
and anaplastic large—cell lymphoma (ALCL). Non-cancerous cells are cells that do not result in the
, l9 -
formation of tumors or neoplasms or the pment of cancer. r, ncerous cells can
contribute to disease, e.g., autoimmune es, and include, for example auto-reactive B-cells.
The terms "cancer cell," "tumor cell," and grammatical equivalents refer to the total
population of cells d from a tumor or a pre-cancerous lesion, including both non-tumorigenic cells,
which comprise the bulk of the tumor cell population, and tumorigenic stem cells (cancer stem cells). As
used herein, the term “tumor cell” will be modified by the term "non-tumorigenic" when referring solely
to those tumor cells lacking the capacity to renew and differentiate to distinguish those tumor cells from
cancer stem cells.
The term "autoreactive" refers to a cell, tissue, protein, dy or other nce that
produces an immune response directed against an organism's own cells, tissues, proteins, antibodies, or
other substances.
The term "subject" refers to any animal (e.g., a mammal), ing, but not limited to
humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment.
Typically, the terms "subject" and n " are used interchangeably herein in reference to a human
subject.
Administration "in combination with" one or more farther therapeutic agents includes
simultaneous (concurrent) and consecutive administration in any order.
The term "pharmaceutical formulation" refers to a preparation which is in such form as to
permit the biological activity of the active ingredient to be effective, and which contains no additional
components which are ptably toxic to a subject to which the tbrrnulation would be administered.
The formulation can be sterile.
{0082] An "effective amount" of an antibody as disclosed herein is an amount sufficient to carry out
a cally stated e. An tive amount" can be determined empirically and in a routine
manner, in relation to the stated purpose.
“he term "therapeutically effective amount" refers to
an amount of an antibody or other drug
effective to "trea " a disease or disorder in a subject or mammal. In some embodiments, the
eutically effective amount of the drug can reduce the number of B-cells; reduce the number of
autoreactive B—cells; decrease the symptoms of disease; or slow the progression of disease. See the
definition herein of "treating". A "prophylactically effective amount" refers to an amount effective, at
dosages and for periods of time necessary, to e the desired prophylactic result. Typically but not
necessarily, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the
prophylactically ive amount will be less than the therapeutically effective amount.
The word "label" when used herein refers to a detectable compound or composition which is
conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. The label can be
W0 35740 PCT/U82012/031648
- 30 _
detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an tic label,
can catalyze chemical alteration of a substrate compound or composition which is detectable.
Terms such as "treating" or "treatment" or "to treat" or "alleviating" or "to alleviate" refer to
therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a diagnosed
pathologic condition or disorder. Thus, those in need of treatment include those already diagnosed with or
suspected of having the disorder. Prophylactic or preventative measures refer to therapeutic es that
prevent and/or slow the development of a targeted pathologic condition or disorder. Thus, those in need
of prophylactic or preventative es include those prone to have the disorder and those in whom the
er is to be ted. In n embodiments, a subject is successfully "treated" if the patient
shows one or more of the following: decreased B-cells; decreased autoreactive B—cells; decreased B-cell
activity; sed aberzant B-cell activity; decreased non-malignant B—cells, decreased non-cancerous B-
cells, reduced immunoglobulin level; reduced morbidity and mortality; improvement in y of life; or
some combination of effects.
"Polynucleotide," or "nucleic acid," as used interchangeably herein, refer to polymers of
nucleotides of any , and include DNA and RNA. The nucleotides can be deoxyribonucleotides,
ribonucleotides, d nucleotides or bases, and/or their analogs, or any substrate that can be
incorporated into a polymer by DNA or RNA polymerase. A cleotide can comprise modified
nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide
structure can be imparted before or after assembly of the polymer. The sequence of nucleotides can be
interrupted by non-nucleotide components. A polynucleotide can be further modified after
polymerization, such as by conjugation with a labeling component. Other types of modifications e,
for example, "caps", substitution of one or more of the naturally occurring nucleotides with an analog,
internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl
phosphonates, phosphotriesters, phosphoamidates, cabamates, etc.) and with charged linkages (e.g.,
phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example,
proteins (e.g., ses, toxins, antibodies, signal peptides, ply-L-lysine, etc.), those with intercalators
(e.g., acridine, psoralen, etc.), those ning chelators (e.g., metals, radioactive metals, boron, ive
metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids,
etc.), as well as unmodified forsns of the polynucleotide(s). Further, any of the hydroxyl groups ordinarily
present in the sugars can be replaced, for example, by phosphonate groups, phosphate , protected
by standard protecting groups, or activated to prepare additional linkages to additional nucleotides, or can
he conjugated to solid supports. The 5‘ and 3’ terminal 0H can be phosphorylated or tuted with
amines or organic capping group moieties of from l to 20 carbon atoms. Other hydroxyls can also be
derivatized to standard protecting groups. Polynnoleotides can also contain ous forms se or
deoxyrihose sugars that are generally known in the art, including, for example, ‘2’~O—niethyl—, Ziflnallyl,
W0 2012/135740 PCT/U82012/031648
_ 21 _
2'-fluoro- or do-ribose, carbocyclic sugar analogs, .alpha.-anomeiic sugars, epimeric sugars such as
arabinose, xyloses or s, pyranose sugars, furanose sugars, ptuloses, acyclic analogs and
abasic nucleoside analogs such as methyl riboside. One or more phosphodiester linkages can be ed
by alternative linking groups. These alternative linking groups include, but are not d to,
ments wherein phosphate is ed by P(O)S ("thioate"), P(S)S ("dithioate"), "(O)NR2
("amidate"), P(O)R, P(O)OR', CO or CH2 ("foranacetal"), in which each R or R' is independently H or
substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (-—O——) linkage, aryl, alkenyl,
cycloalkyl, cycloalkenyl or araldyl. Not all linkages in a polynucleotide need be identical. The preceding
description applies to all polynucleotides referred to herein, including RNA and DNA.
The term r" means a construct, which is capable of ring, and optionally
expressing, one or more gene(s) or sequence(s) of interest in a host cell. Examples of vectors include, but
are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmid, cosmid or phage
vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA
expression vectors ulated in liposomes, and certain eukaryotic cells, such as producer cells.
The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to
polymers of amino acids of any length. The polymer can be linear or branched, it can comprise modified
amino acids, and it can be upted by non-amino acids. The terms also encompass an amino acid
polymer that has been modified naturally or by intervention; for example, de bond formation,
glycosylation, lipidation, ation, phosphorylation, or any other manipulation or modification, such as
conjugation with a labeling component. Also included within the ion are, for example, polypeptides
ning one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as
well as other modifications known in the art. It is understood that, because the polypeptides of this
invention are based upon antibodies, in certain embodiments, the polypeptides can occur as single chains
or associated chains.
The terms "identical" or percent "identity" in the context of two or more nucleic acids or
polypeptides, refer to two or more sequences or subsequences that are the same or have a specified
percentage of nucleotides or amino acid residues that are the same, when compared and aligned
(introducing gaps, if necessary) for m correspondence, not considering any conservative amino
acid substitutions as part of the sequence identity. The percent ty can be measured using sequence
comparison re or algorithms or by visual inspection. Various algorithms and software are known in
the art that can be used to obtain alignments of amino acid or nucleotide sequences. One such non-
limiting example of a sequence alignment algorithm is the algorithm described in Karlin et al, 1990,
Proc. Natl. Acad. Sci, 87:2264-2268, as modified in Karlin et al., 1993, Proc. Natl. Acad. Sci, 90:5873-
5877, and incorporated into the NBLAST and XBLAST programs (Altschul et al., 1991, Nucleic Acids
Res, 25:33 89-3402). In certain embodiments, Gapped BLAST can be used as described in Altschul et al.,
W0 2012/135740 PCT/U82012/031648
_ 22 _
1997, Nucieic Acids Res. 89~3402. BLAST—2, \VLLBLASTLZL {Altschui et al., 1996, Memoirs in
Brigg/raraiogv, 266:460-430), ALIGN, ALIGNQ (Genentech, South San Francisco, California) or Megalign
{:DNAS’DXR) are onal publiciy available software programs that can be used to align sequences, In
certain embodiments, the percent identity between two nucleotide sequences is determined using the GAP
matrix and a gap weight of 40, 50, 60, 70, or
program in GCG software (e.g., using a NWSgapdnaCMP
90 and a length weight of l, 2, 3, 4, 5, or 6). In certain alternative embodiments, the GAP program in the
GCG re package, which incorporates the algorithm of Needleman and Wunsch (J. M0]. Biol.
44-453 (1970)) can be used to determine the percent identity between two amino acid sequences
(e.g., using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4
and a length weight of l, 2, 3, 4, 5). Alternatively, in certain ments, the percent ty between
nucleotide or amino acid sequences is determined using the algorithm of Myers and Miller S,
4:11-17 ). For example, the percent identity can be determined using the ALIGN program (version
2.0) and using a PAM120 with residue table, a gap length penalty of 12 and a gap penalty of 4.
Appropriate parameters for maximal alignment by particular alignment software can be determined by
one skilled in the art. In n embodiments, the default parameters of the alignment software are used.
In certain embodiments, the percentage identity “X” of a first amino acid sequence to a second sequence
amino acid is calculated as 100 x (Y/Z), where Y is the number of amino acid residues scored as identical
matches in the alignment of the first and second sequences (as aligned by visual inspection or a particular
of residues in the second ce. If the length
sequence alignment program) and Z is the total number
of a first sequence is longer than the second sequence, the percent identity of the first sequence to the
second sequence will be longer than the percent identity of the second sequence to the first sequence.
As a non-limiting example, whether any particular polynucleotide has a certain percentage
least 90% identical, and in some
sequence identity (e.g., is at least 80% identical, at least 85% identical, at
embodiments, at least 95%, 96%, 97%, 98%, or 99% cal) to a reference sequence can, in certain
embodiments, be determined using the Bestfit program (Wisconsin Sequence Analysis e, Version 8
for Unix, Genetics er Group, University Research Park, 575 Science Drive, Madison, WI 53711).
Bestfit uses the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:
482 489 (1981), to find the best segment of homology between two sequences. When using Bestfit or any
other sequence alignment program to determine whether a particular sequence is, for instance, 95%
identical to a reference sequence according to the present invention, the ters are set such that the
percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps
in homology of up to 5% of the total number of nucleotides in the nce ce are allowed.
In some embodiments, two nucleic acids or polypeptides of the invention are substantially
identical, meaning they have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, and in
some ments at least 95%, 96%, 97%, 98%, 99% nucleotide or amino acid residue identity, when
W0 2012/135740 PCT/U82012/031648
_ 23 _
compared and aligned for maximum correspondence, as measured using a sequence comparison thm
or by visual inspection. Identity can exist over a region of the sequences that is at least about 10, about
, about 40-60 residues in length or any irategral value etween, and can be over a longer region
than 60-80 residues, for example, at least about 90-100 residues, and in some embodiments, the sequences
are ntially identical over the full length of the sequences being compared, such as the coding region
of a nucleotide sequence for example.
A "conservative amino acid substitution" is one in which one amino acid e is replaced
with another amino acid residue having a similar side chain. Families of amino acid residues having
similar side chains have been defined in the art, irecluding basic side chains (e.g., lysine, arginine,
histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine,
asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine,
leucirge, isoleucine, proline, phenylalanine, methionine, phan), beta-branched side chains (e.g.,
threonine, , isoleucine) and ic side chains (e.g., tye‘osine, phenylalanine, tryptophan,
histidine). For example, substitution of a alanine for a tyrosine is a conservative substitution. In
some embodiments, conservative substitutions in the sequences of the polypeptides and antibodies of the
invention do not abrogate the g of the polypeptide or antibody containing the amino acid sequence,
to the antigen(s), i.e., the CD37 to which the polypeptide or antibody binds. s of identifying
nucleotide and amino acid conservative substitutions which do not eliminate antigen binding are well—
known in the art (see, e.g., Brummell et al., Biochem. 32: 1180-1 187 (1993); shi et al. Protein
Eng. 12(10):879—884 (1999); and Burks et al. Proc. Natl. Acad. Sci. USA 94:.412-417 (1997)).
As used in the present disclosure and claims, the singular forms "a," "an," and "the" include
plural forms unless the t clearly dictates otherwise.
It is understood that wherever ments are described herein with the language
“comprising,” ise analogous embodiments described in terms of “consisting of" and/or “consisting
essentially of’ are also provided.
The term "and/or" as used in a phrase such as "A and/or B" herein is intended to include both
"A and B," "A or B," "A," and "B." Likewise, the term "and/or" as used in a phrase such as "A, B, and/or
C" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or
B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
11. CD37 binding agents
The present invention provides agents that specifically bind CD37. These agents are referred
to herein as "CD37 binding agents." Exemplary inding agents have been described in US.
Published Application No. 2011/0256153, which is herein incorporated by reference in its ty.
The full-length amino acid sequences for human, macaca, and murine CD37 are known in the
art and also provided herein as represented by SEQ ID NOszl—3, respectively.
W0 2012/135740 PCT/U82012/031648
Human CD3 7:
MSAQESCLSLIKYFLFVFNLFFFVLGSLIFCFGIWILIDKTSFVSFVGLAFVPLQIWSKVL
AISGIFTMGIALLGCVGALKELRCLLGLYFGMELLLFATQITLGILISTQRAQLERSLRDVVEKII'IQ
KYGTNPEETAAEESWDYVQFQLRCCGWHYPQDWFQVLILRGNGSEAHRVPCSCYNLSATNDSTI
LDKVILPQLSRLGHLARSRHSADICAVPAESHIYREGCAQGLQKWLHNNLISIVGICLGVGLLELG
FMTLSIFLCRNLDHVYNRLAYR (SEQ ID N031)
] Macaca mulatta CD37:
MSAQESCLSLIKYFLFVFNLFFFVILGSLIFCFGIWILIDKTSFVSFVGLAFVi’LQIWSKV
LAISGVFTMGLALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRAQLERSLQDIVEKTI
QRYHTNPEETAAEESWDYVQFQLRCCGWHSPQDWFQVLTLRGNGSEAHRVPCSCYNLSATNDS
TILDKVILPQLSRLGQLARSRHSTDICAVPANSHIYREGCARSLQKWLHNNLISIVGICLGVGLLEL
GFMTLSIFLCRNLDHVYNRLRYR (SEQ ID NO:2)
Murine CD37 (NP_031671):
MSAQESCLSLIKYFLFVFNLFFFVLGGLIFCFGTWILIDKTSFVSFVGLSFVPLQTWSKV
LAVSGVLTMALALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRVRLERRVQELVLR
TIQSYRTNPDETAAEESWDYAQFQLRCCGWQSPRDWNKAQMLKANESEEPFVPCSCYNSTATN
DSTVFDKLFFSQLSRLGPRAKLRQTADICALPAKAHIYREGCAQSLQKWLHNNIISIVGICLGVGL
LELGFMTLSIFLCRNLDHVYDRLARYR (SEQ ID N023)
In n ments, the CD37 binding agents are antibodies, immunoconjugates or
polypeptides. In some embodiments, the CD37 binding agents are humanized antibodies.
In certain ments, the CD37-binding agents are capable of inducing complement
dependent cytotoxicity, Examples of CD37-binding agents that are capable of inducing complement
dependent cytotoxicy are disclosed, for example, in US. Published Application No. 2011/0256153, which
is herein orated by reference in its entirety. For example, treatment of cells with the CD37—binding
agents can result in CDC activity that reduces cell viability to less than about 80%, less than about 70%,
less than about 60%, less than about 50%, less than about 40% or less than about 35% of the cell viability
of untreated cells. Treatment of cells with the CD37—binding agents can also result in CDC ty that
reduces cell viability to about 70-80%, about 60—70%, about 50—60%, about 40—50%, or about 30-40% of
the cell Viability of untreated cells. In some particular embodiments, the CD37-binding agents are capable
of inducing complement ent cytotoxicity in Ramos cells.
In certain embodiments, the CD3 7-binding agents are capable of inducing antibody dependent
cell mediated cytotoxicity . Examples of CD-37 binding agents that are capable of inducing
antibody dependent cell mediated cytotoxicity (ADCC) are disclosed, for example, in US. Published
Application No. 2011/0256153, which is herein incorporated by reference in its entirety. For example,
treatment of cells with the inding agents can result in ADCC activity that produces at least about
W0 2012/135740 PCT/U82012/031648
.. 25 -
%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at
least about 45%, at least about 50%, or at least about 60% cell lysis. Treatment of cells with the CD37-
binding agents can result in ADCC activity that produces about 10-20%, about 20—30%, about , or
about 40-50% cell lysis. Treatment of cells with the CD37-binding agents can also result in ADCC
activity that produces about lO—50%, about 20-50%, about 30-50%, or about 40-50% cell lysis. In some
particular ments, the CD37-binding agents are e of ng ADCC in Daudi, Ramos,
and/or Granata—S 19 cells.
In some embodiments, the CD37—binding agents are capable of inducing apoptosis. In some
embodiment, the CD37—binding agents are capable of ng apoptosis in the absence of linking
agents. Examples of CD37—binding agents that are e of inducing apoptosis in vitro in the absence
of a cross—linking agent are disclosed, for example, in US. Published Application No. 2011/0256153,
which is herein incorporated by reference in its entirety. For example, treatment of cells with the CD37-
binding agents can induce apoptosis in at least about 15%, at least about 20%, at least about 25%, at least
about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about
55% of cells. In some particular embodiments, the CD37-binding agents are capable of inducing
apoptosis in Ramos cells and/or Raji cells.
In some embodiments, the CD37-binding agents are capable of depleting B—cells. In some
embodiments, the B-cells are autoreactive B-cells. In some embodiments, the B—cells are not cancer cells.
In some embodiments, the B—cells are not turner cells. In same embodiments, the B-cells are not
ous cells, In some embodiments, the B—cells overexpress C1337. In some ments, the B—
cells do not press CD37.
Treatment of cells with CD37-binding agents can result in depletion of at least about 25%, at
least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least
about 55%, at least about 60%, at least about 65%, at least about 70%, or least about 75% of B—cells.
In some embodiments, the CD37-binding agents do not deplete T—cells under the same
conditions in which B—cells are depleted. For example, treatment of cells with CD37—binding agents can
result in depletion of less than about 20%, less than about 15%, less than about 10%, or less than about
% of T-cells. In certain embodiments, the CD37-binding agents deplete at least about 25% of B—cells
and e less than about 10% of T-cells. In certain embodiments, the CD37—binding agents deplete at
least about 30% of B—cells and deplete less than about 5% of T—cells.
In some embodiments, the CD37-binding agents do not deplete monocytes under the same
conditions in which B-cells are depleted. For example, treatment of cells with CD37-binding agents can
result in depletion of less than about 20%, less than about 15%, less than about 10%, or less than about
% of monocytes. In certain embodiments, the CD37-binding agents deplete at least about 25% of B-cells
W0 2012/135740
_ 26 _
and deplete less than about 10% of monocytes. In certain embodiments, the CD37—binding agents deplete
at least about 30% of B-cells and deplete less than about 5% of tes.
In certain embodiments, immunoconjugates or other agents that specifically bind human
CD37 trigger cell death via a cytotoxic agent. For example, in certain embodiments, an antibody to
human CD37 is conjugated to a maytansinoid that is activated in cells expressing the CD37 by protein
internalization. In certain alternative embodiments, the agent or dy is not conjugated to a
maytansinoid or other cytotoxic molecule.
The CD37-binding agents include CD37 antibodies such as CD37-3, 2, CD37-38,
CD37-50, CD37-51, CD37—56 and CD37-57 and fragments, ts and derivatives thereof. The CD37-
binding agents also include CD37-binding agents that cally bind to the same CD37 epitope as an
antibody selected from the group consisting of CD37-3, CD37—12, CD37—38, CD37—50, CD37—51, CD37-
56 and 7. The CD37-binding agents also include CD37-binding agents that competitively inhibit
an antibody selected from the group consisting of CD37-3, CD37-l2, CD37-38, CD37-50, 1,
CD37—56 and CD37-57.
In some particular embodiments, CD3 7-binding agents can be characterized by their ability to
bind chimeric CD37 polypeptides, including /human and macaca/human chimeric polypeptides
desribed in US Published Application No. 2011/0256153, which is herein incorporated by reference in
its entirety, and provided in the table below.
Chimeric Sequence
EPoly-
3 MSAQESCLSLIKYFLFVFNLFFFVLGSLIFCFGIWILIDKTSFVSFVGLAFVPLQIWSKV
;hCD37—
M1 LAISGIFTMGIALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRVRLERRV
TIQSYRTNPDETAAEESWDYVQFQLRCCGWHYPQDWFQVLILRGNGSEAH
RVPCSCYNLSATNDSTILDKVILPQLSRLGHLARSRHSADICAVPAESHIYREGCAQGL
QKWLHNNLISIVGICLGVGLLELGFMTLSIFLCRNLDHVYNRLARYR (SEQ ID 5
i; i NO. 184)
imuCD37-NEISTQRVRLERRVQELVLRTIQSYRTNPDETAAEESWDYAQFQLRCCGWQSPRDWNK
R176 AQMLKANESEEPRVPCSCYNSTATNDSTVFDKLFFSQLSRLGPRAKLRQTADICALPA
SKAHIYREGCAQSLQ(sEQID No1851 A
hCD37— SCLSLIKYFLFVFNLFFFVLGSLIFCFGIWILIDKTSFVSFVGLAFVPLQIWSKV
M45 LAISGIFTMGIALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRAQLERSLRi
5DVVEKTIQKYGTNPEETAABESWDYVQFQLRCCGWHYPQDWQVLILRGNGSEAH ;
RVPCSCYNLSATNDSTILDKVILPQLSRLGPRAKLRQTADICALPAKAHIYREGCAQS 1
LQKWLHNNLISIVGICLGVGLLELGFMTLSIFLCRNLDHVYNRLARYR (SEQ ID
1M1qu1861 M 5
hCD37m MSAQESCLSLIKYFLFVFNLFFFVLGSLIFCFGIWILIDKTSFVSFVGLAFVPLQIWSKV
ECD- FTMGIALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRVRLERRV
H45 QELVLRTIQSYRTNPDETAAEESWDYAQFQLRCCGWQSPRDWNKAQMLKANESEEP
YNSTATNDSTVFDKLFFSQLSRLGHLARSRHSADICAVPAESHIYREGCAQG 1
LQKWHNNLI$1vGICLGVGLLELGFMTLSIFLCRNLDHVYNRLARYR (SEQ ID N0: =
s 1871A AA
hCD37m MSAQESCLSLIKYFLFVNLFFFVLGSLIFCFGIWILIDKTSFVSFVGLAFVPLQIWSKV ;
;‘ECD—H5 LAISGIFTVIGIALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRVRLERth
“27.
W;—IQVELVLRTIQSYRTNPDETAAEESWDYAQFQLRCCGWQSPRDWNKAQMLKANESEEP
RVPCSCYNSTATNDSTVFDKLFFSQLSRLGPRAKLRQTADICAVPAESHIY’REGCAQG
NNLISIVGICLGVGLLELG’FMTLSIFLCRNLDHVYNRLARYR (SEQ ID NO:
;188)
’ hCD37H“;MsAQESCLSLIKYFLFVFNLFFFVLGSLIFCFGIWILIDKTSFVSFVGLAFVPLQIWSKV
ECD-H4 LAISGIFTMGIALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRVRLERRV s
QELVLRTIQSYRTNPDETAAEESWDYAQFQLRCCGWQSPRDWNKAQMLKANESEEPCE
RVPCSCYNSTATNDSTVFDKLFFSQLSRLGHLARSRHSADICALPAKAHIYREGCAQS
LQKWLHNNLISIVGICLGVGLLELGFMTLSIFLCRNLDHVYNRLARYR (SEQ ID NO:
;189)
'iiémné‘i‘lw';MsAQESCLSLIKYFLFVFNLFFFVLWIWILIDKTSFVSFVGLAFVPLQIWSKV
Mac4 LAISGIFTMGIALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRAQLERSLR:
DVVEKTIQKYGTNPEETAAEESWDYVQFQLRCCGWHYPQDWFQVLILRGNGSEAH
RVPCSCYNLSATNDSTILDKVILPQLSRLGQLARSRHSTDICAVPAESHIYREGCAQGL
QKWLHNNLISIVGICLGVGLLELGFMTLSIFLCRNLDHVYNRLARYR (SEQ ID NO:
M3045 LAISGIFTMGIALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRAQLERSLR;
DVVEKTIQKYGTNPEETAAEESWDYVQFQLRCCGWHYPQDWFQVLILRGNGSEAH 5
'5RVPCSCYNLSATNDSTILDKVILPQLSRLGQLARSRHSTDICAVPANSHIYREGCARSLj
hCD37— ;MSAQESCLSLIKYFLFVFNLFFFVLGSLIFCFGIWILIDKTSFVSFVGLAFVPLQIWSKV
MacS LAISGIFTMGIALLGCVGALKELRCLLGLYFGMLLLLFATQITLGILISTQRAQLERSLR.
;DVVEKTIQKYGTNPEETAAEESWDYVQFQLRCCGWHYPQDWFQVLILRGNGSEAH ;
RVPCSCYNLSATNDSTILDKVILPQLSRLGHLARSRHSADICAVPANSHIYREGCARSL;
QKWLHNNLISIVGICLGVGLLELGFMTLSIFLCRNLDHVYNRLARYR (SEQ ID NO: '
192)
In some particular embodiments, the binding of the CD37-binding agents to CD37 does not
require human CD37 amino acids 109-138. Thus, some inding agents bind to a polypeptide
comprising the amino acid sequence of SEQ ID NO:184. In other embodiments, the binding of the CD37—
binding agents to CD37 is disrupted by mutation of human CD37 amino acids 202—243. Thus, some
CD37—binding agents do not bind to a polypeptide comprising the amino acid sequence of SEQ ID
NO:185.
In some embodiments, the CD37-binding agents bind to a ptide of SEQ ID NO:184
and to a polypeptide of SEQ ID NO:186, but do not bind to a polypeptide of SEQ ID NO:185.
In some embodiments, the CD37—binding agents bind to a polypeptide of SEQ ID NO: I 87. In
some embodiments, the CD37-binding agents bind to a polypeptide of SEQ ID NO:187 and a polypeptide
of SEQ ID NO:l88. In some embodiments, the CD37—binding agents bind to a polypeptide of SEQ ID
NO:187 and a polypeptide of SEQ ID NO:1 89.
In some embodiments, the CD37-binding agent binds to a polypeptide of SEQ ID ,
but does not bind to a ptide of SEQ ID NOzl9l. In some ments, the CD37—binding agent
binds to a ptide of SEQ ID N02192, but does not bind to a polypeptide of SEQ ID NOzl9l.
W0 20127135740 PCT/U82012/031648
_ 28 _
{1311119} CD37 peptide fragments to which certain {JEN-binding agents bind to include, but are not
11511111511 to, CD37 fragments ccmprising, ccnsisting essentiafiy Of, 01 consisting ot‘aminc acids 2004243 Qt"
SEQ 173 NO: 5 amino acids 2132142213 or SEQ H3 NO:5, or amino acids 2216343 of SEQ 1‘13 N131. in
some embot11nen1‘» the £133Lbinding agent is specfin(1111/ binds to :21 1111111311 C1337 epitQpe (50111151131111:
amino acids 2029.43 of SEQ ‘13:? N13], In some embodiments, the binding, of the 13133 7—15111d1ng agent 10
CD37 requires 1111511115 acids 2132243 of SEQ ID ‘NO:1 1n scme embodiments, the binding 01': the (31337,-
15111111119, agen1 111 CD37 es amine acids 2013—2213 0.1“ SEQ 1D 750:1. In some e1nbnd1n1en1s, the
binding 15tts1e CD37~55111111ng event to (31133 7 requires 1111111115 acids 221-243 Qf SEQ H3 NO:1.
11331213} es of CD37~b1ndit1gagents with the afctementioned ng prnperties are desctibed
in US. Publiszmd Application No. 201 170256153, which1s herein incorpersted by reference111 11s entirety.
113131211 The C1D37~b1nding agents also finciude (SEW—binding events that comprise the heavy and
119,111 chain CDR sequences of CD373, 131337—12, {1337,68 CD37—513,C1‘337«55 €1337~56 or {7133757,
71113111131157 and fight chain CDRS of CD3 7~3 8, {3337513, 151337—51, 13133766 and (33.1767 1501513111 related
sequences T11e1efcre, the €1.33 7—151111111157, agents can 111515 comprise heavy and .11 ght chain CDR sequences
151211 cemprise a consensus sequence Obtained by ‘the alignment of CI.3'.37~58, (3.133760 C133751, CD37~
56 and (71337—57. The CDR ces of CD373, (353317—12, (311337—38, (35337513 CD 75'1, {75337-56L1.)
and C133”,57 as weli as 15.11: sus sequence 01 , CD3750 (£337—51, 131337-56 and C1337
57 ate (1153151151511 111 Tatfies 1 and 2 beiow.
Table 1: Variable heavy chain CDR amino acid sequences
“ """
Anuboch E 5711611111 1 _11533... YHCDR3
C15373 new (sEQ 1‘15“ 1:1111‘1‘1‘15153511 {SEQ 1D GGYSLAH (“S‘EQ 11‘5‘‘N‘Q‘-6)
2 E 1115mm {s1Q115 ESR61.15 115 13557171115 (15191511551159)
N15.3.3 N5351‘). E
.....
CD37—38 117115115‘1‘15 111576.1111115 1:11:15 1‘15““ 5 GYYGYGAWFVY (SEQ ID
3505.55.3. .
..... 515%“.--
CD37—50 5 51117111111 (SEQ 1D 161LYst11'1s11Q1‘1‘5‘“ GYYGYGAWFAY (SEQ 115‘
5 \014:1 :NQ--55.)-.-
CD3751 11711 (sEQ1D““51111?8115"1\1 (151715“1‘15GYYGFGAWFVY ~(‘S‘E‘Q‘1‘55““
N151.6) \Q1”) N018)
CD3756W1(SEQ 1D GYYGFGAWFAY (‘S‘EQn5“
_m NO2.5.).
CD37-57 3151‘Aw1-1(sEQ1D GYYGYGAWFAY (SEQ ID
CONSENSUS sQEEA or (5111711 1 _ 61 1115? S15E15 151EGYYG[Y or FjGAWF[V or
{8.1513113 NQ25);:115115V01” N} (SEQ 1.1.5 :AEY. (SEQ ID NO27)
##LNQ;2.65- .....
5252-5 *SYGMS (SEQ ID WEPDWEQ .HSYYDTSVDY
NQ571). 1.1 -_
..-..#W1 _ 5--(_S__EQIDNQ173)
252-3 SYQMS (SEQ ID 1 1 HSYYDTSVDY (SEQ ID
Table 2: Variable light chain CDR amino acid sequences
Antlbod VLCDRI VLSD" "I:YLCDR3
CD37-3 ASINIRSNIA “SEQ YATNLAD ISILQ III") QHYWGTTWT (SEQID
“ EN:O30)A
A NQ:2__9__)__ 77777777
CD37-12 RASQ‘SVSTSSYSYEY3 YASNLAS (SIQ II) QHSWEIPYT (SEQID
NQ:”A.»AAAIAAAAAA} A
___________________________________________(SEQID AAAA__WEN033)
38 5 II")
.I ASSSVTYIVIII (SEQ
, E QQWISNPPT(SEQID
I II) NQ:AA3A/1IA)AA 0:35) ENQ:AA3__6__)AAAAA _
"" ,,
ICD37-50SSM VTY\«INISLQNTKIPY ISFQ II)“"""""E QQWSDNPPT (SEQ IDA
1 HINDI“ 14% 2‘039),,
IHumanized
;DISNIPY ISEQID
322 ,,,,,, WWI
__I__w ‘
CD37-51 SA’I‘SSVI‘YVIHISEQDISKLASISEQID
IDN04III ND4") ":EQQWSSNPPT (SEQ IDN043_)_MI
iCD37—56 I’SASSSVYMHISTQ SI). QQWISDPPT(SEQID ;
Humanwr‘d
S (SEQ II")
N047) mew
_MM 77777
CD37—57 SAISSVTY‘EIII ISEQ DISNLAS ISIQI33
. EQQWSDNPPT (SEQ ID
I EDNDIIEILIMI ND49).. MIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII,
Iiumanized
DT‘SNL"\S ISEQ ID
CONSENSUS SA["T""o"; S]SSVTYMHNTS=K Qr NELIii0} 1le QQW[1 or S][S or D][N or
(SEQIDNAQ:52} III AYI(SEQ IQN0: 513 DPPT (SEQ AIADAANQ:_54I
252-3 RASQDISNYLN (SEQ;Y1%:me Ing If)? QQGNALPWT(SEQID
IDNQ:III1I7II4)_MNDWINO 176)
The CD37 binding molecules can be antibodies or antigen binding fragments that cally
bind to CD37 that comprise the CDRs of CD37-3, CD37-12, 0, CD37—51, CD37—56, or CD37—57
with up to four (i.e., 0, l, 2, 3, or 4) conservative amino acid substitutions per CDR.
The CD37 binding molecules can comprise one of the individual variable light chains or
variable heavy chains described herein. Antibodies and polypeptides can also comprise both a variable
light chain and a variable heavy chain. The variable light chain and variable heavy chain sequences of
murine, ic, and humanized CD37-3, CD37-12, 0, CD37-51, CD37-56, and CD37-57
antibodies are provided in Tables 3 and 4 below.
TabIe 3: VariabIe heavy chain amino acid sequences
Antlbody WAmmo SQ ID NO)
IIIIIIIII
muCD37-3 Q‘vQ‘s!KESGPGINAPSQSLSI‘CI ‘v SLIP SIIII I SIIVS‘WVRQI’PGKGLEWLGVIW
wUDUSAIANYHMSIKKDIISIISQVILIxLNSIAQIAAIIIIIAAA'AIYYCAISGIAsYSIIIAIAAAAAA
WE 11WGQG 8.8I888A{S10113N13888 E
E QVQVNLNAAAYAPSQS1 SITLT‘VSG1'8'1II11‘8GV‘8‘8‘8’\71813P?18K8818‘88; .
E GDGSTNY1-1SALKSRL8118.881AHQKSQ‘VFLKLVNUQ11313.1‘1581‘88CAKGGY’8.8.A
E111181101511VTV11183111) .88.) NQ.5111 -1
huCD3W '11
E GGG88N8I88888888888818.88888828SQVFLKLN88..LAAG8‘A8‘8-Y.CANGGY‘88...AQVQVQESGWN7V’APSQTLS11CTVNGFSL188GV888I8I8Q8>8>818888888888G8I'8'18I'.‘
E 8888GQG888/88/88{88G113N1388 II)
huCD373v1 .1 EQIvG8/Q838GPGL8IAP8Q8 I S1‘1CTVSGFSL1TSG‘VSY‘JVRQPPGMN1:888(88888..
E C8DGSTNYHSSLKSRLSEK.88.88888808888888NSLTAADI8‘A‘I8‘88I8:AKGGYSE.A
E 11‘8‘8'11131111V8888 {SEQ113NQ588
muCD3712 E QRYLV'Q‘GPELKKE‘GE8828888.SGYTFTKYKAG888W‘s/111211018181818<8888G
88I888NI8IG8:88<.\8888888888A8881'88A8I8A8I8Q88N888E1331“A8Y’FC’GRGTv
E VAG88I888.88888888888888288:8 N0.593
78161371732 1311YLVQSL11311KK1’181E I‘VKISCK88888888888888888NI8I8<QAQ888888KWMG
88I888NI8‘G8388.\8888888888A8888‘88A8I8‘A8ILQ88NLN888:88A8YESGNGIE‘vI
VAD'WUOGTTL1'V651‘81‘Q1.7.173 NQ 6888
‘muCD37WD8IG8Q888G8>8>88888388288SLTCTVTGYS11SG1G‘8‘8IHW1RQ1PCIK181FW‘xEIYY
88.8SGG1D‘Y‘NPS1KSR1S11RDT8K‘NQFFLRL‘8‘8V188-888A8‘8Y1A81888IG8GE.
E__A8888I888GQG88.8I8-8Ag88Q188NG:11.11. .....
Q'ESCii‘1)1.\71\1‘S172SLSLTLTV'8'G'8I8.81S18118WHW1RQ1PGTNKLEWV111'8""
G11'3Y‘N1‘S1KSR1S1TRDTSK‘NQ111R1SSV1”113131,.581YY1-ARGYYGYG
AWFY’YW '7 1"\ISA (SFQ 113N13: 13‘) E
hu7CD37-38 Q888888.Y1.888883888888.8‘8I8G8 88'818718118118HWERQTPA88888888888888
LYSGGFDY’NPSIRS181S1TR13TS18NQ1TLRLSS‘VIL\131A1YY1‘ARGYYGYG
WGQG1L "7 ‘
7711111513§Y1750 888Q8828881IW~ .
1YSGSTVYSPSLKSRlS11'RD1'SKNHFFLQLNSV1113131A1'YY’1‘A1118YY(1Y1:
1.A.WEAYYVGQGTLY’TVA (SEQ 1.1.3 N13643 .
huCD3750 OYIQLOESAJ’GLLRRSQ‘AS1'1'CY7‘VSGYSITSG1AWHWERQHPGRKE..... .8
1.1.YSGST‘vY’SPSLKSRIS1”1RDTSKNHP1:1.Q1.NSVTAADTATYY”CARGY’YGYG
ANY/1*AY’W1NY1zTLYTVSAgSEQ11318065)
“““““““““““
huCD3751 .. IQ8.VFSGPEVLKPG1:88.81'88: “81">SG1"YYY11YY’1R01PGRGLE‘WRAG'Y};
HYSCxSTNYbPSLQGRISI11113881181314808N88I8A8838AI8888ARGYYGEGA
E8888I8I88IGQ88888888188A 13131:? 888 No67 EEEEEEE
muCD3756 DVQLE‘ESGPDLVKPSOSES1.'8'GI1‘8'I"8G8I88I8‘8C8A88I888888Q8~1"(J\K18 88-88888
E (YAW‘8.A8EW880G888-11‘"8A888G11.3 N88 68)8888SQGTNY’TNPSLKSRVS11111.71.SNNQ811.QLNS‘VTTEDTATYYCARGYYGF -
huCD3756 QVQLQESGFGLVK1’S13S1S1.”:11'1VS18Y’S1T‘8181'A‘818’11W1RQF"GKG11‘?88888888
HYSGGTNYNPSLKSRV81111111810811“:8‘8.Q8.NS‘JTAADTATYY 8::ARGY’YG8‘
GAVE-8A8 88888888888888A ‘88 111180 889)
muCD3757E1‘1VQLQJ}.8G883888888888888'8..I88i'8I17I'1CY8888;.YFAWHWIRQE88888888:W7881888
E LYSGS.1VYSPSIKSR1S1TRD1'S1LNQ1‘1IL131.NSV11'1113TATYY1,I'YRGYYGYG
1DN13I111 ‘
:- Y‘vijI‘xYWGOGNVFYSAESFQ ..
huCD3'1'l75'7""""""""' SGP1Y181.K1‘SQSISLTC1Y1S18Y S11"»G1IAW11‘8‘8’1RQF1318188:6771.FYY’MGYI'
LYSGSFIS‘JY13881811SK1S11RDTS18NQFFLQLNSV1'AAD11A1.YY’CARGYY(1‘11:
EVQ‘V 777712717. . .77 FSSY1xY1S‘V8’Y’RQ11’11KR11YV’VA11
SSGGSYTYSPDSV181811.?11‘81813\AKK1'1.Y1.QMSSLKSEDTAMYYCARii-SYY’
_ 31 _
Table 4: Variable light chain amino acid sequences
““““:Q
1body“““‘“““““m“““““““““““““““““““““““““““““““““““““V1:1A1?)“11:11.1 {$.91} 11.“) N13) “V—‘EE“
muCD37-31D1QMIQS1’AS1EVSVAaFT‘YTE1‘L1111erN115:SNLAWYQQKQGKNPQLL‘YNYA1
1N1.ADGVFSRFSG‘YAYQIA1TQYSLKINSLQSE13F(11YYCQHYWAJTTWTEGGG115
1......
chCD°73 .. 71111.1LA511511:5151A5Y'QQKQLK5FQLLYNYA1
1'NLA1513YF5515551151.sTQ'Y5LK1N5LQ5F1::"1Fc11YYCQEWWGTTW111311511211
LUKRLSEQ 111110.73) Es
huCD37—3 11115511115115 1..5Y<YL:1'KY'1'11L'KANLN . . ANYQQKFQK5FKL1YNYA1
(1.0 and 1.1) :NLADQYIFKKF'5L15Q5QYDY5LK1N5LQFF55FL1'1YYL'Q:1YYY11115711111151.:1'K
Q117% 1
muCD37-12 :151Y11Q5FA51AY'5LL:QK-A115L'KANQ5 '5Y5YLYYY YEKFQQF T
1YA5N1A5<AIFAKF5LI56501151'1'LN1F1FY .;:1:~.F151A'1YY'CQF15WF1FY“1171.11.16 1
'1'KLL1KKE:5FQ 11.5%N15“75.5.?
chcfi3“7“2““1“2““““““““““““““““§1.51571,1Q5FA5LAYSLLIQLLA1151KA5Q5Y'5'155Y5YLYYYYQQNFGQPPKU1K
51YASN1ASGYPAR¥5135135L11'1511'1.N111FV11'11YTAYYY'LQ115YYF1FY'1'FL1L1L‘1
11\U'11\R 151531131???75>...-
muCD37—38 “: Qi‘vi1Q5FA1NI5A5FIILKY'11511135A555YI'TY'N111YYYQQK5L1'1'5FKK5Y'1Y15'15
KLA5QY'FAKF5GGL:51:15Y 51:11SSMFA1111AA1Y’Y’CQQYY15N'FF'1'FL1<1Q'1'KL
8151515175} 11.311017.11w 77777
chCD37—3 8 QW11QQ§PA1MSASPLYENV1N11L5A555Y'1YY111YY'YQQK511“1'5FKKYY1Y15“1'5
15LASGVFAK1\(YGC1‘5L1TSYSLIIS'SMAF1“)AATYYCQQWISNPF“FF(581.11K1
FEAR {<LQ115E5075)
huCD37—38 “:“151571'1QYFA5515A5FGLKY'151“1“E“5A555Y1YN2111YYYQQKT’LYT<FKKYY1YQ1“5“"
1 :KL:A5L1YF.IAKF5L15<I5L1.155515155511;.AEDAA1Y7YLQQYY5NFF1'FLK1L11K1.
11?1.15.11 15LQ 115 NOE'EIjFE
muCD37—50 1151531.“1QYFA1515A FL“ .KY1Y11L5A155171Y“511151:YQQK5LYT5FKKYAILY““1515““
1K1.FYGYFL1111'5L15<I5L115Y5L11551113.IA515AA'1YYLQQYY515NFF1FG<1Q1KL
1.1:1KK15LQ 115 N0.5155
: huCD37—50 1'157L1QSPA11Y1‘5A‘5PG1KY515111:5.75.1555;1Y5I1HYYYQQKFQQYFKKYYLY155'“5““
1:‘NLFYL1Y'FAKF5551.1551'SYSLTISSMEAEDAA1YYLQQ55511NFF1FGQL11'KL' KKY51'Q115 NQ51) 1
huCD37
KLASGYFAKF5115mm15Y'51.11<5MLIALLYIAA1'YYLQQYY55NFFTFQQQYKL. E
515(51:15 115 : _ EEE:
muCD37—56“(11511511281311515A5FLI15KYTN11L5:A555Y1Y. . 'QQNZSGTSPKRWE‘Y’D’I’S
i VPARFSGGGSG1SYS11155;515:5115IAA'1'YY'L:QQW1515FF'1‘FL113GTKL
<51'Q 11::N15 54)
MM£115.15DIVLTQSPAFMSIANPLY‘FKV115111..5715555151MLNYYQQK1>15Q5FKKYY1Y1515EE
huCD37—56
A5QYI'F5K1511QLY5Q1'15Y51115515111A515AA'1YYCQQW1515FF111:1st1KL
L1KK :55Q- 115N133...“1
$511511.“5.’“51.3 ‘~“}1.“le Q15711QS1’A1‘Y1SASPL3EKY1511'L 5““1115557Y1V111AA’YQDKNG'1'5FAFYY1Y“151““5““ g
KLASGYFAKF<1:51156155'5LT155Y1YIA515AA1YYLQQYA'5155FF1FL15L11K1:
1311513190115 N0256
huCD37_.57.::““
W0 2012/135740 2012/031648
_ 32 _
________________________________ NLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSDNPPTFGQGTKL
MINEIKR(SEQ ID NO:872
7777777
252—3 TTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTS
i 3KLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNALPWTFGGGTKL
ELISEQEQ112N9111§>m \\“\V_‘.“I....u.uu.........w......_______...r.r.\\
Also ed are polypeptides that comprise: (a) a polypeptide having at least about 90%
sequence ty to SEQ ID NOsz55—7l or 177; and/or (b) a polypeptide having at least about 90%
sequence identity to SEQ ID NOs:72-87 or 178. In certain embodiments, the polypeptide comprises a
polypeptide having at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at
least about 99% sequence identity to SEQ ID NOS:55-87, 177, or 178. Thus, in cettain embodiments, the
polypeptide comprises (a) a polypeptide having at least about 95% sequence identity to SEQ ID NOsz55—
71 or 177, and/or (b) a polypeptide having at least about 95% sequence identity to SEQ ID NOsz72-87 or
178. In certain embodiments, the polypeptide ses (a) a polypeptide having the amino acid
sequence of SEQ ID NOs:55-71 or 177; and/or (b) a ptide having the amino acid sequence of SEQ
ID NOs:72-87 or 178. In certain embodiments, the polypeptide is an antibody and/or the polypeptide
specifically binds CD37. In certain embodiments, the polypeptide is a murine, chimeric, or humanized
antibody that specifically binds CD37. In certain embodiments, the polypeptide having a certain
percentage of sequence identity to SEQ ID NOss55—87, 177, or 178 differs from SEQ ID NOsz55-87 by
conservative amino acid substitutions only.
Polypeptides can se one of the individual light chains or heavy chains described herein.
Antibodies and ptides can also comprise both a light chain and a heavy chain. The light chain and
variable chain ces of murine, chimeric, and humanized CD37—3, CD37—12, CD37-50, CD37-51,
CD37-56, and CD3 7—57 antibodies are ed in Tables 5 and 6 below.
Table 5: Full-length heavy chain amino acid sequences
“but.............,,."______
Ant1bodx \ FullLenvth Heav» Chain AmmoAcidSequence(SEQ IDNO) \
,,muCD37—3
i QVQVKESGPGLVAPSQSLSITC‘VSGFSLTTSGVSWVRQPPGKGLEWLGVIW
: GDGSTNYHSALKSRLSIKKDHSKSQVFLKLNSLQTDDTATYYCAKGGYSLA
HWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTL
TWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTK
PRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVV
. DVSEDDPDVQISWFVNNVEVHTAQTQTEREDYNSTLRVVSALPIQHQDWM
SGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLT
CMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKN
WVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ IDNO:88)
§ chCD37—3 QVQVKESGPGLVAPSQSLSITCTVSGFSLTTSGVSWVRQPPGKGLEWLGVIW
GDGSTNYHSALKSRLSIKKDHSKSQVFLKLNSLQTDDTATYYCAKGGYSLA
HWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS
EWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
E EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
E WDVSHEDPEVKFNWWDGVEVHNAKTKPREEQYNSTYRWSVLTVLHL
TKEYKTTYVSNKATPAT’TTKTTSKAKT:QT’TETT’QVYTT.TTESRDETTKNQ T
VSTTCT.VKCYTY’PSDTAVEVV’T‘S\TYQETNNYKTTT’T‘VLDSDQSTTLY’SKTTVDKT
‘ ‘TQKSTSTST’EIK YSTQ TD NQ:S9) T
I"Hfiéfié'i'i'fiV‘TBT QVQV’. TTSLYVSVVVKQPEUKLYTEVVTUVTVV
. VSGEST
, . T
GTTGSTNYTTPSLKSRLSTKKDTTSKSQV4TKT.NSTTT\ADTATYYCAKEEYYSEA
HVVT.IQEYTTVTVSSIVSTKGESVTFEAT’SSKSTSGQTAATETCLVKDYiPEPVTVS
\IVNSGALTSGVHTT‘T)AVEQSSLYLYSLSSVVTVT’SSST..(YT.Q.TYTCNVNTTKPSNT 3
KVETKKVEEKSCDKTHTEPECEAPELEGT‘YT’SVELEET’KT’KT)TT.TVTTSRTEEVTCVT
V’TJVSTTEDT’LVKENVV’YVTTTJVTVTT’VAKTKPKFEQYNSTYRVV-SVLTVT.HQ T
TNT/"LNGKEYKCKVSNKATPI‘TT’TEK'T‘TSKxKETQPRET’QVYTLT’PSRDELTKNQ
VST.TCEVKGTYT’SETTAVEVVTLSNTJQEENNYKTTPEVTTTSDQSFEEYSKLTVBK
SKVVQQTYNVESESVTYTTTT‘ALTTNTTY’TQKSLSTSEQ {SEQIT)NO99‘ at”
huCD373V11 TQVQVQESGEGLVAPSQ”STTSTTETVSGTSLTTSGVSVVIRQT’EQKEYLEWTTIVTW g
(TE)(.ESTNYT'TSSTKSKLSTKKDTTSKSQVE’T.KTNSTTAADTATYYCAKCTGYSLA
HVVGQG’T‘LVTVSSASTKGPSVET’EAT’SSKS'T'SGG'T‘AAT..GCT.VKT)YEPEPV'T‘VS
VTI'NSGAL'T'SC:V'TTTEE‘AVLQSSGLYSLSSVVTVESSSLCY'TQ'T‘YTCNVNTTK?SNT
KV'DKKVF.T’KSCTBKTTT‘TCPPCPAPELEGGESVETEPT’KEKTT'T'EMTSRTETTVTCV
VVDVSHEDEEVKENWYVDGVEVITTNAKTKEKEEQY’NS’T'YKVV’SV'LTVETITQ
DVVLNGKEYKCKVSNKATEAE‘TEKTTSKAKGQT’RE.T’QVY"TT.T)T’SKTJETXTKNQ
VSTTCLVKGEYT’STTTAVEWESNGQE‘FNNYKTTT’DVLDSETGSE‘ELYSKTXT‘VUK
SRVVIQQGNVITSLSVVTTTEATTTTTHYTQKSTTSTST’G TST‘Q TD NQ19.1.).
muCD3712 QTQLVQSTYPETKKETTE.TVKTSUYASLYYTTTKY’EyVTNVvVKQl—YQEIKTYTKW‘YTT:
WTNTNTTJESKNAEEEKETKEAEST.ETSASTAYTQTNNEKYEDTATYEEGTEGTV
V’,ADVVGQLYTTLTVSSAKTTAT’SVYET.AEVC{.YDTTGSSV’TEGCLVKGY’EPET-TV
’T‘T'T’VVNSGSESSGVTTTET’AVEQSDTY'TLSSSV'T‘V‘TSSTVVI’T’SQSTTCNVATTT‘ASS
TKVDKKTET’RGPTTKEE,T“PCKCPAE\LLUUESVETTT’T’KTKTYVTTVITTST.SPTVTCV
VVDVSEDDT’TTVIQTSWEVINNV‘3VITTTAQTQTTTREDYNSTLKVVSATPTQHQT)
VVJVITSTsKEEKCKVNNKDLT’AETERTTSKEKSV’RAPQVIYVLT’T’T’EEETVIT'T'KKQV
TTTC.IVTVTDETVTEEDTYVEVV’TNNGKTET..NYKNTTPVTDSDQSYEMYSKLKVE
VERNSYSCSVVTTETYLTDTTTTT’TT ‘YanguK (SEQ TDNQ92) __ __
TVEEEYYI12 ”I \
SGPETKKPGETVKTKEKASETY ’T Y T‘ "'YQMNTYIYKQAQQKQLKYYYKT
WINTNT(YTSRNATEYKGKFA}SLEY8As.TAYY.QTNNTKYEDTIYTYECGRGTV
V'ADVVI’GQG’T‘TTJT‘VSSASTKGPSVFPLAPSSKS’T‘SGG’T‘.IV.AT.GCT..-VKTTYFPTEPVT E
YISYYNSQALY‘KGYH‘T‘YPAVITQSSQLYSLSSWYYPSSSLQY'QYYTCNYNHKPS
K’YKYDKKYEYKSCDKYH‘TCPPCYIAYELLQGYSVKLKPPKPKQYLMTSK'TYIKYI'Y" g
CV’VVDVST-TEDPEVKT‘NWY’V’TXTVI‘EVHNAKTKPREEQY’NSTYRV’VSVL’T‘VL
TNQKEYKCKYSNKALKAYYKKYYSKAKQQYKEPQYYYLPYSKDELYK =
NQVST.Y‘QLYK“TYPSDTAVI’TZWESNGQTTE‘NNYK‘T‘TPPVTDSTTGSFFLYSKLTV
' YYIQK (SEQ m NQ:93Y ‘
T KSTYVV’QQTYNYIESESV‘YTTTTZALTTNTTYT‘O I ‘ I:
muCD3738 DVQTQFSGPDLVIKPSQSLSLTETVTTYYSTT QYYHYYIITRQFPGNKLEVV’MAY’ ;
TYYSGETTDYNPSLKSRTSTTEDTSKNQFTI‘T.KY.SSVTTTLT)TATYY’CARGY’YGYG
AYTIKVYIWGQQ‘T‘LYTYISAAKYYPPSYYYITAPGSAAQ'T'NSKITY'I'LQCLYKQY‘YY
EEVI’T‘VI’T‘WNSGSTSS"G‘VI'TTTFEAV‘LESDLY’TLSSSV’T‘V’PSSMKPSE’T‘V‘TCNVAH
KVDKKTVPRDCGCKPCTC’T‘V’PEVSSVETEPPKPKDV’LT‘T’T‘L’TT’KVI’CTCV‘V’
EVI’TJTSKTTDPEVQFSVVI’FV’DDV’E‘VI‘HTAQ'T‘QPRE.EQFNSTFRSVSELPTMHQDWL I
NGKET’KTKYINSIYAFT‘APTEK'T‘TQK’T‘KGTTT’KVT’QV’Y'T'TPPPKTQMAKDKVSLT
CMYTDFTPESTTV'EwQYYNQQYIAENYKNTQPTTVITNTNGSYTVIY’SKTNVQKSN
V‘vEAEYSTFTESVETTETYLTTNTTTTTEKSTAHSETYK SEQ TD KY '
chCD3738 OVQLOESTJPDLVKESQSTST...TCTVTTYYSTTSEYF YTYIHWTKQ KLEWMAY
T GTIYYSPYLKYKTYYYKDTSK\QEETKT.SSVTTEDTATY’YCARGY'YGYG
AWEYIYIYVGQQ'IYYTVSAASTKGPSVT‘PLAPSSKS’T‘SGGTAATQC}V’KTJYEPE
T PVTY’SVV’NSTYALTSGVHTEPAVTQSSGLYSTSSYYYYPSSSTQTQ“:YY’YCK-VNH
KESNTKVT‘PI‘N:T j____1_g§g§§f_ .. APETTWETGPSVFTYYYKPKDYTMTYKYYT
.....
VT.HQTJVV’LNGKEYKCTLVISNKYALEAT’TEKT1SKAKGQPKET’QV7Y1‘LET‘SRDHT3
TLNQVIST.1‘CT.YVKGE‘V‘PSDTAVEVVE‘SN GQE‘E‘I\‘YTV’KT1EE‘V71YDSDIGST‘TLVSKL1
WT‘QLYNV’E‘SCSV7V1TTEALTTNT1‘Y’1‘QKSLS1SEG (SEQT33NO:9;?)
3huCD3‘7l‘é‘53‘""""""""""1Q‘V"QT(3ESGE‘GTVKE‘SQSLSLTC1‘V"SC“:STTS(.TE{‘1‘V7171TVV’TRQT‘PGKYYLEVVI‘VLAV’
LVSGG1‘DYNEST.KSKTSTTRDTSKNQEELKLSSV71AAD1‘ATYYCY‘ARGV’V"GYG
YAVVI‘EVI‘YVV’GQGTLV’‘T‘V/S SAS‘T‘KGT‘SV’EELAPSSKS‘T‘SGG‘T‘YAAT..G(‘.‘.LV’KT3YEPE
E‘V‘TV’SVV’NSGAL‘T‘SGV‘TEET‘E‘T3AV’TYQSSC:LYSLSSV’V"TVI'T‘SS SLG‘T'Q'T‘YTCNV‘NTT
K1)SN'T‘KVI’TJTLKV’EPKSCDK‘T‘ETTCT‘T‘CPAE’E‘YTYTYGGPSVELET’PKEKDTTYMTSRT‘E’
EV’1‘CV‘V’V1‘3V’STTTT3PEV7K1‘NVV’VVDCY‘V’EVHN‘YAKTKPKET‘Q‘V’NSTVKV‘V"3,71;T
7-LT1Q13WT.YNLYKEYKCKV’SNKALT‘AE’TEK1TSKYAKi.‘TQEKET—‘QV'YTEEPSKDEL1‘1
KNQVSLT‘C1V7K111“V’E‘S‘DTYAV’EVV’ESNLYQT‘E‘YV‘Y’ K1‘11’1’V1.1‘3S13GSTTTYYSKLT
111 111.1113 760 LEVI"QLQ “ ‘YYEDTTYKESQSLSLTCTV’TGI‘TSTT‘SGEYAVVITTVV’TRQT‘PLNKLEWMG‘YT
LYSGST‘VI‘1’LT‘ST.KSRTSTTKDTSK\T11ELQLNSV’1‘1‘E1‘31‘YATY‘Y‘CARGYV’GYCY
AWEYAYVVI‘GQG1‘T.YV’1‘V’ SAAKTTAE‘SVV’PLAPV’C.(1131‘TGSSVIT1.GCT.V’KGYT‘T‘ Y
ET‘V’TLTVVNSUHSSGV’TT'.1‘EEAV’TQSDLV’TLSSSVITV’TSST‘VVIT‘SQSTTC‘NVATTT‘ 5;
ASSTTLVI1C3KKTEE’KGT3T.1K1“CPE‘CKCPAT—‘NLLGGPS V7E‘TE‘T3T’K1K1‘3V’1.T\I11ISTYST—‘1V7
TCV’VI‘ V7DV"SEDDPDV’QTSVV’EV’NNVEV’ETTYAQTQTT'TKEDV’NS‘T‘LK.VV"SYA1.YETQH
QT3VV’TV’TSGKEFKCKVI'NNKJJLEAT‘TEKTTSKE‘KGSV‘RAPQV’V‘V’LET‘T‘EEEMTKK
QYI1'11CVT'V‘TDFIVYPEDIYVEVV’TNAIGK’T‘FTY‘NV’KNTEE‘VI‘TDSDGSYT‘ME’SKEK
\V’EKKTSVVVI’YKNYYSCSY’Y11C"'C11N11111I‘KSFSNTYCK5YYQ1QNQ;9.
huCD3750 QYIQ1QESGEGLLKT’SQSESL1'C1YISG‘Y‘8.11811?AVVITTWKQHYICYNKC1i;YYYKYY 1
11Y YIYSPSTK151115111RD1SKN’KYFTYQ1.NSVTAADT‘ATYYCYARCYYYGVCY'
.AVVIE‘A‘C VVGQGT1.VTV7SAASTTLGPSVE13LAESSKSTSGGTAAT.GCTV’KDYEPET1
PV’TVSWNSGAL’T‘SGV’E1"1‘T‘T‘YAV"1YQSSGLYSLSSV‘V’’T‘VI’ESSSLG‘T‘QTYTCNV’NH
1 *
KPSNTKVDKKVEPKSCDKTHTCPPCPAE‘T‘TYLCYTYPSVIELEEEKT’KDTTVTTSRTP
.Y YY13VY11CDPCYIK1NYYY Y’QCYYI’EYINYIAKTKPKCCQYNYCYRVIVSV1'11
YIL11QDYYI1NCYKCYKCKYSNKALPAETEK’118KAKCYOT‘KT‘PQV’YTLPFSRDLL1' 1
KNQYISL1C1.V’KGEVE8131AV’EWES\GQ1‘E\1NYK111>1>YI113S13CSE‘EL‘YSKLT
_____1__YIQ1<<YKYYIQQQ\Y " NTTYTQKSLSLSP6113113 NO93)
' '
I. .
muCD3751 DYQLCLYCYYQYY. .'' BYSTSSGE‘AVVIHVV’TRQT‘EL.YNKLEVV7VTGVT
TNYSESLKSRTSTTR13SSK‘YQFTLQL1YSVMiTEDTA.1YYC.YARGYV’GFGA
WE‘VYWGQGTLV/1V7 SAYAKTTAT‘SV’VET.Y’AT’VCCYDTTGSSVTLGCT.YV’KG‘: ’
VI"1“1..'T‘VV”NSGSLSSGV’T—TTE‘T‘AV’TYQST‘3LV’ 'T‘LS SSV’TV7TS STVVI‘T’SQST'T‘C‘NVI’AETT‘AS
STKV‘1‘3KKTET‘KGPTTTLT-‘CT-‘PCKCEAT’N 1.YT.YGGESV7ETEPT’KTKDV’LMTSLST’TV’'T‘C
VI‘V‘ V’ 1.3 1‘31‘T3VQTSVV‘FV71‘Y1‘1VTV7EV’ETTAQT‘Q'T‘ETKEDYNSTTYKV‘‘V7SYALT’TQT'1Q‘L3
‘ WMSGKEEKCK‘V’N‘N‘KDLPAPTEKTTSKT’KGSV"RAT’Q‘V’YV71..-E1‘EEEETVTTKTLQV7 t
TLTC.TVIT‘V’1‘T3FJVT1‘ET3TYV’EVVTTNNGKTLLNYKN'T‘ET‘V’TT3ST3GS‘YTVITYSKLKV‘
w—‘......./
:“BEEBWN .vEVQEVI‘ESGE’EV71K‘PLYT‘SLSLTLTVSTTY‘STSSGEAVV71TVVITRT‘TT‘T-‘(YKLYTEVVI‘V’TG‘YT
TTYSGSTNYSPSTQTxKTSTTRDSSTNQT‘TLQLNSV’T‘ASDT‘YA1“!YT‘.KARGYYYL1EC§11A
VVTV’YVV‘GQGTLV’T‘V‘SAYAS1‘KGESVFT—‘LAT—‘SSKSTSGGTAATGCLVIKD‘YEPE? 3
VINSGATYTSGV111‘E1’AVI1.QSSGT.Y‘Y’STSSVV7TV/‘ESSSLGTQ1‘YTCNVNETK
T-‘SN1KV13KKV’TTEKSCDTL‘TTTTLT’E‘CE‘YAT‘ETLGLYE‘SVETYT‘T‘T‘KPKL‘ITLMTSK11‘1:
VIT‘CV’V’V’DVISELE1‘3PTEV7KENW‘YV’DG‘VTV’TTNAK.1‘KEREEQ‘CNST‘YIRV’V’SVLT
VT.TTQDVVILNCKEVKCKV’SNKATPAE‘TEKTTSKAKCTQPKEE’QV‘VTTPE‘SKDTT.T:
KNQV/STTCT.VKQT‘YT‘SDTAV’EV‘Y’SKGQPE\\VKTTYPVLDSDGSTELYSKL‘1‘
{WMVVVVVVVVVVVVVVVVVVVVVVVVV
TTT‘Y’SGGEN17NEST1xSKV’STTRDTSKNQT‘T‘LQLNSVT1ET‘31‘ATYV’CAKGYYGT‘
GAVVIEAVVA7GQ€TTLVIT‘V"SYAAK1‘TE‘T’SV'V’E’T”A131TSAAQTNSMV1‘LGCLV’KGYE‘
"SSV’TV'PSSVTKE‘SL‘YT‘V:CNVIIA
............................................ GC‘KPCKTVPEVSSV’TTTT’T’KPKDV’TTTTTTPKVTCV T
. SSTKV’DKKTVT’KDC
SELT‘TMTTQTNV
1 VVDTSKT)T)PEVQTSVVTVIDDV’EV’HTAQTQPRTTQTNSTTRSV
LNGKETKCRVNSAAPRAPTEKTTSKTKGKT’KAPQVYTTPPPKEQMAKDKVST
TCMTTDPPPEDTTVEVVQVVNGQPAENYKNTQPTMNTNGSV’EVYSKLNV’QKSN
7 AGNTETCSVI’LHTC1TTTNHHTPKSLSTTSPC1K(SEQTD NC):NT.1}
‘ EV’QLQESGPGTVKPSQSLSLTCTV’SGYSTTSC717EA‘sV’HVVTRQEPGKT:LEWMGYT
HYSGGTNYNPSLKSRV STTREPTSKNQTELGLNSVTTAAT)T7.ATYYCARGYYGE
GAVVPPAYWGQGTLVPVSAASTKGPSVPPLAPSSKST7SGC3TAAT.GC’TV7KDY7EP
TEPV’.7VS‘WNSC5IALTSGVHTEPAVT.QSSGT1‘17SLSSVVTVPSSSLGTQT‘17T7CNV7N E
i TTKPSNT7KVTEKKVEPKSCDKTHTC7.T’PCPAPET.7LCsCsPSVPLEPPKPKDTTMTSKT T
IPEVTCVV7VDV'SHEDPEVKENWYV’T)GVEV7HNAKTKPREEQYNS"1YRVV7SV7LTTVLHQDVVLNGKEVKCKVSNKALPAPTLKTTSKAKGQPRTPQVYTLPPSRDETTKNQV’SLPCLVKG‘TYPSTHAVEVVESNGQPENNYKT7T7PPVLT‘ASDGSETLYSKLE
muCD1757
LYSGSTVV'SPST.KSRTSTTRDTSKNQTTLQLNSV7TTEDTA7TV7YC:ARGYYGYG
AWEA717VV’V:QGTLVTV SAAKTTAPSVYPLAPVCGT)TT7GSSVTLGCLV’KGYEP i
EPVTLTVVNSCTSLSSGVHTEPAVLQSDLYTLSSSVTVTSSTWPSQSTTCNVATTPE
E ASSTKVDKKTEPKGPTTKPCPPCKCPAPNLLGGT’SVPTEPPKTKTDVT.MTSLSPTV
E TCVVV7T3V7SE17DDPE3VQTSVV’EVNN7VEVPTTAQTQTTTREDYNSTTRVV78.ATPTQTT?
QT)VVMSGKLTKCKVNNKT)LPAFTERTTSKPKGSVRAPQVYVLPPT‘EEEMT7KK
QVTLTC‘.MVTHTMPEDTVVEWTNNGK7T7PT \YKNTEPVTDSDGSYEMYSKT.R
VEKKNVV'1/1waSC511;ITELJLTT\TTTT DNGT93)
77E§5ET3§7~5 I I 77777§7QVQT 11 1. ‘KCYLT‘VVVTUYT
LYSGST7VYSPSTKSRTSTTRDTSKNQPTLGTNSV’TAADTATYYCAKGYYGVG
AWEIAYVVGQGTT.V7T7V7SAASTKGPSVPLVT’SSKSTSGGTAAT..GCLV’KDYEPE?
VNSGALTSGVTTTET)AV’TQSSGT‘1SLSSVVTVPSSST.G77TQTYTCNVNTT
VDKKVEPKSCDKTTTTCT’PCPAPET.LCsGPSVELEPPKPKL)TLMTSR7TP;
EV77TCV’VVDVSHEDPCV’KTNVVYVDGVEV’T—TNAKTKPRECQYNSTYRVV’SVLT;
VV’LNGKEYKCKVSNKIALPAPTEKTTSKAKCTQPREPQVYTLPPSRDELT771
KNQVSLTCLVIKGEYPSL‘AAVTVVTS‘TGQPENNYKTTPPVLDST‘GSEETYSKLTT
777TPVQVVESGGDLVKPGC 1
KTSCAASGPTTSSYGMSVVVKQTPDKKTEVV777VIACT
SSGGSV’TYSPDSVKGRETTSRT)NAKKTL‘1LQMSSLKSET)TAMY‘7CARTTSY 7‘71
DTSVT)YVVGQGTSVTVSSAKTTAT‘SV'V’P7T.1APVCGDTTGSSV'TLGCTAI’KGYPP
EPVTL'T'VVNSGSLSSGVT—TT‘PPAV’LQSDLV’TLSSSVTVTSSTWPSQSTTCNVAHP
ASSTKV'DKKTEPRGPTTKPCPPCKCPAPNT.1T1GGPSVETEPPKTKDV’LMTSLST‘TV7
TCVVV’DVSETJUETJVQTSVVEVNNVEVTTTAQTQTHREDYNSTLKVVSALT’TQTT
QDVVTVTSGKEPKCKVNNKTJLPAPTERTTSKPKGSV7K1APQV’V7VLPPPEEEMTKK
QV’TLTCMVTDPMPEDTYV’EVVTNNGKTELNYKNTET’V7T.T.)ST)GSV’EMYSKLK
ukwwmwmmummmmszm«11011111017%
Table 6: ength light chain amino acid sequences
77DTQV’T’T
SV’SVGET \I . 7NV’AT
NLADGVPSKESCzSGSGTQYSLKTNSLQSETEMPG777TVYCC‘HYV1CSTTWTTIGGGTKT
LETKRADAAPTVSTPPT‘SSEQLTSC1CTASVVICPLNNPYPKBTNVKWKTDGSTRQ
NGVLNSV‘VTDC.PDSKDST7‘17STVTSS771TT7TT.1TKT}PYERTT\TS‘1TCEAT7HKTS7TSPTVKST1
FNRNEQTVPQ 111 N1": 10¢:
chCD373
-36—
VPSRFSGSGSGTQYSLKFNSLQSEDFGTYYCQHYWGTTWTFGGGTK
LEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQE
SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKE
SFNRGEC (SEQ ID NOJ91 ;
huCD373 DIQMTQSPSSLSVSVGERVTITCRASENIRSNLAWYQQKPGKSPKLLVNVAT
E110 and 1.1) NLADGVPSRESGSGSGTDYSLK1NSLQPEDFGTYYCQHYWGTTWTEGQGTK;
1 LEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQ;
E SGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKE
C(SEQID NO 1071 =
DIV, QSPASLAVSLGQRATISCRASQSVSTSSYSYLY *QQKPGQPPKLLIK
71,,,..,,,,,,,,,,,,,,,,,,,,, ASGVPARFSGSGSGTDFTLNIHPVEEEDTATYYCQHS 11PYTFGGG
TKLEIKRADAAPTVS11PPSSEQLTSGGASVVCFLNNEYPKDINVKWKIDGSE
EVKSFNRNEC1‘SEQ1DRQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPINO11181
'Efiéfii‘i‘i‘z'" DIVLTQSPASLAVSLGQRATISCRASQSVSTSSYSYLYWFQQKPGQPPKLLIK
YASNLASGVPARFSGSGSGTDETLNILD’VEEEDTATYYCQHSWEIPYTFGGG
ETKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNA
ELQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV
GEC1SEQID NO11191 _1
_____
Eiiiii‘ébfil‘fi" SPAIMSASPGEKVTMTCSASSSVTYMHWYQQKSGTSPKRWIYDTS
EKLASGVPARFSGGGSGTSYSLTISSMEAEDAATYYCQQWISNPPTFGGGTKL
EEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQN
GEVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSF E
ENRNEC 1SEQ ID NO 110)
chCD‘é‘YEEWmW1QIVLTQSPAIMSASPGEKVTMTCSASSSVTYMHWYQQKSGTSPKRWIYDTS_
KLASGVPARFSGGGSG1SYSLTISSMEAEDAATYYCQQWISNPPTFGGGTKLE
EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYEREAKVQWKVDNALQSE
GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS;
111111
WENRGEC(SEQ 1DN0111)
huCD3738 EDIVLTQSPASMSASPGERVTMTCSASSSVTYMHWYQQKPGTSPKRWXDTS ;
EKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWISNPPTFGGGTKLI
EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSE
GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSE
FNRGEC (SEQ ID NO 1 12)
fimuCD‘i‘ii‘Sfiwm"E"Q1VLTQSPAIMSASPGEKVTMTCSATSSVTYMHWYQQKSGTSPKRWIYDTS
KLPYGVPGRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSDNPPTFGSGTKL E
EIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSEE?QN
GVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSF
_E NRNEC (_SEQID NO:113_1_
757)‘ EIVLTQSPATMSASPGERVTMTCSATSSVTYMHWYQQKPGQSPKKWHDTS E
NLPYGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSDNPPTFGQGTKL
EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSE
. GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSE
FNRGEC1SEQID NO 1141 777777
muCD3751 EQIVLTQSPAIMSASPGEKVTMTCSATSSVTYMHWYQQKSGTSPKRWIYDTS ;
1 KLASGVPARFSGSGSGTSYSLTISNMEAEDAATYYCQQWSSNPPTFGSGTKL
1 EIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQN
E : GVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSF
huCD37-5 1 1EIVLTQSPATMSASPGERVTMTCSATSSVTYMHWYQQKPGQSPKRWIYDTS
KLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPPTFGQGTKL
EIKRTVAAPSVFIFPPSDEQLEKSGTASVVCLLNNFYPREAKVQWKVDNALQSWE
W0 2012/135740 PCT/U82012/031648
_37_
EGNSQE‘WTEQBS‘Kfifififs'sTLTLsflfiYEWKfiKV§Kf§i§fifi65§§fifii§W4
FNRQEC_SEQ ID NO: 116.: 1
muCD37-56 QIVLTQSPAFMSASPGDKVTMTCSASSSVTYMHWYQQKSGTSPKRWIYDTS
E KLASGVPARFSGGGSGTSYSLTISTMEAEDAATYYCQQWISDPP‘EtGGGTKL
EIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQN
EGVLNSWTDQDSKBSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSF
NRNEC (SEQ ID NO 117)
Ehucfig‘fig""""“""""‘E“DIVLTQSPAFMSASPGEKVTMTCSASSSVTYMHWYQQKPDQSPKRWIYDTS
NLASGVPSRFSGGGSGTDYSLTISSMEAEDAATYYCQQWISDPPTFGQGTKL;
EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSE:
GENSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS
‘FNRGEC @139 ID NO 1 18)
muCD3757 QlVLTQSPAIMSASPGEKVTMTCSATSSVTYMHWYQQKSGTSPKRWIYDTS
E PARFSGSGSGTSYSLTISSMLAEDAATYYCQQWSDNPPTFGSGTKL
EIEKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQN
GVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSF
huCD3757 EIVLTQSPATMSASPGERVWSSVTYMHWYQQKPGQSPRRWIYDTS
NLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSDNPPTFGQGTKL;
AAPSVFIFPPSDEQLKSGTASVVCLLNNPYPREAKVQWKVDNALQSE
GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSE
(SEQ ID NO:___1_2__(_))
EEEEEEEEEEEEEEEEE
252-3 QTTSSLSASLGDRVTISCRASQDISNYLNWYQQKPDGTVKLLIYYTS
EKLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNALPWTFGGGTKL
EELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQ :
NGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKS
FNRNEC“(SEQIDNQ: 180)
Also provided are polypeptides that comprise: (a) a polypeptide having at least about 90%
sequence identity to SEQ ID NOs:88-104 or 179; and/or (b) a polypeptide having
at least about 90%
sequence identity to SEQ ID NOS:105-120 or 180. In certain embodiments, the polypeptide comprises a
polypeptide having at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at
least about 99% sequence identity to SEQ ID NOs:88-l20, 179, or 180. Thus, in certain embodiments, the
polypeptide comprises (a) a polypeptide having at least about 95% sequence identity to SEQ ID NOs:88-
104 or 179, and/or (b) a polypeptide having at least about 95% sequence identity to SEQ ID NOs:105-120
or 180. In certain embodiments, the ptide ses (a) a polypeptide having the amino acid
sequence of SEQ ID NOs:88-104 or 179; and/or (b) a polypeptide having the amino acid sequence of
SEQ ID NOs:105-120 or 180. In certain embodiments, the ptide is an antibody and/or the
polypeptide specifically binds CD37. In certain embodiments, the polypeptide is a murine, chimeric, or
humanized arétibody that specifically binds CD37. In certain embodiments, the polypeptide having a
certain percentage of sequence ty to SEQ ID NOs:88-120, 179, or 180 s from SEQ ID NOs:88-
120, 179, or 180 by conservative amino acid substitutions only.
In n embodiments, the CD37 antibody can be the antibody produced from a hybridoma
selected from the group consisting of consisting of ATCC Deposit ation PTA—10664, deposited
with the ATCC on February 18, 2010, ATCC Deposit Designation PTA-10665, deposited with the ATCC
-38—
on February 18, 2010, ATCC Deposit Deisgnation PTA—10666, deposited with the ATCC on February 18,
‘10, ATCC Deposit Designation PTA~10667 deposited with the ATCC on February 18, 2010, ATCC
Deposit Designation traumas, deposited with the ATCC on February 18, 20W, ATCC Deposit
Designation P'T.A~i0669, deposited with the ATCC on February 18, 2010, and ATCC Deposit
Designation PTA»10670, deposited with the ATCC. on February 18, 2010 can Type Culture
Collection (ATCC) at 10801 University Boulevard, Manassas, Virginia 20E iii). In certain embodiments,
the antibody comprises the VH—CDRS and the VI..~CDRS of the antibody produced from a bydridoma
selected from the group consisting ofPTA~10665, P13840666, VIA-10667, I’ll/7140668, PTA~10669, and
670.
In certain embodiments, the CD37 antibody can comprise a light chain encoded by the
recombinant plasmid DNA phuCD37-3LC (ATCC Deposit ation PTA-10722, deposited with the
ATCC on March 18, 2010). In n embodiments, the CD37 antibody can comprise a heavy chain
d by the inant d DNA phuCD37—3HCV.1.0 (ATCC t Designation 723,
deposited with the ATCC on March 18, 2010). In certain embodiments, the CD37 antibody can comprise
a light chain encoded by the recombinant plasmid DNA phuCD37-3LC (PTA-10722) and a heavy chain
encoded by the recombinant plasmid DNA phuCD37-3HCV.l.0 (PTA—10723). In certain embodiments,
the CD37 antibody can comprise the VL—CDRs encoded by the recombinant plasmid DNA phuCD37-3LC
(PTA-10722) and the VH-CDRs encoded by the recombinant plasmid DNA phuCD37-3HCV.1.0 (PTA-
Monoclonal antibodies can be prepared using hybridoma methods, such as those described by
Kohler and Milstein (1975) Nature 256:495. Using the hybridoma method, a mouse, hamster, or other
appropriate host animal, is immunized as described above to elicit the production by lymphocytes of
antibodies that will cally bind to an immunizing antigen. Lymphocytes can also be immunized in
vitro. Following zation, the lymphocytes are isolated and fused with a suitable myeloma cell line
using, for example, polyethylene glycol, to form hybridoma cells that can then be selected away from
unfused cytes and myeloma cells. Hybridomas that produce monoclonal antibodies ed
specifically against a chosen antigen as determined by immunoprecipitation, immunoblotting, or by an in
vitro binding assay (e.g. mmunoassay (RIA); enzyme-linked immunosorbent assay (ELISA)) can
then be propagated either in vitro culture using standard methods (Goding, Monoclonal Antibodies:
Principles and Practice, Academic Press, 1986) or in vivo as ascites tumors in an animal. The monoclonal
antibodies can then be purified from the culture medium or ascites fluid as described for polyclonal
dies above.
] Alternatively monoclonal antibodies can also be made using recombinant DNA methods as
described in US. Patent 4,816,567. The polynucleotides encoding a monoclonal dy are ed
from mature B—cells or hybridoma cell, such as by RT-PCR using oligonucleotide primers that specifically
~39—
amplify the genes encoding the heavy and light chains of the antibody, and their sequence is determined
using conventional ures. The isolated polynucleotides encoding the heavy and light chains are then
cloned into suitable expression vectors, which when transfected into host cells such as E. coli cells, simian
COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not ise produce
immunoglobulin protein, onal antibodies are generated by the host cells. Also, recombinant
monoclonal antibodies or fragments thereof of the desired species can be isolated from phage y
libraries expressing CDRs of the desired species as described (McCafferty et al., 1990, Nature, 3482552-
554; Clackson et al., 1991, Nature, 352:624-628; and Marks et al., 1991, J. Mol. Biol., 222:581-597).
The polynucleotide(s) encoding a monoclonal antibody can further be modified in a number
of different manners using recombinant DNA technology to generate alternative antibodies. In some
embodiments, the constant domains of the light and heavy chains of, for example, a mouse monoclonal
antibody can be substituted 1) for those regions of, for example, a human antibody to generate a ic
antibody or 2) for a non-immunoglobulin polypeptide to generate a fusion antibody. In some
embodiments, the constant regions are truncated or removed to generate the desired antibody fragment of
a monoclonal antibody. Site-directed or high-density mutagenesis of the variable region can be used to
optimize icity, affinity, etc. of a monoclonal dy.
] In some embodiments, the monoclonal dy against the human CD37 is a humanized
antibody. In certain embodiments, such antibodies are used therapeutically to reduce antigenicity and
HAMA (human anti—mouse antibody) responses when administered to a human subject. Humanized
dies can be produced using various techniques known in the art. In certain alternative
embodiments, the antibody to CD37is a human dy.
Human antibodies can be directly prepared using various techniques known in the
art.
Immortalized human B lymphocytes immunized in vitro or isolated from an immunized dual that
produce an antibody directed t a target antigen can be generated (See, e.g., Cole et al., Monoclonal
Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boemer et al., 1991, J. Immunol, 147 (1)186—
95; and US. Patent 5,750,373). Also, the human antibody can be selected from a phage library, where
that phage library expresses human antibodies, as bed, for example, in Vaughan et al., 1996, Nat.
h., 14:309-314, Sheets et al., 1998, Proc. Nat’l. Acad. Sci., 95:6157162, Hoogenboom and
Winter, 1991, J. Mol, Biol., 2272381, and Marks et al., 1991, J. Mol. Biol, 222:581). Techniques for the
generation and use of antibody phage libraries are also described in US. Patent Nos. 5,969,108,
6,172,197, 5,885,793, 6,521,404; 731; 6,555,313; 6,582,915; 6,593,081; 6,300,064; 068;
6,706,484; and 7,264,963; and Rothe et al., 2007, J. Mol. Bio., 376:1182 (each of which is incorporated
by reference in its entirety). Affinity maturation strategies and chain shuffling gies (Marks et al.,
1:992, chnolngy »783, incorporated by reference in its entirety) are known in the art and can
be employed to generate high att‘inity human antibodies.
Humanized antibodies can also be made in transgenic mice ning human
immunoglobulin loci that are capable upon immunization of producing the full repertoire of human
antibodies in the absence of endogenous immunoglobulin tion. This approach is described in US.
Patents 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and 5,661,016.
This invention also encompasses bispecific antibodies that specifically recognize a CD37.
Bispecific antibodies are antibodies that are capable of specifically recognizing and binding at least two
different epitopes. The different epitopes can either be within the same molecule (e.g. the same CD3 7) or
and bind a
on different molecules such that both, for example, the dies can specifically recognize
CD37 as well as, for e, 1) an effector molecule on a leukocyte such as a T—cell receptor (e.g. CD3)
below.
or PC receptor (e.g. CD64, CD32, or CD16) or 2) a cytotoxic agent as described in detail
Exemplary bispecific antibodies can bind to two different epitopes, at least one of which
originates in a polypeptide of the invention. Alternatively, an ntigenic arm of an immunoglobulin
molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T
cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG so as to focus cellular
defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used
to direct cytotoxic agents to cells which express a ular antigen. These antibodies possess an antigen-
binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE,
DPTA, DOTA, or TETA. Techniques for making bispecific antibodies are common in the art (Millstein
et al., 1983, Nature 305:537—539; Brennan et al., 1985, Science 229:81; Suresh et al, 1986, Methods in
Enzymol. 121:120; cker et al., 1991, EMBO J. 10:3655—3659; Shalaby et al., 1992, J. Exp. Med.
175:217-225; Kostelny et al., 1992, J. Immunol. 148:1547-1553; Gruber et al., 1994, J. Immunol.
152:5368; and US. Patent 5,731,168). Antibodies with more than two valencies are also contemplated.
For example, trispecific antibodies can be prepared (Tutt et al., J. Immunol. 147:60 (1991)). Thus, in
certain embodiments the antibodies to CD37 are multispecific.
In certain embodiments are provided an dy fragment to, for example, increase tissue
penetration. s techniques are known for the production of antibody fragments. Traditionally, these
nts are derived via proteolytic digestion of intact antibodies (for example Morimoto et al., 1993,
Journal of Biochemical and Biophysical Methods -117; Brennan et al., 1985, Science, ). In
certain ments, antibody fragments are produced recombinantly. Fab, Fv, and scFv antibody
fragments can all be sed in and secreted from E. coli or other host cells, thus allowing the
production of large amounts of these nts. Such antibody fragments can also be isolated from the
dy phage libraries discussed above. The antibody fragment can also be linear dies as
described in US. Patent 5,641,870, for e, and can be monospecific or bispecific. Other techniques
for the tion of antibody fragments will be apparent to the skilled practitioner.
W0 2012/135740
_ 41 _
According to the present invention, techniques can be adapted for the productior’: of single-
chain antibodies specific to CD37 (see US. Pat. No. 4,946,778). In addition, methods can be adapted for
the construction of Fab expression libraries (Huse, et al., Science 75-1281 (1989)) to allow rapid
and effective identification of monoclonal Fab fragments with the desired specificity for CD37, or
derivatives, fragments, analogs or homologs thereof. Antibody fragments can be produced by techniques
in the art including, but not limited to: (a) a F(ab')2 fragment produced by pepsin digestion of an antibody
molecule; (b) a Fab fragment generated by ng the disulfide bridges of an F(ab')2 fragment, (c) a Fab
fragment ted by the treatment of the antibody le with papain and a reducing agent, and (d)
Fv fragments.
It can further be desirable, especially in the case of antibody fragments, to modify an antibody
in order to increase its serum half-life. This can be ed, for example, by incorporation of a salvage
receptor binding epitope into the dy fragment by mutation of the riate region in the antibody
fragment or by incorporating the epitope into a peptide tag that is then fused to the antibody fragment at
either end or in the middle (e.g., by DNA or peptide sis).
Heteroconjugate antibodies are also within the scope of the present invention.
Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for
example, been proposed to target immune cells to unwanted cells (US Pat. No. 4,676,980). It is
contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein
chemistry, ing those ing crosslinking agents. For example, immunotoxins can be constructed
using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this
e include iminothiolate and methylmercaptobutyrimidate.
For the purposes of the present invention, it should be appreciated that modified antibodies
can comprise any type of variable region that provides for the association of the antibody with the
polypeptides of a human CD37. In this regard, the variable region can comprise or be derived from any
type of mammal that can be d to mount a humoral response and generate immunoglobulins against
the desired antigen. As such, the variable region of the modified antibodies can be, for example, of
human, murine, man primate (e.g. lgus s, macaques, etc.) or lupine origin. In some
embodiments both the variable and constant regions of the modified immunoglobulins are human. In
other embodiments the variable regions of compatible antibodies (usually derived from a non-human
source) the
can be ered or specifically tailored to improve the binding properties or reduce
immunogenicity of the molecule. In this respect, variable regions useful in the present invention can be
zed or otherwise altered through the inclusion of imported amino acid sequences.
In certain embodiments, the variable domains in both the heavy and light chains are altered by
at least partial replacement of one or more CDRs and, if necessary, by partial framework region
ement and sequence changing. Although the CDRs can be d from an antibody of the same
PCT/U82012/031648
_ 42 _
class or even ss as the antibody from which the framework regions are derived, it is envisaged that
the CDRs will be derived from an antibody of different class and possibly from an antibody from a
different species. It is not alway necessary to replace all of the CDRs with the complete CDRs from the
donor variable region to transfer the antigen binding capacity of one variable domain to another. Rather,
in some cases it is only necessary to transfer those residues that are necessary to maintain the activity of
the antigen binding site. Given the explanations set forth in U.S. Pat. Nos. 5,585,089, 5,693,761 and
,693,762, it will be well within the competence of those skilled in the art, either by ng out routine
mentation or by trial and error testing to obtain a functional antibody with d immunogenicity.
Alterations to the variable region notwithstanding, those d in the art will appreciate that
the modified antibodies of this ion will comprise antibodies (e.g., full-length antibodies or
immunoreactive fragments thereof) in which at least a fraction of one or more of the constant region
s has been deleted or otherwise altered so as to provide desired biochemical characteristics such as
reduced serum half-life when compared with an antibody of approximately the same immunogenicity
comprising a native or unaltered constant region. In some embodiments, the constant region of the
modified antibodies will comprise a human constant region. Modifications to the constant region
compatible witl‘: this invention comprise ons, deletions or tutions of one or more amino acids
in one or more domains. That is, the modified antibodies disclosed herein can comprise alterations or
modifications to one or more of the three heavy chain constant domains (CH1, CH2 or CH3) and/or to the
light chain constant domain (CL). In some embodiments, modified constant regions wherein one or more
domains are partially or entirely deleted are contemplated. In some embodiments, the d antibodies
will comprise domain deleted constructs or variants wherein the entire CH2 domain has been removed
(ACH2 constructs). In some embodiments, the omitted constant region domain will be replaced by a short
amino acid spacer (e.g. 10 residues) that provides some of the molecular flexibility typically ed by
the absent constant region.
Besides their configuration, it is known in the art that the constant region es several
effector functions. For example, binding of the C1 component of complement to antibodies activates the
complement system. Activation of complement is important in the opsonisation and lysis of cell
pathogens. The activation of complement also stimulates the inflammatory response and can also be
ed in autoimmune hypersensitivity. r, antibodies bind to cells via the Fc region, with a PC
receptor site on the antibody Fc regior: binding to a Fc or (FcR) on a cell. There are a number of Fc
ors which are specific for ent classes of antibody, including IgG (gamma receptors), IgE (eta
receptors), IgA (alpha receptors) and IgM (mu ors). Binding of antibody to Fc receptors on cell
surfaces triggers a number of ant and diverse biological responses including engulfment and
destruction of antibody-coated particles, clearance of immune complexes, lysis of antibody-coated target
2012/031648
— 4C\l—J
eeliis by kiiier cells (called antibody-dependent cell—mediated cytotoxicity, or ADCC), reiease of
inflammatory mediators, placental transfer and control ofimrnunogiobuiin tion.
{GM-’35} in certain embodiments, the CD37~binding antibodies provide for altered effector functions
that, in turn, affect the. biologicai profiie of the. administered antibody. For example, the deietion or
inactivation (through point mutations or other means) of a constant region domain can reduce Fe receptor
binding of the circulating modified antibody. in other cases, it. can be that constant region modifications,
consistent with this invention, moderate compiement binding and thus reduce the serum half iife and
nonspecific association of a conjugated cytotoxin. Yet other cations of the constant region can be
used to ate disulfide linkages or accharide moieties that allow for enhanced localization due
to increased antigen specificity or antibody lity. Similarly, modifications to the constant region in
accordance with this invention can easily be made using well known biochemical or molecular
engineering techniques well within the purview of the skilled artisan.
gotiiztti} In n embodiments, a CD3 7—binding agent that is an antibody does not have one or more
effector functions. For ce, in some ments, the antibody has no antibody—dependent cellular
cytotoxicity (ADCC) activity and/or no complement-dependent cytotoxicity (CDC) ty. In certain
embodiments, the antibody does not bind to an F0 receptor and/or complement factors. In certain
embodiments, the antibody has no effector function.
] It will be noted that in certain embodiments, the modified antibodies can be engineered to
fuse the CH3 domain directly to the hinge region of the respective d antibodies. In other
consteucts it can be desirable to provide a peptide spacer between the hinge region and the modified CH2
and/or CH3 domains. For example, compatible ucts could be expressed wleerein the CH2 domain
has been deleted and the remaining CH3 domain (modified or unmodified) is joined to the hinge region
with a 5—20 amino acid spacer. Such a spacer can be added, for instance, to ensure that the regulatory
elements of the constant domain remain free and accessible or that the hinge region remains e.
r, it should be noted that amino acid spacers can, in some cases, prove to be immunogenic and
elicit an unwanted immune response against the construct. Accordingly, in certain embodiments, any
omitted altogether, so as to
spacer added to the construct will be relatively non-immunogenic, or even
in the d biochemical ies of the modified antibodies.
Besides the deletion of whole constant region s, it will be appreciated that the
antibodies of the present invention can be provided by the partial deletion or substitution of a few or even
a single amino acid. For example, the mutation of a single amino acid in selected areas of the CH2
domain can be enough to substantially reduce Fc binding. Similarly, it can be desirable to simply delete
that part of one or more constant region domains that control the effector function (e.g. complement CLQ
binding) to be modulated. Such partial deletions of the constant regions can improve selected
characteristics of the antibody (serum half-life) while leaving other desirable functions associated with the
PCT/U82012/031648
, 44 _
subject nt region domain intact. er, as alluded to above, the constant regions of the
sed dies can be d through the mutation or substitution of one or more amino acids that
es the profile of the resulting construct. In this respect it can be possible to disrupt the activity
provided by a ved binding site (e.g. Fc binding) while substantially maintaining the configuration
and immunogenic profile of the modified antibody. Certain embodiments can comprise the addition of
characteristics such as decreasing or
one or more amino acids to the constant region to e desirable
increasing effector function or provide for more cytotoxin or carbohydrate attachment. In such
embodiments it can be desirable to insert or ate specific sequences derived from selected constant
region domains.
] The present invention further embraces variants and equivalents which are substantially
homologous to the chimeric, humanized and human antibodies, or antibody fragments thereof, set forth
herein. These can contain, for example, conservative substitution mutations, i.e. the substitution of one or
more amino acids by similar amino acids. For example, conservative substitution refers to the substitution
acid
of an amino acid with r within the same general class such as, for example, one acidic amino
with another acidic amino acid, one basic amino acid with another basic amino acid or one neutral amino
acid by another neutral amino acid. What is intended by a conservative amino acid substitution is well
known in the art.
The polypeptides of the present invention can be recombinant polypeptides, natural
polypeptédes, or synthetic polypeptides comprising an antibody, or fragment f, against a human
CD37. It will be recognized in the art that some amino acid sequences of the invention car; be varied
without significant effect of the structure or function of the protein. Thus, the invention further es
variations of the polypeptides which show ntial activity or which include regions of an antibody, or
fragment thereof, against CD37 protein. Such mutants include deletions, insertions, inversions, s,
and type substitutions.
The polypeptides and analogs can be further modified to contain additional chemical moieties
the biological half
not normally part of the protein. Those derivatized es can improve the solubility,
life or absorption of the protein. The moieties can also reduce or eliminate any desirable side effects of
proteins and the like. An overview for those moieties can be found in REMINGTON'S
PHARMACEUTICAL ES, 20th ed., Mack Publishing Co., Easton, PA .
The isolated polypeptides described herein can be produced by any suitable method known in
the art. Such methods range from direct protein synthetic methods to constructing a DNA sequence
encoding isolated polypeptide sequences and expressing those sequences in a le transformed host.
In some embodiments, a DNA sequence is constructed using recombinant technology by isolating or
synthesizing a DNA sequence encoding a wild—type protein of interest. Optionally, the sequence can be
W0 2012/135740 PCT/U82012/031648
mutagenized by site-specific mutagenesis to provide functional analogs thereof. See, e.g. Zoeller et al.,
Proc. Nat’l. Acad. Sci. USA 81:5662-5066 (1984) and US. Pat. No. 585.
In some embodiments a DNA sequence encoding a polypeptide of interest would be
constructed by chemical synthesis using an oligonucleotide synthesizer. Such oligonucleotides can be
designed based on the amino acid ce of the d ptide and selecting those codons that are
favored in the host cell in which the recombinant polypeptide of interest will be produced. Standard
methods can be applied to size an isolated polynucleotide sequence encoding an isolated
polypeptide of interest. For example, a complete amino acid sequence can be used to construct a back—
translated gene. Further, a DNA oligomer ning a tide sequence coding for the particular
isolated polypeptide can be synthesized. For example, several small oligonucleotides coding for portions
of the desired polypeptide can be synthesized and then ligated. The individual oligonucleotides typically
contain 5' or 3' overhangs for complementary asembly.
Once assembled (by synthesis, site-directed mutagenesis or another method), the
polynucleotide sequences encoding a particular isolated polypeptide of interest will be inserted into an
expression vector and operatively linked to an expression control sequence appropriate for expression of
the protein in a desired host. Proper assembly can be confirmed by nucleotide sequencing, restriction
g, and sion of a biologically active polypeptide in a suitable host. As is well known in the
art, in order to obtain high expression levels of a transfected gene in a host, the gene must be ively
linked to transcriptional and translational expression control sequences that are functional in the chosen
expression host.
] In certain embodiments, recombinant expression vectors are used to amplify and express
DNA encoding antibodies, or fragments thereof, against human CD37. Recombinant expression vectors
are replicable DNA constructs which have synthetic or cDNA-derived DNA nts encoding a
polypeptide chain of an anti-CD37 antibody, or fragment thereof, operatively linked to suitable
transcriptional or ational regulatory elements derived from ian, microbial, viral or insect
elements having
genes. A transcriptional unit generally comprises an assembly of (1) a genetic element or
a regulatory role in gene expression, for example, transcriptional promoters or enhancers, (2) a structural
or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate
transcription and ation initiation and termination sequences, as described in detail below. Such
regulatory elements can include an operator sequence to l ription. The ability to ate in a
host, usually conferred by an origin of replication, and a selection gene to facilitate recognition of
transformants can additionally be incorporated. DNA regions are operatively linked when they are
functionally d to each other. For example, DNA for a signal peptide (secretory leader) is operatively
linked to DNA for a polypeptide if it is expressed as a sor which participates in the secretion of the
polypeptide; a promoter is operatively linked to a coding sequence if it controls the transcription of the
._ 45 a
if it is positioned so as to
sequence; or a ribosome binding site is operatively linked to a coding sequence
permit translation. Structural elements intended for use in yeast expression systems include a leader
enabling extracellular secretion of translated protein by a host cell.
sequence Alternatively, where
recombinant protein is sed t a leader or transport sequence, it can e an N-terminal
methionine e. This residue can optionally be subsequently cleaved from the expressed recombinant
protein to provide a final product.
The choice of expression control sequence and expression vector will depend upon the choice
of host. A wide variety of expression host/vector combinations can be employed. Useful expression
vectors for eukaryotic hosts, include, for example, vectors comprising expression control ces from
SV40, bovine papilloma virus, adenovirus and cytomegalovirus. Useful expression vectors fer bacterial
hosts include known bacterial plasmids, such as plasmids from Esherichia coli, including pCR l, pBR322,
pMB9 and their derivatives, wider host range plasmids, such as M13 and filamentous -stranded
DNA phages.
Suitable host cells for expression of a CD37-binding polypeptide or antibody (or a CD37
protein to use as an antigen) include prokaryotes, yeast, insect or higher otic cells under the control
of appropriate promoters. Prokaryotes include gram negative or gram positive organisms, for example E.
coli or i. Higher eukaryotic cells include established cell lines of ian origin as described
below. Cell-free translation systems could also be ed. Appropriate cloning and expression s
for use with bacterial, fungal, yeast, and mammalian cellular hosts are described by Pouwels et al.
ng Vectors: A Laboratory Manual, Elsevier, N.Y., 1985), the relevant disclosure of which is hereby
incorporated by nce. Additional information regarding methods of protein production, including
dy production, can be found, e.g., in US. Patent Publication No. 2008/0187954, US. Patent Nos.
6,413,746 and 6,660,501, and International Patent Publication No. WO 04009823, each of which is
hereby incorporated by reference herein in its entirety.
Various mammalian or insect cell e systems are also advantageously employed to
s recombinant protein. Expression of recombinant proteins in mammalian cells can be performed
because such proteins are generally correctly folded, appropriately modified and completely functional.
Examples of suitable mammalian host cell lines include the COS-7 lines of monkey kidney cells,
described by Gluzman (Cell 23:175, 1981), and other cell lines capable of expressing an appropriate
vector including, for example, L cells, C127, 3T3, Chinese hamster ovary (CHO), HeLa and BHK cell
lines. Mammalian expression vectors can comprise nontranscribed elements such as an origin of
ation, a suitable promoter and enhancer linked to the gene to be expressed, and other 5' or 3' g
nontranscribed sequences, and 5' or 3' nontranslated sequences, such as necessary ribosome binding sites,
a polyadenylation site, splice donor and acceptor sites, and transcriptional ation sequences.
Baculovirus systems for production of heterologous ns in insect cells are reviewed by Luckow and
Summers, Bio/Technology 6:47 .
The proteins produced by a transformed host can be purified according to any suitable
method. Such standard methods e chromatography (e.g., ion exchange, y and sizing column
chromatography), centrifugation, differential lity, or by any other standard technique for protein
purification. Affinity tags such as hexahistidine, maltose binding domain, influenza coat sequence and
glutathione-S-transferase can be attached to the protein to allow easy purification by passage over an
appropriate affinity column. Isolated proteins can also be physically characterized using such techniques
as proteolysis, nuclear magnetic resonance and x-ray crystallography.
] For example, supematants from systems which secrete recombinant n into culture media
can be first concentrated using a commercially available protein concentration filter, for example, an
Amicon or ore Pellicon ultrafiltration unit. ing the concentration step, the concentrate can be
applied to a suitable purification matrix. Alternatively, an anion exchange resin can be employed, for
example, a matréx or substrate having pendant laminoethyl (DEAE) groups. The matrices can be
acrylamide, agarose, dextran, cellulose or other types ly employed in protein purification.
Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various
insoluble matrices comprising sulfopropyl or carboxymethyl groups. Finally, one or more reversed-phase
high performance liquid chromatography LC) steps employing hydrophobic RP-HPLC media,
be employed to further purify a CD37-
e.g., silica gel having pendant methyl or other aliphatic groups, can
binding agent. Some or all of the foregoing purification steps, in various combinations, can also be
employed to provide a homogeneous recombinant protein.
Recombinant protein ed in bacterial culture can be isolated, for example, by initial
extraction from cell pellets, followed by one or more concentration, salting—out, aqueous ion exchange or
size ion tography steps. High performance liquid chromatography (HPLC) can be employed
for final purification steps. Microbial cells ed in expression of a recombinant protein can be
disrupted by any convenient method, including freeze-thaw g, sonication, ical disruption, or
use of cell lysing agents.
Methods known in the art for purifying dies and other proteins also include, for
example, those described in US. Patent Publication No. 2008/0312425, 177048, and
2009/0187005, each of which is hereby incorporated by reference herein in its entirety.
In certain embodiments, the CD37—binding agent is a ptide that is not an antibody. A
variety of methods for identifying and producing non-antibody polypeptides that bind with high affinity to
a protein target are known in the art. See, e.g., Skerra, Curr. Opin. Biotechnol, 18:295-304 (2007), Hosse
et al., Protein Science, 15:14-27 (2006), Gill et al., Curr. Opin. Biotechnol, 17:653-658 (2006), Nygren,
FEBS J., 275:2668-76 (2008), and Skerra, FEBS J., 275:2677-83 (2008), each ofwhich is incorporated by
W0 2012/135740
reference herein in its entirety. In certain embodiments, phage display techeology has been used to
identify/produce the inding polypeptide. In n embodiments, the polypeptide comprises a
protein scaffold of a type selected from the group consisting of n A, a lipocalin, a fibronectin
domain, an ankyrin consensus repeat domain, and doxin.
In some embodiments, the agent is a non-protein molecule. In certain embodiments, the agent
is a small molecule. Combinatorial chemistry libraries and techniques useful in the identification of non-
protein CD37-binding agents are known to those skilled in the art. See, e.g., Kennedy et al., J. Comb.
Chem, 10:345—3 54 (2008), Dolle et al, J. Comb. Chem, 9:855—902 (2007), and Bhattacharyya, Curr. Med.
Chem., 8:1383—404 (2001), each of which is incorporated by reference herein in its entirety. In certain
further embodiments, the agent is a carbohydrate, a glycosaminoglycan, a glycoprotein, or a proteoglycan.
in certain embodiments, the agent is a nucleic acid aptamer. Aptamers are polynucleotide
molecules that have been selected (e.g., from random or mutagenized pools) on the basis of their ability to
bind to another molecule. In some embodiments, the aptamer comprises a DNA polynucleotide. In
certain alternative embodiments, the aptamer comprises an RNA polynucleotide. In certain embodiments,
the aptamer comprises one or more d nucleic acid residues. Methods of generating and screening
c acid aptamers for binding to proteins are well known in the art. See, e.g., U.S. Patent No.
163, U.S. Patent No. 5,683,867, U.S. Patent No. 5,763,595, U.S. Patent No. 6,344,321, U.S. Patent
No. 7,368,236, U.S. Patent No. 5,582,981, U.S. Patent No. 5,756,291, US. Patent No. 5,840,867, U.S.
Patent No. 7,312,325, U.S. Patent No. 7,329,742, International Patent Publication No. WO 02/077262,
International Patent Publication No. WO 984, U.S. Patent Application Publication No.
239134, U.S. Patent Application Publication No. 2005/0124565, and U.S. Patent Application
Publication No. 2008/022773 5, each of which is incorporated by reference herein in its entirety.
III. Immunoconjugates
The t invention is also directed to conjugates (also referred to herein as
conjugates), comprising the D37 antibodies, antibody fragments, and their functional
lents as disclosed herein, linked or conjugated to a drug or prodrug. Suitable drugs or prodrugs are
known in the art. The drugs or prodrugs can be cytotoxic agents. The cytotoxic agent used in the
cytotoxic ate of the present invention can be any compound that results in the death of a cell, or
induces cell death, or in some manner decreases cell viability, and includes, for example, maytansinoids
and maytansinoid analogs. Other suitable cytotoxic agents are for example benzodiazepines, taxoids, CC-
1065 and CC-1065 analogs, duocarmycins and duocarmycin analogs, enediynes, such as calicheamicins,
dolastatin and atin s including auristatins, tomaymycin derivaties, leptomycin derévaties,
methotrexate, cisplatin, carboplatin, ubicin, doxombicin, vincristine, vinblastine, lan,
cin C, chlorambucil and morpholino doxorubicin.
W0 2012/135740 PCT/U82012/031648
_ 49 _
Such conjugates can be prepared by using a linking group in order to link a drug or prodrug to
the antibody or functional equivalent. Suitable linking groups are well known in the art and include, for
example, disulfide groups, thioether groups, acid labile groups, photolabile groups, peptidase labile
groups and esterase labile .
The drug or prodrug can, for example, be linked to the anti-CD37 antibody or fragment
f through a disulfide bond. The linker molecule or crosslinking agent comprises a reactive chemical
thereof. The reactive chemical groups for
group that can react with the anti-CD37 antibody or fragment
reaction with the cell-binding agent can be N-succinimidyl esters and N—sulfosuccinimidyl esters.
onally the linker molecule comprises a reactive chemical group, which can be a dithiopyridyl group
that can react with the drug to form a disulfide bond. Linker molecules include, for example, N-
imidyl 3-(2-pyridyldithio) propionate (SPDP) (see, e.g., Carlsson et al., m. J., 173: 723-737
(1978)), N—succinimidyl 4-(2-pyridyldithio)butanoate (SPDB) (see, e.g., US. Patent No. 4,563,304), N-
succinimidyl 4-(2—pyridyldithio)2—sulfobutanoate (sulfo—SPDB) (see US Publication 'No. 20090274713) ,
N—succinimidyl 4-(2-pyridyldithio) oate (SPP) (see, e.g., CAS Registry number 341498-08—6), 2-
iminothiolane, or acetylsuccinic anhydride. For example, the antibody or cell binding agent can be
modified with crosslinking reagents and the dy or cell binding agent containing free or protected
thiol groups thus derived is then reacted with a disulfide- or thiol-containing maytansinoid to e
ates. The conjugates can be purified by chromatography, including but not limited to HPLC, size-
exclusion, adsorption, ion exchange and y capture, is or tangential flow filtration.
In another aspect of the t invention, the anti-CD37 antibody is linked to xic drugs
via disulfide bonds and a polyethylene glycol spacer in enhancing the potency, solubility or the y of
the immunoconjugate. Such cleavable hydrophilic linkers are described in W02009/0134976. The
additional benefit of this linker design is the desired high monomer ratio and the minimal aggregation of
the dy-drug conjugate. Specifically contemplated in this aspect are conjugates of cell-binding
agents and drugs linked via disulfide group (-S-S—) bearing polyethylene glycol spacers ((CH2CH20)H=H4)
with a narrow range of drug load of 2-8 are described that show relatively high potent biological activity
toward cells and have the d biochemical properties of high conjugation yield and high monomer
ratio with minimal protein aggregation.
Specifically contemplated in this aspect is an anti-CD37 antibody drug conjugate of
formula (I) or a conjugate of formula (1'):
CB—[X1+CH24:H2CHHNY—D]m (I)
[D—Y-(-CH2—CHZO~~~)n—X1]m-CB (1')
wherein:
CB represents an anti-CD37 antibody or fragment;
D represents a drug;
X represents an aliphatic, an aromatic or a heterocyclic unit attached to the cell—binding agent
via a thioether bond, an amide bond, at carbamate bond, or an ether bond;
Y represents an aliphatic, an aromatic or a heterocyclic unit attached to the drug Via a
disuifide bond;
{39:75} i is =3 or t;
{00176} m is an integer from 2 to 8; and
{00177} n is an integer from 1 to 24.
{00178} In some embodiments, m is an integer from 2 to 6.
{00:79] In some embodiments, m is an integer from 3 to 5.
{00180} In some embodiments, n is an integer form 2 to 8. tively, as disclosed in, for example,
US. Patent No. 6,441,163 and 7,368,565, the drug can be first modified to introduce a ve ester
suitable to react with a cell-binding agent. Reaction of these drugs containing an activated linker moiety
with a inding agent provides another method of producing a cell-binding agent drug conjugate.
Maytansinoids can also be linked to anti—CD37 antibody or fragment using PEG linking groups, as set
forth for example in US. Patent 6,716,821. These PEG non-cleavable g groups are soluble both in
water and in non-aqueous solvents, and can be used to join one or more cytotoxic agents to a cell binding
agent. Exemplary PEG linking groups include heterobifunctional PEG linkers that react with cytotoxic
agents and cell binding agents at opposite ends of the linkers through a functional dryl or disulfide
of the synthesis of a cytotoxic
group at one end, and an active ester at the other end. As a general example
conjugate using a PEG linking group, re “erence is again made to US Patent 6,716,821 which is
ineoiporated entirely by reference herein. Synthesis begins with the reaction of one or more cytotoxic
agents hearing a ve PEG moiety with a ceii—‘oinding agent, resulting in dispiacernent of the terminal
active ester of each reactive PEG moiety by an amino acid residue of the ceh g agent, to yield a
cytotoxic conjugate comprising one or more cytotoxic agents eovaientiy handed to a eeii g agent
through 21 PEG iinking group, Alternativciy, the cell g can be modified with the hifiinctionai PEG
crossiinker to introduce a reactive- disultide moiety (such as a idisttifide), which can “then he treated
with a thioi—eontaining niaytansinoid to e a conjugate. in another method, the ceii g can he
ed with the bit‘ttnctionai PEG crosstinker to introduce a thiol moiety which can then. can he treated
with 2t reactive disuttide-containing tnaytansinoid (such as a pyridyidisuitide), to provide a conjugate.
Antibody-maytansinoid conjugates with non—cleavable links can also be prepared. Such
crosslinkers are described in the art (see US ation No. 69933) and include but are not limited
to, N—succinimidyl 4—{maleimidomethyl) cyclohexanecarboxylate (SMCC). In some embodiments, the
antibody is modified with crosslinking reagents such as succinimidyl 4-(N-maleimidomethyl)—
cyclohexane—l—carboxylate (SMCC), sulfo-SMCC, maleimidobenzoyl—N-hydroxysuccinimide ester
W0 35740 PCT/U82012/031648
_ 51 _
(MBS), sulfo-MBS or succinimidyl-iodoacetate, as described in the literature, to introduce l-lO reactive
Hashida et al, J. Applied Biochem., 56—63
groups (Yoshitake et al, Eur. J. Biochem., 101 :395—399 (1979);
; and Liu et a1, m., 18:690-697 (1979)). The modified antibody is then reacted with the thiol-
containing maytansinoid derivative to produce a conjugate. The conjugate can be purified by gel filtration
h a Sephadex G25 column or by dialysis or tangential flow filtration. The modified antibodies are
treated with the thiol—containing maytansinoid (l to 2 molar equivalent/maleimido group) and antibody-
maytansinoid conjugates are purified by gel filtration through a Sephadex G—25 column, chromatography
on a ceramic yapatite , dialysis or tangential flow filtration or a combination of methods
thereof. Typically, an average of 1-10 maytansinoids per antibody are linked. One method is to modify
dies with succinimidyl 4-(N—maleimidomethyl)—cyclohexanecarboxylate (SMCC) to uce
maleimido groups followed by reaction of the modified antibody with a thiol-containing maytansinoid to
give a thioether—linked conjugate. Again conjugates with 1 to 10 drug molecules per antibody molecule
result. Maytansinoid conjugates of antibodies, dy fragments, and other proteins are made in the
same way.
In another aspect of the invention, the CD37 antibody is linked to the drug via a non—
cleavable bond through the intermediacy of a PEG spacer. Suitable crosslinking ts comprising
hydrophilic PEG chains that form s between a drug and the anti-CD37 antibody or fragment are
also well known in the art, or are commercially ble (for example from Quanta Biodesign, Powell,
Ohio), Suitable PEG-containing crosslinkers can also be synthesized from commercially available PEGs
themselves using standard tic chemistry techniques known to one skilled in the art. The drugs can
be reacted with bifunctional PEG-containing cross linkers to give compounds of the following formula, Z
X1 ( CH2 CHz—O )n Yp D, by methods described in detail in US Patent Publication 20090274713 and
in W02009/0134976, which can then react with the cell binding agent to provide a conjugate.
Alternatively, the cell binding can be modified with the bifunctional PEG inker to introduce a thiol-
reactive group (such as a maleimide or etamide) which can then be treated with a thiol-containing
maytansinoid to provide a conjugate. In another method, the cell g can be modified with the
bifunctional PEG crosslinker to introduce a thiol moiety which can then be treated with a thiol-reactive
maytansinoid (such as a maytansinoid bearing a maleimide or haloacetamide), to provide a conjugate.
Accordingly, r aspect of the present invention is an D37 antibody drug conjugate
of formula (II) or of formula (E'):
CB—[XH—CHz—CHZ--»O—),,—Yp—D]m (I?)
[D-Yp—(—CH2—CH2—O—)n—X1]m—CB (if)
wherein, CB represents an anti-CD37 antibody or fragment;
{00184} D represents a drug;
WO 35740
.. 52 ..
X represents an aliphatic, an aromatic or a cyclic unit bonded to the cell—binding agent
via a thioether bond, an amide bond, a carbamate bond, or an ether bond;
Y ents an aliphatic, an aromatic, or a heterocyclic unit bonded to the drug via a covalent
bond selected ferom the group consisting of a her bond, an amide bond, a carbamate bond, an ether
bond, an amine bond, a carbon-carbon bond and a hydrazone bond;
1 is 0 or 1;
p is 0 or 1;
m is an integer from 2 to 15; and
n is an it‘steger from 1 to 2000.
In some ments, m is an integer from 2 to 8; and
In some embodiments, n is an integer from 1 to 24.
In some ments, m is an r from 2 to 6.
In some embodiments, m is an integer from 3 to 5.
In some embodiments, n is an integer from 2 to 8. Examples of suitable PEG-containing
linkers e linkers having an N-succinimidyl ester or N—sulfosuccinimidyl ester moiety for reaction
with the anti—CD37 antibody or fragment thereof, as well as a maleimido— or haloacetyl-based moiety for
reaction with the compound. A PEG spacer can be incorporated into any crosslinker known in the art by
the methods described herein.
Many of the linkers disclosed herein are described in detail in US. Patent Publication
Nos. 20050169933 and 20090274713, and in WO2009/0134976; the contents of which are entirely
incorporated herein by reference.
The present ion includes aspects wherein about 2 to about 8 drug molecules ("drug
load"), for example, maytansinoid, are linked to an anti-CD37 antibody or fzagment thereof. "Drug load",
as used herein, refers to the number of drug molecules (e.g., a maytansinoid) that can be attached to a cell
g agent (e.g., an anti-CD37 antibody or fragment thereof). In one aspect, the number of drug
molecules that can be attached to a cell binding agent can average from about 2 to about 8 (e.g., 1.9, 2.0,
2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4,
4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8,
6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1). Nzi—deacetyl-Nzi—(3-mercapt0-l-0x0propyl)-
maytansine (DM1) and NT-deacetyl-NT-(4-mercapto—4—methyloxopentyl) maytansine (DM4) can be
used.
Tiéius, in one aspect, an immunocongugate comprises 1 maytansinoid per antibody. in
another aspect, an immunocongugate ses 2 maytansinoids per antibody. In another aspect, an
immunocongugate comprises 3 maytansinoids per antibody. In another aspect, an immunocongugate
comprises 4 maytansinoids per antibody. In another aspect. an immunocongugate comprises 5
2012/031648
_ 53 _
maytansinoids per antibody. In another aspect, an immunocongugate comprises 6 maytansinoids per
dy. In another aspect, an immunocongugate comprises 7 sinoids per antibody. In another
aspect, an immunocongugate comprises 8 maytansinoids per antibody.
In one aspect, an immunoconjugate comprises about 1 to about 8 maytansinoids per antibody.
In another aspect, an immunoconjugate comprises about 2 to about 7 maytansinoids per dy. In
another aspect, an immunoconjugate comprises about 2 to about 6 sinoids per antibody. In another
aspect, an immunoconjugate comprises about 2 to about 5 maytansinoids per antibody. In another aspect,
an immunoconjugate comprises about 3 to about 5 maytansinoids per antibody. In another aspect, an
immunoconjugate comprises about 3 to about 4 sinoids per antibody.
In one aspect, a composition comprising immunoconjugates has an average of about 2 to
about 8 (e.g., 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9,
4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3,
6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1) drug molecules (e.g.,
maytansinoids) attached per antibody. In one aspect, a composition comprising immunoconjugates has an
average of about 1 to about 8 drug les (e.g., maytansinoids) per antibody. In one aspect, a
composition comprising immunoconjugates has an average of about 2 to about 7 drug molecules (e.g.,
maytansinoids) per antibody. In one aspect, a composition comprising conjugates has an average
of about 2 to about 6 drug molecules (e.g., maytansinoids) per antibody. In one aspect, a composition
comprising immunoconjugates has an average of about 2 to about 5 drug molecules (e.g., maytansinoids)
per antibody. In one aspect, a composition comprising immunoconjugates has an average of about 3 to
about 5 drug molecules (e.g., maytansinoids) per dy. In one aspect, a composition sing
conjugates has an average of about 3 to about 4 drug molecules (e.g., maytansinoids) per
antibody.
} in one aspect, a composition comprising immunoconjugates has an average of about 2 d: 0.5,
about 3 :1: 0.5, about 4 i 0.5, about 5 i 0.5, about 6 I 0.5, about .7 ;+.- 0.5, or about 8 i 0.5 drug molecules
(e.g., maytansinoids) attached per antibody. In one aspect, a ition comprising immunoconjugates
has an e of about 3.5 2+: 0.5 drug molecuies (e.g., sinoids) per antibody.
{002025 The anti4CD37 antibody or fragment thereof can be modified by reacting a. bifunctional
crosslinbing reagent with the anti—CD37 antibody or fragment f, thereby ing in the covalent
attachment of a linker molecule to tbe anti~CD37 antibody or fragment thereof. As used herein, a
"bifunctional crosslinking reagent" is any chemical moiety that covalently links a cell—binding agent to a
drug, such as the drugs described herein. In another method, a portion of the linking moiety is provided
by the drug. In this respect, the drug comprises a linking moiety that is part of a larger linker molecule
that is used to join the cell-binding agent to the drug. For example, to form the maytansinoid DMl, the
side chain at the C—3 hydroxyl group of maytansine is modified to have a free sulfliydryl group (SH). This
W0 2012/135740
_ 54 _
thiolated form of maytansine can react with a modified cell—binding agent to form a conjugate. Therefore,
the final linker is led from two components, one of which is provided by the crosslinking t,
while the other is provided by the side chain from DMl.
The drug molecules can also be linked to the antibody molecules through an intermediary
carrier molecule such as serum albumin.
As used herein, the expression "linked to a cell—binding agent" or "linked to an anti—CD37
antibody or fragmen " refers to the conjugate molecule comprising at least one drug derivative bound to a
cell-binding agent anti-CD37 antibody or fragment via a suitable linking group, or a precursor thereof.
One linking group is SMCC.
In certain embodiments, cytotoxic agents useful in the present ion are maytansinoids
and maytansinoid analogs. Examples of suitable maytansinoids include esters of maytansinol and
maytansinol s. Included are any drugs that inhibit microtubule formation and that are highly toxic
to mammalian cells, as are sinol and maytansinol analogs.
Examples of suitable maytansinol esters include those having a modified aromatic ring and
those having ations at other positions. Such suitable maytansinoids are disclosed in US. Patent
Nos. 4,424,219; 746; 4,294,757; 4,307,016; 4,313,946; 4,315,929; 4,331,598; 4,361,650; 4,362,663;
4,364,866; 4,450,254; 4,322,348; 4,371,533; 5,208,020; 5,416,064; 5,475,092; 5,585,499; 5,846,545;
6,333,410; 7,276,497 and 7,473,796.
In a n embodiment, the immunoconjugates of the ion utilize the thiol-containing
maytansinoid (DMI), formally termed Nzi—deacetyl-NZZB—mercapto—1- oxopropy1)-maytansine, as the
cytotoxic agent. DMl is represented by the following structural formula (111):
o 91%
T SH
9' \ <3
«“3. - 9x, ;«
, x. - w , K .V- \ .14
\ .2- \Y \x‘ \xE-e" ' \rA:‘~.-
U l K ,
l K ,
:, t 1
.=: t
" 4,
-\,\~/
\ ~"flA\‘L‘O_
\k, ,‘v"\\ /‘:\,
/ .v" N, &
‘,\" \' H" ‘ N H
I O
MeO (111)
In another embodiment, the conjugates of the t invention utilize the thiol-containing
sinoid acetyl-N27(4—methy1mercapto—l- oxopenty1)—maytansine (e.g., DM4) as the
cytotoxic agent. DM4 is represented by the following structural formula (IV):
23' \ 2:
2 C.
wa \2 3 2222\2
wa/‘l «(g-"Lu,
2, y"\\ %‘\
i \‘fig «~+:L\ i
S C N 0
M90 HO H (IV)
Another maytansinoid comprising a side chain that contains a sterically hindered thiol bond is
N2,~deacetyl-N-2’(4-mercapto-l—oxopentyl)—maytansine (termed DM3), represented by the following
structural formula (V):
Meé (V)
] Each of the maytansinoids taught in US Patent No. 5,208,020 and 7,276,497, can also be used
in the conjugate of the present invention. In this , the entire disclosure of 5,208,020 and 7,276,697
is incorporated herein by reference.
Many positions on maytansinoids can serve as the on to chemically link the linking
moiety. For example, the C—3 position having a hydroxyl group, the C-14 position modified with
hydroxymethyl, the C-15 on modified with hydroxy and the C—20 position having a hydroxy group
are all expected to be useful. In some embodiments, the C-3 position serves as the position to chemically
link the linking moiety, and in some particular embodiments, the C-3 position of maytansinol serves as the
on to chemically link the linking moiety.
Structural representations of some conjugates are shown below:
W0 2012/135740 PCT/U82012/031648
z \r .-
CI ’
‘ \ I' o
i I
2 MeO Q
‘N“'“\,.~-"‘\\ «:3 R' E V O
\f’w o
,‘3 E .J" \O
E : N 0 Ab = Antibody
MeO HO H
DM1: R=H, q=1
3 DM4: R= CH3,q=2
A, n =1-24 g 2-8
Ab—PEG—Mal-DM 1/DM4 (VI)
3+ "1
o o
g H
N S -, i
g 91"! 0
Cl Q I N/\/U\N/\,QO\\;~"“}~4\. $‘N
g E i
E “Jib \ “O, H
",- MeO\‘/_fl\ \{IN -.__“\\ \\ ‘5‘} O \‘a
.,\ \3 {/1 O 1*”
‘\f} xi i
E E". \O
\“wy\\ /““‘
Fri” fiN/koV,” Ab = An‘ubody.
MeO HO H
Ab-PEG4-Ma1-DM1 (VII)
{ /‘
Z 0
3 Med H0 H Ab = Antibody
. R' = H or Me
i DM1: R=H, q=1
i DM4: R= CH3, q=2 :
= 1-24
K «2192-8
AbPEG—SIA—DMl/DM4 (VIII)
s‘M‘Kf/WMflN j k
\ ‘\..»v-“' _\,
k : ‘\
s = O
MeO HO
C—DMl
Ab = Antibody
Ab-SPP—DMl (XI)
_ 58 -
f“ ’"x
t O
S \
\\ ,
O O
9' \ Et ? . a
3‘ ..
MeO\/\ N \1.7-» ,./\,
w IҤ \a
\\\\
Ab—A_ m1'b d0 y
”“aim/“kl,..«""\,\_,,_..._i>\, x
MeO HO H
“ _,.3 2-5
Ab—SPDB-DM4 (XII)
e» w\
.5 SOs-N5
s i
VT HMAb
\8 2" x\\ , \XY},
r’ ‘O
“We, ~\_ /_.a\ i k Ab=Antibody
§ V" x
3 \S 5 N O :
‘ MeO HO H
“a, “9“"
Ab-SulfO-SPDB—DM4 (XIII)
Several ptions for producing such antibody—maytansinoid conjugates are ed in
US. Patent Nos. 6,333,410, 6,441,163, 6,716,821, and 7,368,565, each of which is incorporated herein in
its entirety.
In general, a solution of an antibody in aqueous buffer can be incubated with a molar excess
of maytansinoids having a de moiety that bears a reactive group. The reaction mixture can be
quenched by addition of excess amine (such as ethanolamine, taurine, etc). The maytansinoid-antibody
conjugate can then be purified by gel filtration.
The number of maytansinoid molecules bound per dy molecule can be determined by
measuring spectrophotometrically the ratio of the absorbance at 252 nm and 280 nm. The average
number of maytansinoid molecules/antibody can be, for example, about 1—10, 2-5, 3-4, or about 3.5. In
one aspect, the average number of maytansinoid molecules/antibody is about 3.5 i 0.5.
Anthracycline compounds, as well as derivatives, intermediates and modified versions
f, can also be used to prepare anti-CD37 immunoconjugates. For example, doxorubicin,
bicin derivatives, doxorubicin intermediates, and modified doxorubicins can be used in anti-CD37
conjugates. Exemplary compounds are bed in , which is herein incorporated by
reference in its entirety. Such compounds e, for example, compounds of the following formula:
W0 35740 PCT/U82012/031648
_ 59 _
wherein R1 is a hydrogen atom, hydroxy or y group and R2 is a C1-C5 alkoxy group, or a
pharmaceutically acceptable salt thereof.
Conjugates of dies with maytansinoid or other drugs can be evaluated for their ability to
suppress proliferation of various unwanted cell lines in vitro. For example, cell lines such as the human
lymphoma cell line Daudi and the human lymphoma cell line Ramos, can easily be used for the
assessment of cytotoxicity of these compounds. Cells to be evaluated can be d to the compounds
for 4 to 5 days and the surviving ons of cells measured in direct assays by known methods. IC50
values can then be ated from the results of the assays.
The immunoconjugates can, according to some embodiments described herein, be internalized
into cells. The immunocongugate, therefore, can exert a therapeutic effect when it is taken up by, or
internalized, by a CD37—expressing cell. In some particular embodiments, the immunoconjugate
comprises an antibody, antibody fragment, or polypeptide, linked to a cytotoxic agent by a cleavable
linker, and the cytotoxic agent is cleaved from the antibody, antibody fragment, or polypeptide, wherein it
is internalized by a CD37-expressing cell.
In some ments, the immunoconjugates are capable of depleting B-cells, e.g.
active B-cells. For example, in some embodiments, treatment with an immunoconjugate results in a
depletion of at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about
45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, or
at least about 75% of s.
In another aspect of the invention siRNA molecules can be linked to the antibodies of the
present invention instead of a drug. siRNAs can be linked to the antibodies of the present invention by
methods ly used for the modification of oligonucleotides (see, for example, US Patent
Publications 20050107325 and 20070213292). Thus the siRNA in its 3’ or 5’—phosphoromidite form can
be reacted with one end of the crosslinker bearing a hydroxyl functionality to give an ester bond between
the siRNA and the crosslinker. Similarly reaction of the siRNA phosphoramidite with a crosslinker
bearing a terminal amino group results in linkage of the inker to the siRNA through an amine.
atively, the siRNA can be derivatized by standard chemical methods to introduce a thiol group.
W0 2012/135740 PCT/U82012/031648
_ 60 _
This thiol-containing siRNA can be reacted with an antibody, that has been modified to uce an
active disulfide or maleimide moiety, to produce a cleavable or non cleavable conjugate. Between 1 — 20
siRNA molecules can be linked to an antibody by this .
III. Polynucleotides
In certain embodiments, the invention encompasses polynucleotides comprising
polynucleotides that encode a polypeptide that specifically binds CD37 or a fragment of such a
polypeptide. For example, the invention es a polynucleotide comprising a nucleic acid sequence
that s an antibody to a human CD37 or encodes a fragment of such an antibody. The
polynucleotides of the invention can be in the form of RNA or in the form of DNA. DNA includes
cDNA, genomic DNA, and synthetic DNA; and can be —stranded or single—stranded, and if single
stranded can be the coding strand or non-coding (anti-sense) strand.
In certain embodiments, the polynucleotides are isolated. In certain embodiments, the
cleotides are substantially pure.
The invention provides a cleotide comprising a polynucleotide encoding a ptide
comprising a sequence selected from the group consisting of SEQ ID NOsz4—l20.
The invention further es a polynucleotide comprising a sequence selected from those
shown in Tables 7—10 below.
Table 7: Variable heavy chain polynucleotide ces
mmVHPolvnucleotide Sequence(SEQ_:IDNO)
§mUCD37-3 3°gtgmagtcaggacctggcctggtggcgccctcacagagcctgtccattacatgcactg
tctcagggttctcattaaccacctctggtgtaagctgggttcgccagcctccaggaaagggtctggagtg
gctgggagtaatatggggtgacgggagcacaaactatcattcagctctcaaatccagactgagcatcaag
aaggatcactccaagagccaagttttcttaaaactgaacagtctgcaaactgatgacacagccacgtact
Iactgtgccaaaggaggctactcgttggctcactggggccaagggactctggtcacagtctctgca (SEQ IDNO: 121)
{fichCD373 aagcttgccaccatggctgtcctggcactgctcctctgcctggtgacatacccaagctgtgtcctatcacaggtgcaggtg
tcaggacctggcctggtggcgccctcacagagcctgtccattacatgcactgtctcagggttctcattaaccac
ctctggtgtaagctgggttcgccagcctccaggaaagggtctggagtggctgggagtaatatggggtgacgggagcac
. aaactatcattcagctctcaaatccagactgagcatcaagaaggatcactccaagagccaagttttcttaaaactgaacagtz?
ctgcaaactgatgacacagccacgtactactgtgccaaaggaggctactcgttggctcactggggccaagggactctggg
itcacautctct*cagcctctacvaam‘wccc(SEQIDNQ: 122)
huCD37-3v10 aagcttgccaccatgggttggagctgcattattctgtttctggtggccaccgccaccggtgtgcactcacaagtccaagtc
1““ caagaatctggtccaggtctggtggccccttcccaaactctgagcatcacctgtaccgtttctggttttagccttaccacctc
itggtgtgagttgggtacgccaaccacccggtaagggtctcgaatggctgggtgtaatctggggtgatggttccacaaatt
accatccttccctcaagtcccgccttagcatcaaaaaggatcacagcaaaagtcaagttttcctgaaactgaatagtctgac
agcagccgatacagccacctactattgcgccaagggtggttatagtcttgcacactggggtcaaggtaccctcgttaccgt:
umnniflctcctcactagtaccaaz.fgeccc(SEQIDNQ:I23} __ j
t huCD37—3vll aagcttgccaccatgggctggagctgtatcattctgtttctggtggcgacagctactggggtccactcccaagtgcaggta
caagagtccgggcctggattggtcgcaccaagccagaccctctctatcacttgtaccgttagcgggttctctctgacaacc
Gtgfaztgagttgggtga=x(cagccaccaggaaagggactxtiagtggctgggggtgatttg 2* g
W0 2012/135740 PCT/U82012/031648
_ 61 _
: LaaactatcaitccagtcfiaaatL’nggtLGtLLattaaz.c1d&z,dCCZ€idLId.idfCtCfiflngL1' aaactcaaLagLL.
gaaagccOcafiacactgaacgafiactfiLgLLaaaHUaLL
sjaLLLivtLaiLLgcatcazicaaa L.c{SEQ 113‘ N(J:1 "’
V..LLLL.L“.......
777777....LLLLLLLLL““““.._. 5...“...«n
muCD3712 EcagamcagiL‘tggtg agtctggacm anLIgaagdagLLt‘ggdgq(magma... U
Lfictgggta‘tacattcacaaagtatggaaigaactgggtgaagcaggct'aamadawvtfiaaagtg
{*aafiLngggdLagrtttgcctic
1 gatgggctggataaacaccaacactggagagtcaagaaatgc
3 tctflggaaacctctgccacvcactrILLi‘att‘LQcaLzatLaaLaLLLEL:aaatatgaggacacggctacat
E2:131nggaaggggL-LgtagLLgLLoaLtggngcaaLLdLLaciLtLaLagtLtLLLca (SEQID
L....,,_............................ . .1 VVV........ ....LL.LLL..LL........
V........... .LL.............._._................
gchCD37- 12 gc3LLatggg-aogiLaioca‘aaiLLLL'tiLtgotcgctaLtuLmLLggt9:91.LtLaLaLaitLaa1‘91;
ttcaaagiggccmoathbaoaaagLagggaaaoatwaaadtaathLLaaggca mggfiacactficacaaa
gtficggcai(53.81;{9.331033%amcccagggcaagf “{LLLadana‘iga0'{Egg}3'9:LaaiaccaacactcDgazg
agtLtL-iwaatLLigavgaomaaggpccwffloficwcdggagaca'w gccagcac.LagLLfiacctgcaaafi
aaLaatLtgaagtatgaEgltdgdgfldfiLCLfimGEGCgELNngLac-tgLLgfigLLagactggggacaaggtacca
‘ act);m‘cLaLLva3:caL{$12.00LL (QLQ 11) N(J:126}"3v" “W.L........._.‘“............ ... ....VVVV.V.....................L
L.,a Digcagm4337335333,:«Ctgat.CtgéfigdadcfimkdfitLLttLLaLmaLLLgL (3O
teactggctactccatoaccagtgamiggctggcac.tggaicLLL”castfiLLaOLaaaaagctga3'0
atggatggcctacaiacmiacagig.{giggcacto6LtaLaaLLLathLtLama‘rtLULLatL‘"Ltac
aLILLvagacaLfi‘“ am‘tLttLLLgLfiofigfik1gt£VaLv1chiJaz§E~Y’lcaC&gLcacai
afiactgtgcagdrwcLaLtaLULUacgg{VLLtogmUmscwgwcLaaggactctggmac
l”i?§s:33f:§.<.§fl;11}.3§91” _...-
___________________________________________
«any...,,,,,,,,H,..”,,......,,..................................___.._chCD3738 E aagcfigccaccatg gciggag‘itgiatcafictgmfio3190mmLGLLLLLiWaLLLLatLLLLLaotLLaaLtLL
aggaatctggccm‘gacctacttaaUL‘VLiLLcagaO'cLILrccctoaLLTgLameLagbamLicaatca'L‘aiLLag
octfigt‘Ltgficac‘woatcasmaatitLLLgoLaacaagttggviatogatgthiacafictgtatagngjgggtaccg 5 1:)
attacm L‘Li Lthcaaga9ccgaaL‘zMatLaLLai—Jf(rataLawLacLLaa-‘caamfitctm QLLtcag{(2:ngt:
acia"°ga.dg..3.iacgcta.taLtattgtPLLagmLtaLtaiggaiat’rgfiLdtLguLOELLLthggggccaggga
acccm‘tagggg34mg. v; '
a ' V ;, 33)
. .7.....L...LLLLL“3.““....L.....
hUCB37'38 aagcétgcc' “3&th,gtigga'5 ctggzLiLLdLiLaLaogtLLangc
aagavtLLguicgmguggaaacccaocLaLtLLcTL.gtLtLaLLLLmeiLt.LLigthaLtLtmaLcagtgg1&1").
0{toggLtgvcafiggmmggwg‘mcLL‘9«{taagvggctggagto93*ggbLatatatLLt9faLaUL3332123933"c
gai‘tacaaLtcL.agtctgaayaficafiga{€304.4thcQLLLLaLawLaaaaaccafit’rmLLnogthgCtsigi .
: ’*d0LtgagaLaLchLtaLnaLtafiotngtggmLidtgngtowLLIggmgtgtafivqggacaaw
’ ‘ ' ‘ “c @331955‘foHJNQ: 179)
_ » -_.
muCD37-50
ag gLagLfiLagg gt aggucdgacLiofiganLLtttLaJLLdLmLaLtLaLctcactg
{LaLWOLtaL:CLthcaLLagtagmchtcC,L'1L£6gatLL69agttmaggaaacaaaaégga
ggga.taLaLaLtL{110391353918gLaLtgthLagLLLaitctcaaaagt-c.gaatctctam
actegagacactLLaaLaaLLaLLtLLiLLLLLagttoaartL-Lfih'acgamaLaLagLLde‘:(O g
.......... afiaLtngaagwggmLLaivgitaL‘LLLgcLtggmgcfiactggggccaagggaLLtciggtLac
L.:3:3:ct:,_..:ca<83“
..“a””,.V,..,..,,,,..‘,.........................................'Hii‘éfié'ifimw 33»ngKELCLlLLc‘l‘nggbgig’kaLOLataatLLthLt gtigciactctaccvcavtccafi'VL'wggtgcagctgL
figgagtccggCCCCi‘flOL-EULiCddUL‘LfiL-RagagtLtgaotrgacfiEL‘LEgmLWLLMLaGLtagccagcg
gmcgcfiggLaLfgLLfiLagaLducatLLwLLaaLaaacgflagtogatog&atacdmtLtaLE’LaLOcLLaaLL
g:ctattchthcLLtgaaatnccggatcacmiaLccgtL33:10acmtaagaas.LaWLtQLachtgaaLaflLvtt' L<{Lagugacamocam013k1:81.{EEGCLngjLUd'LéifldU’gLitnggdgcfigvfLthtacthggLLad90
' 5CflCC-G
muCD3751 cagLtléflggfigtLfiboakabchtgfiammHLLLaL‘LLtuLaLiLa.LEgLaLtg3
IcactggciacLieaLLLLLangmLOLLEggLacfggamggagiticcaggaaacaaadgga
3:333«Egg,thaLstaLaLtdLaUELLagL-aLtaaL‘taLaocLLamNcaaaagtcgaatctctam
actsg2agactcatLcaagaaLLagficficctmaE,ttLaaLtLtLLLaLtdLigaagaLacagccacat
E gcaagvawaiaaatgvgmcngLLt9.j€ttLina.[Ugggccaagggactciggtcac
“L La ssmmxo 133)
AagcttgLLaLLaLngLLLLLLfiLLatLaLLLtgmLtggtggccactgwacirm
" ,L
LLLaOGaaichf-L:1321"“C(- try! (n \ , »'\ L- 4 (L .,
WO 35740 PCT/U82012/031648
_ 62 _
W1”ggctttgcttggcactggattcggcagtttccaggcaagggactogaatggatgggctacatccattacagtggctcaac
caattacagccctagcctgcagggccgaatctctattaccagggatagttctattaaccagtttttcctgcagcttaattccgt
gactgcctctgacacagcaacttactattgcgcccotggctactacoggttcOgagcctgtttgtatactggggtcaggg
muCD3756 gatgtgcagcttcaggagtcaggacctgacctogtgaaaccttctcagtcactttcactcacctgcactg
tcactggctactccatcaccagtggttttgcctggcactggatccggcagtttccaggaaacaaactgga
atggatgggctacatacactacagtggtggcactaactacaacccatctctcaaaagtcgagtctctatc .3
actcgagacacatccaagaaccagttcttcctgcagttgaattctgtgactactgaggacacagccacatattactgtgcaa
actatggtttcggggcctggtttgcttactggggccaagggactctggtccc
Lemmag3SEQ1D NQ:13332)33
h CD37—56 aagcttgccaccatgg0gtggagctgcattatcctgttcctcgtcgccaccgcaaccggcgtccactcccaggtgcagct
: gcaagaaagcgggccaggattggtaaaaccttcccagtctctgagtcttacttgtaccgtatctggatacagtatcacatct
ggcttcgcctggcattggattcgccagtttcccggcaaggggcttgagtggatggggtatattcattattctggaggtacca
actacaacccttccctgaagagtcgagtctcaattaccagggacacttccaagaaccaattctttttgcagcttaattcagtg
accgctgccgacaccgctacttactactgcgcccgggDctactatgggtttggtgcctggttcgcctactggggccaggg
muCD37-57 gatgtgcagcttcaggagtcaggacctgacctgfigaaaccttctcaotcactttcactcacctgcactg
i tcactggctactccatcaccagtggttttgcctggcactggatocggcagtttccaggaaacaaactgga
atggatgggctacatactctacagtggtagcactgtctacagcccatctctcaaaagtcgaatctctatc 33
actcgagacacatccaagaaccagttcttcctgcagttgaattctgtgactactgaggacacagccacatattactgtgcaa
gagggtactatggttacggcgcctggtttgcttactggggccaagggactctggtcactgtctctgca (SEQ ID
311L133.) ___w
huCD37—57 aagcttgccaccatgggctg0agctgcatcattctgtttctggtggccacagcaactggcgttcacagtcaagtccaactg
caggagagcggccccggactcctgaaaccatctcagtcactcagtctgacatgtactgtgagcggctacagcattacctc
aggcttcgcttggcattggatcaggcagttccccggaaaaggtctggagtggatggggtacattctgtacagcggcagta
cagtgtattcaccctccttgaaatctaggatatcaatcacacgtgatacaagcaaaaatcagttcttcctccagctgaactcc
gtcaccgccgcagacacagcaacctattattgtgctcgcggatactacggatatggcgcatgttcgcctattggggcca
ggggacactcfituaccgtttccrgccocctccacaaaLiLCCC(SEQIDNQ:135__)_\v. \:_____ ____ .1
252-3 gaggtgcaggtggtggagtctgggggagacttagtgaagcctogagggtccctgaaactctcctotgcagcctctggat
tcactttcagtagctatggcatgtcttgggttcgccagactccagacaagaggctggagtgggtcgcaaccattagtagtg
gtggtagttacacctactctccagacagtgtgaaggggcgattcaccatctccagagacaatgccaagaaaaccctgtac
ctgcaaatgagcagtctgaagtctgaggacacagccatgtattactgtgcaagacatagttactacgatactagcgtcgac
tactggggtcaagaacmiségcgtctccwMSEQlDNO182) 3
Table 8: Variable light chain cleotide sequences
1 l
VL PolxnucleotldeSequence(SEQ1D NO)
1 muCD37-3 cagatgactcagtctccagcctccctttctgtatctgtgggagaaactgtcaccatcacatgtc
E gageaagtgagaatattcgcagtaatttagcatggtatcagcagaaacagggaaaatctcctcagctcct
E ggtcaatgttgcaacaaacttagcagatggtgtgccatcaaggttcagtggcagtggatcaggcacacag
tattccctcaagatcaacagcctgcagtctgaagattttgggacttattactgtcaacattattggggta
‘1fl1x“WWWMMA_uHA“Euctaca1‘{ft/acattcggtggaggcaccawctm‘aaatcaadcct(SEQ112NQ:136)
i3rchCD37-3 gaattcgccaccatgagtgtgcccactcaggEcelggggttgctgctgctgtggcttacagatgccagatgtgacatccag
atgactcagtctccagcctccctttctgtatctgtgggagaaactgtcaccatcacatgtcgagcaagtgagaatattcgca
tagcatggtatcagcagaaacagggaaaatctcctcagctcctggtcaatgtgcaacaaacttagcagatggtgt 1
gccatcaaggttcagtggcagtggatcaggcacacagtattccctcaagatcaacagcctgcagtctgaagattttggga E
cttattactgtcaacattattggggtactacgtggacgttcggtggaggcaccaagctggaaatcaaacgtacg (SEQ ‘
333311) No 137) _
huCD37—3 gaattcgccaccatgggt‘tggtcctgcatcatcttg‘tttctcgtggccacagccaccggtgttcactctgatatacaaatgac
(1.0 and 1.1) tcaaagcccttccagtttgagcgtaagtgtgggtgaacgcgtaacaatcacctgtaoagctagtgaaaacatccgcagta
T1,”,Mflflflflwu. tattctctggttcaaottcg
g_maccGattattcacttaao’ttcaactcacc:t
accagaacatttcgcctacatatta
ictgtcaacaactactgg«4.1cgtacgacctggacattcggtcaagrtactaagccggaaatcaagcgtacg {SEQ 113
WM) 1
muCD37 12 gacattgt ctaacacaccctcctgc151;cttaotgtatctctg
fiwccc'wccaaactcagta‘a tacgatact‘atttgtactggttccavcao'Laaaggacagcc
fiacccaaactcficatcaactatgacaacxtamatctggggtca'V°caggttcagtmcact{2g
tctgggacagacttcaa‘cccaacatcatcctotggaggaooagcatactgcaacatattacwtcaac
' "
iacac‘1tO_gaooattccgtacacattcggacgcgacmazctggaaataaaas
...........................g.
chCD37-12 oaattcoccaccatgc"ttgvtcctgtamacctOEtctcggtgcancccractgccgmatactgatattctacis:act005
gtcaccagccagtctcficamgtccct00occ'tgcgtgcaccatcccctccccogcctcacagtccUtgagcac1a
gctcttattcctatctctactgctttcaacagaagccawaagcc‘ctacgctgctvatcaaotacnctccaacctcgc
caccgmcttcccgctagattctctggttccggtagcUgaact’satttcactttgaacatccacccccttgaggaaagga
tacc ccacttacéattctcaacactcttgaoacattccttaacctttgcaggaogaacaaagctccaaattaaacctacg
13:5ch . .». 1
muCD37—3 8 caaattgttctcacmagtctccagcaatcatgtctocatctccacgggacaagotctcacctgca
gtgccagct‘aao'tgtaacttacatmactovtaccaagaagtcawcacct aaaagatggat
ttatgacacatccaaactcocttctggaotccctmtcccttcactYfY’ggtUggtcgggaacctcttac
tctctcacaatcaocascatggaccctcaacatcctcccacttattac1gccagcagtgP‘xz rgattactaam
i ‘
cacccac: .tcc ‘ c’vgaccaagctgcaaattaaacc) (SEQ 11)
___..uu_............"“......____________________
“c“ \<“““
chC1337-38 gaattc; caccatgcgctggtcctotattacctgtttctcctgcccacaociataggtgttcattctcaJ L .ttgtgctgac
ccaatcaccavctattatvtccgtagcccggccagaaagagacaatfiacatctaowcta01tcttctgtgacttacat
gcattggtatcaacagaagtcaggtaccagtcttaagcgttooatcwccacacatccaaactcxtcutccg.. CC? agtccctg
cagcggaggtgggtc.ccaccagttamac'gaccatatcctct'ttgmacctcaacawctoctacitatta
ttgtcaacaatggatttctaaccccccccaccttiggtggngaacaaagctggagatcaagcgtacg (SEQ ID
N132142)
: gaattcgccaccatccvv{gotcctgcattattctgttcttggtcgccacto1tactcccgacactctattctvctcacaCy "unannflflflrflwr
. E
c 121510311“debkfiulgfcLUCt'CCCCGEEZQ1gEUC(milk*c'ttgtcatoctctoccagttcctcg:.gacatatatgc
~ attwtatcaccaaaaacggtacctctccaaaaaatggatcctacgacacttcaaagcttowtaggcgttcctgcca
t gattttccgggtctgggictggcacttcaacagtctgacccttwtt’catgaancivaagacgca‘ccacctattactgt
t .\
t cagcagtggatttcaaatctccaccitcggcggcgyaacaaactggagataaagcgtacv 1113
‘ w NO: 143,
caaattcttctcacccagttccagcaacatgtciocatctxcac.g ggacaaggtcaccatgacdgca
gtgccacctcaagtgtgacttacatgcactgstaccagcagaagtcagg;acctcccccaaaagatggatuatgaca">
1,.V......_________ ctgccttatgagtccxtggtcgtttcactggtacgggtctgggattactctctcacaatcagcagcatgg
antarctoaagatoctoccacttattactgccaocao‘rgwagtoataacccccccacgttcggctcggggacaaagttgga
{3EQMID N01143:
Wmflflfl,flflfl,”,, ccaccatgccacfi“‘atrtcattattctctr‘tugttgctacgmaggagtacatag oasaagtccicac
gcattcgtatcaocaaaagcct“occaatcccctaaaagctgga‘tctaccatactttta'atccocataccctgtgcccgc
aafmttctcongagtgfigcagtogagcacrtatagtctcaccatcactiaatggaagtagaogtgcagcaacctatt
acctcaocaotgvt"gataatcccgctacttttggtcagggtacaaaficumwattaagcctac ( ‘EEQ 1D
‘?_:__
muCD37-5 1 caaattgttctcacccagtctccagcaatcatgtctgcatctccaggggagaaggtcaccatgacctgca
gtgccacctcaagtgtgacttacatgcactggtaccagcagaagtcaggcacctcccccaaaagatggatttatgacaca
tccaaactggcttctggagtccctgctcgcttcagtggcagtgggtctgggacctcttactctctcacaatcagcaacatgg
aagatgctgccacttattactgccagcagtggagtagtaacccacccacgttcggctcggggacaaagttgga
am(SEQID149146),,,,,,,,,,,,,,WM
1111163637351 .
t gaattcgccaccatgggatggagctgtattattctgttcctggttgctactgctactggcgtccattccgagatagtcctcac
t ccccgcaaccatgagtgcctcccctggggagcgagtgactatgacttgttccgccacttcttcagttacctatat
\ gcattggtatcagcagaaacctggacagtctccaaagcgttggatttacgacacctccaacctggcttcaggagttcctgc
1 taggttcagcggatctgggtctggcacaagttattcactcaccattagttccatggaggccgaagatgccgctacttactac
1 tgtcagcagtggagcagcaacccccctacattcgggcagggaactaagctggagatcaaacgtacg (SEQ ID
Lcccap—Magcauuu. ........"v. ___NO:14_7)
W0 2012/135740 PCT/U82012/031648
_ 64 _
muCD3756¢ gttctcacccagtctccagcattcatgtctgcatctcCaggggataaggtcaccat9acct9ca
gtgccagttcaagtg?acttacatgcactggtatcagcagaagtcaggcaoctcccccaaaagatggatttatgacacat
tggcttctggagtccctgctcgcttcagtggcggtgggtctgggacctcttac
acaatcagcaccatggaggctgaagatgctgccacttattactgccagcagtggattagtgacc
EECacccaCOTtCMaggg ggaccaaoctggaaataaaacm(SEQIQNQ:__148) ..
E huCD3756 gaattcgccaccatgggctggtcct tatcatcctgtttctggtggcaaccgctactggg ttcaCECtatattgtcctgacg g g
E :
E acagagtccagccttcatgagtgcttctcccggagaaaaggtcacaatgacttgttcagcttcctcctccgtcacatacatg
E cattggtaccagcagaagcCtgaccagagtcctaagaggtggatctatgatacaagcaatctggcttccggtgtcccctc
E ccgcttttcaggcggcggaagcggaactgactatagcCttaccatctcctcaatggaagccgaggacgctgctacatatt
E E actgccagcaatggatcagcgaccctcctactttcggacagggaacaaaattggaaattaagcgtacg (SEQ ID
—57 caaatt9ttctcaccCagtctccageaatCatgtctgcatctccaggggagaaggtcaccatgaCCtgca
Egtgccacctcaagtgtgacttacatgcactggtaccageagaagtcaggcacctcocccaaaagatggatttatgacaca
tCcaaactggcttctggagtccctchgcttCagtggcagtgggtctgggacctcttactotctcacaatcagcagcatggE
Eaggctgaagatgctgccacttattactgccagcagtggagtgataacccacccacgttcggctcggggacaaagttgga E
aataaa‘CmfSEQ ID NO:150) E
huCD3 7-57 gaattcgccacCatggggtggtcctgtattatcctgttcctggtcgcaaccgccacaggcgttcactccgagatcgtgttga
1 ctcagagcccagccaCCatgtCCgcttCCCCCggggagagagtgacaatgacttgttccgccacaagttctgtaacctac
atgcattggtaccagcaaaaaccaggacagagtccccgtcgttggatttatgatacctctaacctggcttcaggcgttcctgE
CCcgcttttctggtagtggatctgggacttcctatagccttaccataagctctatggaagccgaggacgccgctacatacta
ctgccagcagtggagtgataacccccccaccttcgggcagggaaccaaattggagatcaaacgtacg (SEQ ID
No912 _I.
252-3 E gatatccagatgacacagactacatcctccctgtctgcctctctgggagacagagtcaccatcagttmagggc
53 aagtcaggacattagcaattatttaaactggtatcagcagaaacCCgatggaactg’ctaaactcctgatctactac
acatcaaaattacactcaggagtcccatcaaggttCagtggCagtgggtctggaacagattattctctcaccatt
agcaacctggagcaagaagatattgcCacttacttttgccaacagggtaatgcgcttccgtggacgttcggtggE
aggcaccaa9ctaactcaaacgg (SEQ ID NQ: 183)
Table 9: ength heavy Chain polynucleotide sequences
Antlbodx ~ HeaV ham Pol‘nucleotlde SC}:EuenCC (SEQID NO‘
E ___.“ __
__enfth
ChCD373 aagctthCaccatggctgtcctggcactgctcctctgcctggtgacataCCCaaoctgtgtcctatcacaggtgcaggtg
aaggagtcaggacCtggcctggtggcgCCCtcacagagcctgtccattacatgcactgtctcagggttctcattaaccac
ctctggtgtaagctgggttcgcCagcctccaggaaagggtctggagtggctgggagtaatatggggtgacgggagcac
aaactatcattcagctctcaaatCCagactgagcatcaagaaggatcactccaagagccaagttttcttaaaactgaacagt
ctgcaaactgatgacacagccacgtactactgtgccaaaggaggctactcgttggctcactggggccaagggactctgg
E tcacagtctctgcagcctctacgaagggcccatcagttttccccttggctccaagttctaaatccacaagcggtggaacag
Ctgcactgggatgcctcgttaaagattatttccctgagcctgtgacagtgagctggaatagcggagcattgacttcaggtgt
gCacactt‘ttcccgctgtgttgcagtCctccggtctgtadcactgtccagtgtcgtaaccgtcccttctagcagcttgggaa
CCcagaCctacatctgtaacgtcaaccataaaCCatccaacacaaaggtggataagaaggttgaaccaaagagctgtga
taagacacatacatgccctccttgtcctgcaccagagctcctcggaggtccatctgtgttcCtgtttccccccaaacccaag
gacactcttatgatctctcgtactccagaggtcacctgtgttgttgtcgacgtgagccatgaagatcccgaggttaaattcaa
ctggtaCgtggatggagtcgaggttcacaathCaagaCcaagcccagggaggagcaatataattctacatatcgggta
gtgagcgttctgaccgtgctcCaccaagattggctcaatggaaaagagtacaagtgcaaggtgtccaaeaaggctcttcC
cgctcccattgagaaaactatctccaaagccaaggggcagccacgggaaccccaggtgtatacattgcccccatctaga
gacgagctgaccaagaaccaggtgagtctcacttgtctggtcaaggggttttacccttctgacattgctgtagagtgggag
tctaacggacagccagaaaacaactacaagacaactcccccagtgctggacagcgacgggagcttcttcctctactcca
agttgactgtagacaagtctagatggcagcaaggaaacgttttctcctgctcagtaathatgaggctctgcacaatcacta
iaéf
W0 2012/135740 2012/031648
., 55 _
aaLaatLtggtssLatgtstkgt;{90LsLtTsLaaaLtLtriavsaLLasLtgtaLsmstqgtfiLagLst‘taLeaLstL
ng‘tgt*aottgggtL'tsgse'assetsLngtaagggttsgaatgfisiLgg:gtaaktggggtgatgg‘tsLaLaaa‘tt
assatsst‘tssstsaagtsLLgLLttaOLatLaaaaaggatsasagstaaaagtsaagtfitestgaaaLtgaatagtstgas
agsagsLgatasafisLasLmsLaLtgLLLL‘aaopaget‘tataotLfioeasasingtLaaggas:sstsgfiassg
stsstsagstagtassaagggscsatsaotLttsLLLttgo'iLsaaLrtstaatssasaagsggtggaasagstgsast
ggga'n'gLLgt‘taaagattattzsLstgagsstgtgasagtgagLtggaatagsggagsaflgasttsaggtgtgeasLa
fittcsLscgstgtgttgsagtsstssggtstgtastsastgtssagtgtsgtaaesgtsesfietagsagsttgggaasssaga
setasatstgtaaegteaassataaassatssaasasaaaggtggatmgaafggfttvaassaaagaostotgataagasasatasaigssstssttc
’tsstgsacsagavst"sggaggtL‘LatstofgttLstLtttsLsLsLaaaLsLaaogasast
atststsgtasLLsaf‘aggtsaLLtvtgttrttfisgasgtguossatoaaoatsLsgawtiaaafisaaLLgta
L4UtggatggagtLgaogttsasaatgseaagasaagesszngaggamaatotaaustasatahngmgtLao"
asLUtthLsaLLaaattggstsaatggaaaagag‘tasaagto(aaggtgtcLaasaagthLttsLsgLtss
auto«gmaaLtatLtLLaaaLssaaagggsaossangcaaLL"‘f3gigtataeat‘tgssescatstagagasga
0sigaL‘saaoaasLaggwagtLimLagistggtLaagggnttLtaL‘L‘ttstgasai‘tgstgtagag‘tgLgaUtLtaaL
ggasagssaoaaaasaastasaagaLaLtLiLL‘LLLag‘wstgoaLageUasggg'=g7-'L‘.tts’ztssEL‘tastssaagttga
. LtgtagasaagtLtagatggLagLaaggaaaLLtLttctsLtgL‘tLagtaatgLatgtgLsetigeasaatsactatasss
: asaaaiLaL tssstta{essay *tL‘aLLLHag (SEQ ID N0:33)1:LL'.LLLLLLL.4\:L LLLLLLLLLLLLL“ __......LLLLLLLLLLLLLLH
LLLLLLLLLLL.QM-elh
huCDS ”3% 1 L
L aaosttgLsasLaiLmLtUgathomiLattstgfitstggtggsgasagstastg<3LgtsL34Ltsssaagtgsaggta
L saagsgtseggLsthafttggtsgsaLs'agesagaLsststLtatsast‘tgtaLLgttagsgg.magasaase
3 agtogax‘rgao{tagg‘tgaggsagssassaggaaagggastggaGiggstgggggtgatttggmsosogeagsa
i aaaLtatLaaLLag‘LLmaatstsggitgtssatLaaaaaao22LsataotaaatLtsaagttLtLstg'LaasELaatagsL4t
. 1 gasagssgsagasastgstasgta'taetUsgssaaawaoLataLwtLtggctsastgt‘tasaggggawsiggtgassgtgtsatssgsateaasaaagggLseatLagttitLLLLELLULLLLaagttsLaaotsLaL'taLsggtggaaeagstgcactgggatgsstLgttaaagattatttsLstwTestO’tgasathaaLtm‘hataggggLattoa"ttsa0giLtosasasttttsLsthgm‘iLLant"‘tLLLoILLOXasXLaLtgtLLagiLtegtasgt‘tstLLagsaws‘LtgggrxLLLagaLLLaft‘taamtcaasataaaLLatsaLar210n“taagaaggt‘tgaaLLaaa'raoswtga
L taagaeaeatasatgLsL‘iessttgtssttgea:‘agag‘tsstsg‘gtsLa‘isigtottsLtwmsLLesstaasssaag
aLaLtLttagateteisLgtastscagaaag tLgtg,tttg’ttgtLfigaLLtLaLLsatoaagatsssgaggfiaaatsaa .
csaagsseagggax'gageaatasaattstmatatsgggta
: ggtaL4stggatggagLLgaoUttLaLaatocLaag
gtgagsgt‘tLtgasLgtgstssaLsaagatflthLaatggaoagta'm‘gtg‘aaggtgLL‘2a‘saaggsLtsttss
sgsta‘:LLattgagaaaaLtatLtLsaaasL4aagfiggsesaLL‘gggaascsLaggtO'tatasatV—VLL.L‘a‘tstaga
stgassaagaasLagatoagtstsasttgtggstaaggggtttiaLsLttsMaLa‘tthgtaga'Itgggag .4
tstaasggasagssagaaaaeaaLtasaagaLaasrsesesagtgLtggaLaosganggaosmttststaetesa .
atwttgastotaoasaantiwarW‘LgsaaggaaaLgmstsLtthsugiLawLagaggctctgLasaatcas‘ra L L
{LLLLLagaaatmLt gggxg 0 ED NO:E34) L
V V __V_ a
* aa;7“ft0sLaLsangY'thgtsa’tgLataatLstsmLtggtsthaLtaLwLsggigtosasLLaLa'Ta‘a‘Lathgg t
shCDB’Y—lZ
ttsaaagtggLsLagagLtgaaaaagsLaggggaaasagtgaaaataagitge:aggsa‘zssggttasasmsasaaa
gtasggsatgaastgggtsaagsagvsssaGggLaagggBLtLaaatwatoggtg;at‘Latassaasastggsg
agtstaggaatgsigaggagitmagggLs'igtttssst‘LLavestoga0aLaaUtgLsavsasavsfiasstgsaaats
i } aasaatstoaaotatgawatmagsaaLetatttefigs0gL:sgLggca01LmfisaUaLtggovasaaggtaesaLsagaLtg‘ia‘LLLagtgLsagsastaagLssafLathisst‘tgfgen.Laagttstaaatssasaagsggtggaa I
sagstgsastgggatgsstegfiaaagattatfisedgageLtgtgasagtgagstggaatagsggagsa‘ttgasttsag .
, .
‘ gtgtgsasaemisssvstvtgttgsaotsstesggtstgtasteastgtssagtgtsgtaasegtessttstagsagsfigg .
LLLLLLLLL............... L. .
vaasLsa2asstasatdgmasusaasataaascatesaacaeaaaggtggataagaaggttgamsaaagagst‘g
tga‘taagasasatasaz‘.gssL.4ts4s tgtLLLgsaseagagstsLtsopaag‘tsatLtgamLetgtt‘tssssssaaassc
aggasaststtatgatststsgiactssagaggtsasetgtgttgttgtegaaLsgtgagLsatgaagatssegaggttaaati
Laastggtasgtggatggagtsgaggttsasaatgseaagassaagsssagggaggageaatataattstasatat‘cgg
,,,..4,””,.,.:.:.:.,............ gtagtgagLgastgassgtgctssaesaaga‘ttggstsaatgoamafiagtaeaagtgmagvtgts't'iasmogststtsssgstsssattgagaaaastatstesaaagssaaggggsagsLLasgggaasLsLaggtomfaLatigsseatstagagaegagstgassaagaassa7gbagtstsaettgtstggtLaaggggttttaLsLttLtgasattosagagt.gggagtstaasggasaossagaaLaaL'qstasaag 2:422astsLsLsagtgLtggasagLLaLngathtsttsszctast"‘aavtiLaLtLlaaLaagtstagatUUsaoLa'tggCza'tsgtt;LtLstoLisaotaatosatgagthLtgLasaatLasmtasssat‘aaatsasLLthLttagLsLags; ‘ (fit-1‘3.”{W0 11) NO: 15
-66—
EchCD37—3 8“ ;gefigeggaze;giggg51gig‘Egga;5Migft’aiggt‘Eggs;a;Eggagem‘eaagigeaaasa""g;
aggaatctggccctgacctggttaagccatctcagagcctctccctgacctgcactgttacaggatactcaatcacatcag
gctttggctggcactggatcagacaatttcccgggaacaagttggaatggatggcttacattctgtatagcgggggtaccg
atccttccctcaagagccgaatctctatcaccagggatacaagcaagaaccaattttttctccgcctcagctctgtg
actaccgaagataccgctacttactattgtgccaggggctactatggatatggtgcatggttcgtctattggggccaggga
accctggtgactgtgagcgctgcctctaccaagggcccatcagttttccccttggctccaagttctaaatccacaagcggt
ggaacagctgcactgggatgcctcgttaaagattatttccctgagcctgtgacagtgagctggaatagcggagcattgact
Etcaggtgtgcacacttttcccgctgtgttgcagtcctccggtctgtactcactgtccagtgtcgtaaccgtcccttctagcag
E cttgggaacccagacctacatctgtaacgtcaaccataaaccatccaacacaaaggtggataagaaggttgaaccaaag
agctgtgataagacacatacatgccctccttgtcctgcaccagagctcctcggaggtccatctgtgttcctgtttcccccca
aacccaaggacactcttatgatctctcgtactccagaggtcacctgtgttgttgtcgacgtgagccatgaagatcccgqgg
ttaaattcaactggtacgtggatggagtcgaggttcacaatgccaagaccaagcccagggaggagcaatataattctaca
tatcgggtagtgagcgttctgaccgtgctccaccaagattggctcaatggaaaagagtacaagtgcaaggtgtccaacaa
ggctcttcccgctcccattgagaaaactatctccaaagccaaggggcagccacgggaaccccaggtgtatacattgccc
ccatctagagacgagctgaccaagaaccaggtgagtctcadtgtctggtcaaggggttttacccttctgacattgctgtag
agtgggagtctaacggacagccagaaaacaactacaagacaactcccccagtgctggacagcgacgggagcttcttcc
tctactccaagttgactgtagacaagtctagatggcagcaaggaaacgttttctcctgctcagtaatgcatgaggctctgca
huCD3738 aagcttgccaccatgggttggagctgcatcattcttttcctggtcgctactgcaactggagtccactcacaggtccagctgc
ccggtcctgggcttgtgaaacccagccagtccctcagtctcacctgtactgtctctggctactctattaccagtgg
gttcggctggcattggattaggcagtttcccggtaaggggctggagtggatggcatatatcctgtacagcggaggaacc
gattacaacccaagtctgaagagcaggatcagcattacccgggacacaagcaaaaaccagtttttccttcggctgtctagt
gttacagctgcagacaccgctacttactattgtgctcggggttactatggctatggggcttggtttgtgtattggggacaag
s gcactcttgtgaccgtgagcagcgcctcaacaaagggcccatcagttttccccttggctccaagttctaaatccacaagcg
E gtggaacagctgcactgggatgcctcgttaaagattatttccctgagcctgtgacagtgagctggaatagcggagcattg
acttcaggtgtgcacacttttcccgctgtgttgcagtcctccggtctgtactcactgtccagtgtcgtaaccgtcccttctagc
E agcttgggaacccagacctacatctgtaacgtcaaccataaaccatccaacacaaaggtggataagaaggttgaaccaa
E agagctgtgataagacacatacatgccctccttgtcctgcaccagagctcctcggaggtccatctgtgttcctgtttccccc
caaacccaaggacactCttatgatctctcgtactccagaggtcacctgtgttgttgtcgacgtgagccatgaagatcccga E
E ggttaaattcaactggtacgtggatggagtcgaggttcacaatgccaagaccaagcccagggaggagcaatataattcta
E catatcgggtagtgagcgttctgaccgtgctccaccaagattggctcaatggaaaagagtacaagtgcaaggtgtccaac
aaggctcttcccgctcccattgagaaaactatctccaaagccaaggggcagccacgggaaccccaggtgtatacattgc
ccccatctagagacgagctgaccaagaaccaggtgagtctcacttgtctggtcaaggggttttacccttctgacattgctgt
agagtgggagtctaacggacagccagaaaacaactacaagacaactcccccagtgctggacagcgacgggagcttctt
cctctactccaagttgactgtagacaagtctagatggcagcaaggaaacgttttctcctgctcagtaatgcatgaggctctg
cacaatcactatacccas;aaatcactgtcccttagcccagggtgactcgag: (_SEQ"I_D_NQ:157)
E-huCD3750 “g““unnuuuu...mu"......mmx-"z‘"nu..."w...w.
\\\\\\\\\\\\\\\\\\\\\\\\\\Wu—hw
ccggccccggcctgctcaagccttctcagagtctgagtctgacttgtactgtttctggctacagcataaccagcgE
gtttcgcttggcactggatcagacagcatcccggcaacaaactggagtggatgggatacatactgtactcaggctcaact
gtctattccccctccctgaaatcccggatcagtattacccgtgacacttctaagaaccatttttttctgcagctgaacagcgtt
accgcagctgacactgcaacctactactgtgcccggggatattatggatacggagcttggttcgcttactggggccaagg
caccctcgtaactgtgagtgctgcttccaccaagggcccatcagttttccccttggctccaagttctaaatccacaagcggt
ggaacagctgcactgggatgcctcgttaaagattatttccctgagcctgtgacagtgagctggaatagcggagcattgact
Etcaggtgtgcacacttttcccgctgtgttgcagtcctccggtctgtactcactgtccagtgtcgtaaocgtcccttctagcag
cttgggaacccagacctacatctgtaacgtcaaccataaaccatccaacacaaaggtggataagaaggttgaaccaaag
agctgtgataagacacatacatgccctccttgtcctgcaccagagctcctcggaggtccatctgtgttcctgtttcccccca
aacccaaggacactcttatgatctctcgtactccagaggtcacctgtgttgttgtcgacgtgagccatgaagatcccgagg
ttaaattcaactggtacgtggatggagtcgaggttcacaatgccaagaccaagcccagggaggagcaatataattctaca
tatcgggtagtgagcgttctgaccgtgctccac'caagattggctcaatggaaaagagéacaagtgcaaggtgtccaacaa
tcccgctcccattgagaaaactatctccaaagccaaggggcagccacgggaaccccaggtgtatacattgccc
ccatctagagacgagctgaccaagaaccaggtgagtctcacttgtctggtcaaggggttttacccttctgacattgctgtag
agtgggagtctaacggacagccagaaaacaactacaagacaactcccccagtgctggacagcgacgggaocttcttcc
t3:CCttagCCC
—51 E; 3:5
I ggCttthttggCCCtggafiCWcavu‘tCC210th2121310bg2‘3C3tgiatvgdtgggCtaCatCCattdCagto0th23C.
caattaCabCCCtagCCth2tggchgiatCtCt2itt21CCa2gataowtts:attaaCCagtttttCCta"~;,Ctt23312tcC9C.’
f gaCtg‘CctCtoacacama21CttactattvcgCCCUthCtdCtan.1CooattCCtwtttfitdtathggt'102223
caCCCthLCatgtctcagC
chctctaCCCagC,gCCCratcajC,[titsCCCt:-.gg3..3CCdagttcta2123mmCatwcwt
ggartcagC‘thCCtgggathtctC‘2gttaaagattatttCCCtgagCCtgtgacagtgagctggaatagszggagcattgaact;
tcaggtgtgcacaCttttCCCgctgtgttgcagtCCtCCO‘gtCtgtathqctgtccaototcUt‘)accgtcwttctaficag
CttgggaaCCcagaCCmca[CtgtmtcgtcaaCcataaaCCatCCaacaCa'ta‘wtgantagaagflttmeC21mg
2131:0thgfifaagfi-‘JfiCat?!{SaigCCCiCCfigKUECEICC$2ivtCCtCW-raggtCCat ”tottmtvtttCCCCcca
aacccaaggacacEcttatgatctctcgtactCcagaggtczwtgtgttott CgaCng‘ioCCaI‘FaitgatCCCgng 3
ttaaattcaactggtacgtggatggagtcbItogttcticaatt.23233g2CCC412ngccagggavoagCaatCtdattCtaCa 3
tatcgggtagtwavcgttctgdchthtCCaCC'ta2tt0gCtC312ttg22t312331‘2331,32:23.10tgc2taoptC‘tCC2t'xsd21 3
ggctcttCCCCgCtCCC‘a‘ttg.agaaddttatCtCCaa'thcaaggggCcagCCaC;’gfidLCLCEi};jtgtatamtthCC 3
CcatCtaC'tga“0210:1033.caagaaCCaggtgagtCtCadtfitCtggCC3121gg0Ctttt21CCC:tts:tgaCattoctotag 3
agtaggagtctaacggacagCcag21212123C21aCt23Ca31g2‘3CaaCtCCCCC.gtgutggacagngngbgCttcttCC. C
tCt31CtCCaagjtgactstavacaagtctagatgngagC:a2:maaaCC‘ttttctcctgctcaataatm:atgaggCtCttha .
3 ‘ 3
C23C 21312333203: ‘taaatCaCtsztcscttax- act ”3%...EEEQ 11} N31):t."‘3,3m 3
"huCD37—56 3
aagC‘tthCC‘CCt,gggtggagcthtttatCCtgttCCtC{CgCC’d-CCQCédCbnggtLLdCtCC(23100tf’C‘a‘FCE 3
: 3
gcaagaaagcgggCCaggattggtaadm/CttCCCdCtCtCtoaUtcttacttgt1CCUt31tCtggammgtatcacatct 3
ggCttcgcctggmttgcattCUCCCCtttCCCgoC212tgqucttomtg-Vamp?gtCtCttthttCttCt 3
_ a 3
21CtacaaC:ccttCCCtgaagagtC9.21gtCtCaat‘taCC§,E,ded(,fikcaagaaCC‘aattcttttt.gCagCttaattcagtg t
CCULC. 021‘thng-tacttactactpcgcccgC,ggCt21Ct2tt3 igtttggtgcctggttcb7CCta.CtggggCC-2tggC—r
UaCCCtggthCCgttgCtCC.gCCtCCamaaggWC‘atCattttCCCCttCCCtCC3121CttCt32‘321tCcacaagC
tCCaavmtctgca.gggatoCCtCott2t21gfittattthC‘tgaCtgtvaCacwagtggadtdfiCCgaCCattCaC
tthrIgtotgcaCacttétc"CovtotgttCC21»*CCCtCngtC.tgtz1thatothaotCtCCtadCgtCCCttCtzth2233:,
Cttgggaa»;‘CC213123103:moatctgtaantC-aaccat212121CC21‘tCC2331C11C‘21aagotgoat’taoaaggttfiaaCCaaav
agthtgdtawacaC‘ataCztthCCtCCHf‘TCQT‘T”aCCuC,"'iCCthUdg, C2 otgttCCtot‘tCCCCMa
2323CCCadggaCaCtCttCtgatctctCotCCtCCagaggtCaCC‘tCtUttqttgtC322Cgtg C“-W2312102131901»agg
ttaaattcaaCtgntaCGtggmggaflwa'iCttcacmtgcm023C021m.CCCoggL,magcadt31tC23ttC.2tCa
tatcgggtagtoaocgttCtoaCCgtUthcaCcaagattv0CtwatggaaaagagtacQagtfiCdagCtgtCCaacaa
2 gCtCtthchtCCC2ttt-1omaact'ttCthttaavccamgchthCMCCCg31CCCC2‘383‘t0t‘1taC23tth“
sactCtagmaCtzagCt1221mm210232103.aggtvagtctcm‘t‘rtctvgt2121523,?>ttLC1CCCttCtgaCCttvctgttg:04
3 aggtC'vagtCtdaCUgCtmwC2.g3221231aC213taCaaga.Ca21CtCCCCC2tgthtggaCagCganggagCttCtth
x tcta‘thaaCtthtCtnthacaaCtC3.10zatagcaocaaUgaattcyttttttcctgctCagtaatgcatgaggCtctgca 5
3 " ID 330360)
3 ggtt'tnCC132232123{nggitCCCttdz- CCangtoaCtC ______________________________
huCD37—57 CCCaCcatgggCtggwgC 31 :atcattCtgrttCtootgC acaccaaCthCttcaC233,1:0212TtCCaaCtj
cagggagCLigCC-C‘Cfiga'tCC-toaadCcaCtCtCagtcaCta3gctgac2twt31CthCa'fCWCL21igcattacctc‘
aggcttc37:0ttggC2 ttvodtmeathCCCCgaaaACotCt;:10r,tggatgvggmCattCtgtaCdQngCagta 1
ttCaCCCtCCtt:32:atCtdggatatCattCfiCaCCtCatacafi3.0213213at1WCEYLC‘C"‘§.,Ctga£ECi‘V"
: gtcaCCCgccgcagac21C30CaaCCtattdttUthtwggflfiCtdCCCmatgfichatayttCOCCtdtttzwrszC1 3
gr:g23C2CLCCYLUaCCthuchchCCCC2132123,;ggCCC231Ca33ttttCCCCtthCtCCmf‘ttctuaatCCdeg
ngtggaaCarrCt'iCdCtgggatCCCthttaaaoattatttCCCtUagCCCgtCaCaCt”Ct'roaatagcggagCat
tgacttmggtgt3T"23C23CttttCCC3rC{Giotto&OtkCECCQgTLfgtaCTKaLTgtC2tgtfitCm3123CCrrtwcttCta
gcagcttoomaCCC2131.1chatCtUtaaCCtCaaC312323233.CatCCaaCaCaaaqgtggatadzaaftgttgaaCC
2.2311621:th£2,1magacac21tacatguCCtCCttUtCCthCthamCCtCCtcggaggtCcatCtgtgtthtgtttCCC
CCC323aCCCa'tgfiCthCtCttawatCtCthtaCa0athC21CC.tgCattwttgtCtt'tcvtgagC23tg2331g23tCCC
gaggttaaattCaathtngggdtggwtm UgttcaCaatgccaagaCCaaOCCCdgg‘21g31agC31-21t2tt2321tt
ctaCi-tta‘tcgggt21;;thCgt:gttCtCachtCC‘t313Cdegdfi“‘JLiCdcflggddégigdgtfiCaaott?0&§lggt9ffijc
aacaaggctcttccCchCitCCCttmaaaaactatCtCcaaaUCCaaggcagCCanwaaCCC‘aggtetatacat
EQCCCCcatCtagggacga C ggggttttaCCcttCtg‘2332231131;
‘ ' ‘
‘ ‘
' “ “ “ 3323-3 ' ' <‘“3223C63.923gc
4 4 4.4.“\\\L“..........,,_.w~aaaL““A. gcafgawc"LLLLLLLLLLL‘‘L
w________ L“\“FL‘LLLWLLLLW”
Antlbod E
chCD373 Od&EECELLfiLCLHé3thLLoaLiLagtLLtgggLfigctotthgIOthtaC'xgatg"*agaigtLaLa‘iLLag
aigaLtLagiLmLagL.CECLL‘LE’ELtgiaioigtgggagaaadgtcaooatcaoatgtLgagoaagigagaaLaitLgCa
gtaatttag0atggtatoagcagaaamgggaaaatotoCtCagCEcctggmaaigflgcaacaaaofiagoagatggtgi
aagCfiLagtvgcagtfi‘O‘atcaggcaoaoagtafiocottcaagatcaaoagcctgcagtczgaagatmggga
CfiattactgtoaacattaitggggtaotacgiggaogficthgaggoaccaagotggaaatcaaaogtacQfitggow
cazccatLtgtofiLatLt o{LwaigaocaOECaaatLtggaaLfgLoiatgitgwigCotontoaamaLfiota
tCLCagagaggoLaaagtaCaoioLaaggtogataachLoC’iLoaatgggiaaotoccaggagagtgto3Cagagc
aocaaggaagoaoctaLCOLL?‘agoagoaocotgacgotgam433LgLagdLiaC"agdaawcaaaot
oiaC0LLthoaaotLaLoLanagggoctgagotogcocgtoaoaaagagcitLaacaggggagagtgfiag3
v“n“... .LLLLLLLLLLLLLL“
“““LLLL‘LLL—Mg“4.(son)3359.162)
mhuCD37-3 aa’tLgCLaLLatgth . LgLaLLaLttott:CtgigchaoagocaccggiLtiLauLigatamLaaatoaL
(1.0 and 1.1) i ECLiachLttCLagtttgtaagigtjggigmgcgtaacaatoaoLtomgdLoiagiaaaacaiccgoagta
231i.thLaiggtacoaaCaaaagoLaggiaavts:aLLtaaacthtc:ItomtwfigotuowCLtcvotgatvgtUtgo
oiioaogatiLiLiggficaggttongLoamfioatiadgaicaaLtLaLtLoaaCLaCaagaitingiacama
LtgtoficatomC4ogcoatotgatgigcagttgaaatctggaaotgogc:“LCgtgLLLgLigaaiaaLttCtaICLod
gagaggoCaaavtaoagtggqawtggataaogcoctcoaatcgggtaaLE'LCLL4aggg.smgtglLaciigagoaggao L
deaagLacamaLLtaoaOCLtLagCgem:oCtgachtgagcaaagcaqaL wgagaaaczxsaaagtotacgc L K
: 3
gime canggLotGaCLtgoC-CgiLacaadgaCLtiLaai'gggagagtgttag (SEQ ID C
NO: 163) \
chCD3712 \
gamogLCaCLai0ggflggtofigtataatCLtgttLtivvEggLL4chLgLmagchmgataotgutafigiactoact \
“Mann“...m... \
CGgtoaooagcoagtCtggCagiothLtggPocagcgtgocaocaCicctgcogggoLtoaLjttoCGIgaooaCta 3
gctcfiafiootatciotaotggtfio:aLagaeLocCaggasacoCLoiaLg:gtCigatcaagt'(LochtccaaCCrcgo \
CagoggcortwoootagafioLLiovtiLCoLLwCooaaotoamoao‘mgaaLa{LLaLLLLgitggggaagagga
_.... taCLgCLaLfiaLLtaItgtLaacaotcfigggacattLLKaLaLLm0Gaagamaaoaaagotogaaatt'aagcgtzwg
Wfluflfl.”flu—”y,"5...... gtggLWLdL:tctgtcfioatcttcocCLC:1thgatgaUCaatLgaaatN0gaaothCtotvfificivodgdgdai
aacttomtcocagagaggLfaaagtaCagtgoa.aag.g0aiaaLCLLLiLLaatLLgUEaaL{L‘ooao0agagtha
caoagoaggaLagCaagg:agCaLLtoLagLotoaocavmCoigac(5cigagLaz=a0Ca<>aLtacgavaaaLa
totaorrLLtoLgaagtaCCLatcagggoCdgagotogcocgt'tascaaagzthtLaamggaqagangfia I
Nmmmmw“
-~—»~»--—»« ~- —-—
chCD37—3 8 aft“gCLaLC'ttghLLiggtLLtg afLatCLLgtttLtLgtggoLaoamacéggtgficaitchagafimgdgdoof
LaatLaLoaUCEafiatgtLogLagerCLCggCoagaaaatfiaLmioaatgtzagC2L1:gthctotgacfiaoaf ......
_;cattggtatoaaLagJAgLL,ggtaco:chC“aanogfiggaflmogaodwfiw ggLLthggaotLCLtCa4
LCigjL‘LCanggaootgnmooggoaLagtiatLaLtgchatatLCLCtaLfivm:igaagaUerLLaLmnta
itgtcaaoaatggamotaaoufiCCocoaLCitggthngaaLadagLtgflagangogaLLUtfigLWCaLLaL
L otgtottLElK/HLLLLLKatLtgp'Hg‘hOk/imga"(1E LaaLLGLLLLtottotthCtgotgaataaaofictatLLoa
\ oasaviacafitgmawtggataaLgCLCCcoaa‘ngggiaCocaggagagtgtcawoaaoaqgao
3 .LgceLaggaL30LaCLtaLavLLtageagoaCCC.gacwctgagL(1:130agauaogagameaaagtctacgo
otgLg3.agtLaLCCaimgggoowc,agotcgCLgodagaagathiLaacaggggagagtgtiag (SEQ T53
M3365) .34._V_______.,...........u..auu“an“.............
huLDfl38 C70tLogLLaoLaiOggatggtLLtgLafiafttgmflwtwocacgLCBCtggficaLLo‘macmotgtcaca
.agtC‘LCLagLLLLaLtg[LigLi‘tCCLLoootfiagooggtvaLoatgaLgctotgCcagficotoogtgacatamtgo
Ci‘LaaaaaoatggmotaCoaLaottcaaaaofigcat'avgogfioctocoa
‘ attogtatoagoaaaaaoccvgt'o
0215.333:"”5bgifliflgbtvtoobfiticscatacagtotngcattagtELLatogaacdggaga’rgcagccaoCmLiaCtgt
aaLoaaaowvavaiaaam0&3.ngggLot-cacoa‘mfsw
““17“.L“ .w m“L““LL‘L‘LLL‘LL.
W0 35740 PCT/U82012/031648
icttcatcttCCCOCcatCtgatgaoC.agtwaaatctggaaC.EgCCtCtJttgtgLCEgCEgaataaCCtC.taECCCagagaogccaaagtaCagtggaarrgttwatcmCg1.CCECcaachggtadCtCCCaggagagtomEEC-3oaacavgacaficaaggz(ECCagCaCCtaCCgCCtCagcagCaCCCtCaCCctfiagaaaocawCECECCCwaaaCaCaaaotCEaCCCthCgaagECaCCatCagggcctgagCtCUCCCgECaCaCCagagCthaaCanggdrragwttag (SEQ ED0
CCCCCCCCCCC
CCCCCCCCCCCCCCCCCCC
CCC__C._.....C ........
CCC. CCCCCCCCCCCCCCCCCC
“(11:thaCCatzqgttogtCatocatwtCtgttCCCCqer’CaC0C1ggagtauiawtwCECE’EO‘ECCELEEC
CCaddgtCCthtdCtatgtCth.CagcCCCEggagdgCgtgtgamatgacttuELEgLECELCCaa‘VtgtgaCatacar
qcattggtatCagcaaaagCCtggCCCa‘CCCCCtaaaaggtggatctacgataCttCtaatcthCatangtgEUCCC0C
aaggttCtCCGggagtgg"agtvgcaCCCOfiatagtctC'tccatcavttcaatggaagcagaggatgcagcaaCCtdttC
attotCauCagtogthgtttaatCCCCCtaCtttthICItggtaCaaag-tvgaoaEtaagcgtacge’tggctficacmt
ctgtCEtCatctEC.CCUCCatCtgatgagcagttgaaatctooaactscCCctfittgtgtOCCEgCtgaataaCtECtatCCCC21
E35 (-£9 {:3O 0"? {'3C ('215-4» ('130 S12{21)W(38OCE‘TJfl3) 311)(D ,4.(3 (.3 (2 a: 0‘53 (3:; 9.2(1'2”‘3:'3».(—1- If;P4 ('2m f”) {3) (TC? ($2)?
1 3" "109:1:GM 52':Q {If}0 ('3 '99E"C.)ionIn,200 330HQa»).0‘"(IQ$1)(7%33H“E3321: .....
agCaaggaCagCaC.CtaCagCCtCCgCagCCECCCtg1.OCtoagCaaagCagaC‘CCECvagaaCCmagic50381894 Cg
gtcaCCCCtCCEggchtgaqctchCCCCgtCCC2aangCttCaCCCgggaoagtgttavg‘EEQ EDC
N0113]}
huLD3/5E" gaa‘ttchC.caCatgggamgaCctgtattattCtottCtggtthtaCtht'ECtgCgt C<Y£Egdta0ECCECEC
CcagaggcattggtaCCchCa‘CcatgagCCCCtCCcCEUngaGCgactgactatoaCttottCCUCCaCttCttcast.aCCtatat
tcagcagamm1:0gaCCgtCtCCCCEa(*CgttgggtttacgacamtCCaaCCtggCttCCCCmCO’EtCCth
taggttcagcggatC‘tgCgCEggcaoaagttamathaCCattwttCCatooagfiCCCaaoatocCgCtaCttaCtCEC
E tgtcagcagtggagC23.CCECECCCCCCtaC'EttcggUCdgaCECtathogagatca‘EaCtacggtggC‘tgcaCCa
.‘ tCtgtCttcatcttCCCgCLaECELaEOclO0124.055)afiaECEEQEdciW°CECEUEEgI0EgCCEOCIOEaEfi'ECE’ECEaECCCC.
1 gagaggCCaaaOE'tcaathCEamtogat'tachCCtCcaa’CnggtadCCCaggCad9EOEL8k8g&9939gdC
1 11:;
E agC;saggaCagCaCctacachtCagcagcacmz gaCgCtCagC'EaagCagaCtEsmdaca‘aaagtctaCgC '
1 CtgcgaagECdCCCatCaggCCCtoaUCECgCCgtcaCaa1gCgCtCCaacagg gagagtgttagE‘EEQ ED
E N‘IXEESEE)
huCD3756 gaattcgccCECCCCEgggctg CCtthEEWECCtgtttCtggtgCaathaCtgggfittca".C‘tgatatthCCCgaC
acagagftCCdgCCEtCaEgagthItCtCchgaGaClaw0fECaanaCtEgttCagCt‘CCCCctcccgtcacatacatg
cattggtaccagcagaagcctgaCaEgagthta13021CCtogatCtatUataCaagCaaECtggC'ttccggtgtCCCCEC
' aaitco 1Cate/t1110mmC.(31:1:aCC.'tEC:‘-‘C:CtCaat10211100322112,211:OCEOCEEECatatt
1 CC *CttttcaggcggcE: 150%) 27 Fara 07: I:
1 aCthCaecaatooatcaocCCCcCctCCtCCCEtCCCgCCCC~aaCaa'tattfig'tdattadetaC:r_,gtgg;g1‘:.1:game;
atctgtCtthtCttCCOCCatctoatoagcagtt»aaatCtggEacthCCttCg‘towthCtgctaataacttCtatCCC4
agagaggCcaawtCiCaotggaaogtqqmfiadchcCtCCaatcg{gtaactcccaggagagtgtcacagagcagga
CaoCaaCCaCaoC'tcCtCCCCUCCtCavcaocCaCCC‘mac‘rtgagccaaagcagactzngagaaaCacaaagtctacg
CC‘thgaagtcaCCCdtCagggCCtfiaaCthCCCthacaaaUaaCttCadCaggggdgagtgttag (SEQ ID
NO:E69)
EEuCEB?57 = gaatthCCdccatggggtggtC*tgtttatCCtottcthtcgCaCCCCCCCCECaoocgtaCthgaOotcgtvttva
C'ECagaocmaCCcaccatgtcchttCCCCgoogaoaga*acaatUaCttOCCCgCCaCaCEOCCCzotaaCCtaC
that11mtdCC91<>CaaaaacCag113301CCCgtcgttggatttaEgatCtCCtCtam.CEOOCEECagCgEtCCtg 1 1
ttt‘Ctttotaatgg'ttngggCttcctdEaOCCttaCCataaOCECCCthoaaUcCwaawCCgCtacataCta 1
ctgccagcagtggagtgataaCC.CCCCCCCCtthggCaggngCCaaat‘ggaoatcaaacgtangtggCthCCC 1
atctgtCtticatCE‘ECchCCCtCtgatgagcagttgaaatCtggaacEgCCtCtoEtOEgtoCctgctgaataacttctaCC
1310aGagchaaagtaCaCztgfiaaggtgataacocCctCC'thWstdaCtCCCaggagaotgtcaCCC-agt.gga
cattcaaggacaUCdCCtaCCGCC[CagC'EgCa.CCtganCtgdt—CcaaetvcagactaCgagaaacacaaagtctacg
g CCthgaaotCCathggg-CtgagctcgCCCgtcacaaagagc :1acaggggagagtgttag (SEQ EEE
N0E201
513G225} Also pmvECECCE is a cEeoEECEC having at ECast about 95%. at ECaSt about. 96%. at. 11:21:11; about
97%, at 583551: about 98%, m at ECast about 99% C identity to SEQ ED NOS:E‘2E—E7€), E83. or E83.
Thus, in 12611211311 em‘bvdiments, the poEynucECCtiCEC comprises (a) a. CECC‘CiCEC E1avi1‘1g at ECasE about
95/6 sequence ECECEEEEEV t0 ‘1)“Q ED N05: 121‘ ~ E 35 E524. E, or 182., ” (E3) 21 pCEynuCECCtECEC having at
11321211: CEbCuEQ5/CSCC1CCCCC Edcnttty to SEQ ED NOS: E36 ESE E62 E76, 0': E8E. E11 Cartam embodnnents. the
W0 2012/135740
.. 7g} -
polynucieotide comprises (a) a polynucleotide having the nucieic acid ce of SEQ II.) NQs: 121—
135, 152-161 or 132; and/or (b) a polynucleotide having the nucleic acid sequence of SFQ II.) NOS:
136»-
2—170, or .183.
In same embodiments, the pclyiiucleetide encodes the iight chain encoded by the recnmbinant
plasmid DNA phuCD37—3LC (ATCC Deposit Designation PTA-10722, deposited with the ATCC on
March 18, 2010) or a light chain that is at least about 85%, at least about 90%, at least about 95%, or at
least about 99% to the light chain encoded by phuCD37-3LC (PTA-10722). In some embodiments, the
polynucleotide encodes the heavy chain encoded by the recombinant plasmid DNA phuCD37-3HCV.1.0
(ATCC Deposit Designation 723, deposited with the ATCC on March 18, 2010) or a heavy chain
that is at least about 85%, at lesat about 90%, at least about 95%, or at least about 99% identical to the
heavy chain encoded by phuCD37—3HCV.1.0 (PTA—10723). In certain ments the polynucleotide is
the recombinant plasmid DNA phuCD37-3LC (PTA—10722) or the recombinant plasmid 7-
3HCv.1.0 (PTA—10723).
In certain embodiments the polynucleotides comprise the coding sequence for the mature
polypeptide fused in the same reading frame to a polynucleotide which aids, for example, in expression
and secretion of a polypeptide from a host cell (e.g. a leader sequence which functions as a ory
sequence for controlling transport of a polypeptide from the cell). The ptide having a leader
sequence is a preprotein and can have the leader sequence cleaved by the host cell to form the mature
form of the polypeptide. The polynucleotides can also encode for a proprotein which is the mature protein
plus additional 5' amino acid residues. A mature protein having a prosequence is a proprotein and is an
inactive form of the protein. Once the uence is cleaved an active mature protein remains.
] In certain embodiments the polynucleotides comprise the coding sequence for the mature
polypeptide fused in the same reading frame to a marker sequence that allows, for example, for
purification of the encoded polypeptide. For example, the marker sequence can be a hexa—histidine tag
supplied by a pQE-9 vector to provide for ation of the mature polypeptide fused to the marker in
the case of a bacterial host, or the marker sequence can be a hemagglutinin (HA) tag derived from the
influenza hemagglutinin protein when a mammalian host (e.g. COS-7 cells) is used.
] The present invention further relates to variants of the above described polynucleotides
encoding, for example, fragments, analogs, and derivatives.
The polynucleotide variants can contain alterations in the coding regions, non-coding s,
or both. In some embodiments the cleotide variants n alterations which produce silent
substitutions, additions, or deletions, but do not alter the properties or activities of the encoded
polypeptide. In some ments, nucleotide variants are produced by silent substitutions due to the
degeneracy of the genetic code. cleotide variants can be produced for a variety of reasons, e.g., to
a 7} _
optimize cedon expression for a particuiar host ifchange sedans in the human mRNA to those preferred by
a bacterial host such as E.. call).
{00231} Vectors and cells comprising the polynucleetides described herein are also ed.
IV. Metheds 9? use and plmmraeetxticai eompesitiens
£00232] The CD37—binding agents (including antibodies, immunoconjugates, and polypeptides) of the
invention are useful in a y of applications including, but not limited to, therapeutic treatment
methods, such as the treatment of cancer, such as B—cell malignancies, autoimmune diseases, and
inflammatory diseases. In certain embodiments, the agents are useful for depleting B-cells. In certain
embodiments, the agents are useful for depleting autoreactive B—cells. In n embodiments, the agents
are useful for ing peripheral B-cells. In certain embodiments, the agents are useful for preventing
inappropriate T—cell stimulation. The T-cell stimulation can be in connection with a B-cell pathway. The
methods of use can be in vitro, ex vivo, or in vivo methods. In certain embodiments, the CD37-binding
agent or antibody or immunoconjugate, or polypeptide is an antagonist of the human CD37 to which it
binds.
In one aspect, anti—CD37 antibodies and conjugates of the invention are useful for
detecting the presence of CD37 in a biological sample. The term "detecting" as used herein encompasses
quantitative or qualitative detection. In certain embodiments, a biological sample comprises a cell or
tissue. In certain embodiments, such tissues include tissues that express CD37 at higher levels relative to
other tissues, for e, B—cells and/or B—cell associated tissues.
In one aspect, the ion provides a method of detecting the presence of CD37 in a
biological . In certain embodiments, the method comprises contacting the biological sample with
an anti-CD37 antibodyunder conditioes sive for binding of the anti-CD37 antibody to CD37, and
detecting whether a complex is formed between the D37 antibody and CD3 7.
In one aspect, the invention provides a method of diagnosing a disorder ated with
increased expression of CD37. In certain embodiments, the method comprises contacting a test cell with
an anti-CD37 antibody; determining the level of expression (either quantitatively or qualitatively) of
CD37 by the test cell by detecting binding of the anti-CD37 dy to CD37; and comparing the level of
expression of CD37 by the test cell with the level of expression of CD37 by a control cell (e.g., a normal
cell of the same tissue origin as the test cell or a cell that expresses CD37 at levels comparable to such a
normal cell), wherein a higher level of expression of CD37 by the test cell as ed to the control cell
indicates the presence of a disorder associated with increased expression of CD37. In certain
embodiments, the test cell is obtained from an individual ted of having an mune disorder or
inflammatory disorder. In some embodiments, the disorder is associated with increased expression of
CD37. In some ments, the disorder is associated with increased number of B—cells. in some
embodiments, the disorder is associated with increased ty of B—cells-
W0 2012/135740 PCT/U82012/031648
_ 72 _
In certain embodiments, a method of diagnosis or detection, such as those described above,
comprises detecting g of an anti—CD37 antibody to CD37 expressed on the surface of a cell or in a
membrane preparation obtained from a cell expressing CD37 on its e. In certain embodiments, the
method comprises ting a cell with an anti-CD37 antibody under conditions permissive for binding
of the antiC‘D37 antibody to Cl3_,'I, and detecting whether a complex is formed between the anti—CD37
antibody and CD37 on the oeli surface An esterCiplaiy assay for detecting binding of an anti—C5937
antiboC'lV to C12733, exptessed on the suitace ot a oeoilis a "FACT 3" assay
{68237} Certain other methods can he used to detect g oi: antiC{”33.1 antibodies to CD37, Such
methods e, but are not d to, antigen~binding assays that are weell known in the art, such as.<
westein biots, radioimmunoassays, ELlSA (enzyme linked inimunosorbent assay), ”sandwich”
oassays, imniunopreoipitation assays, fluorescent innnnnoassays, protein A iminunoassays, and
innnunohistooheniistry {lHC}.
{£30238} in n embodiments, anti—CD37 antibodies are iabeied. Labels inciode, but are not limited
to, iabels or es that are detected directly (such as cent, ehromophoric, electron-dense,
chemiluminescent, and radioactive iabels), as well as moieties, such as enzymes or ligands, that are
detected indirectly,eCg”tinonsh an enzymatic reaction or moleeuiar interaction
{00239} in certain embodiments, anti—CD37 antibodies are immobilized. on an insolnbie matrix.
lization entails separating the anti-CD37 antibody from any CD37 that remains free in solution.
this eonyentionaily is. accomplished by either insohihiiizins, the anti-Cl337 antibody hetero the assay
procedure, as by adsorption to a watei’ninsoluhle matrix or surface (Bennich et al, US. Pat. No
"3,72 ,7603, or by oovaient coupling (for example, using aldehyde erossuiinhing), or by
insolahilizing the anti~CIi33IantibodV after torination of a eoinpiex between the anti-CD3antibody and
CD?"3 , , gby imntunoprecipitation.
{N32436: Any of the above ments of diagnosis or detection can be carried out using an
oeoniugate ot the invention in place oi or in addition to an antiCE337, dy.
in certain embodiments, the disease treated with the C3D37~hinding agent is an autoimmune or
inflammatory disease. In certain embodiments, the mune or inflammatory disease is selected from
the group consisting of psoriasis, dermatitis, systemic scleroderrna and sclerosis, responses associated
with inflammatory bowel disease, Crohn's disease, tive colitis, respiratory distress syndrome, adult
respiratory distress syndrome (ARDS), dermatitis, meningitis, encephalitis, uveitis, colitis,
glomerulonephritis, allergic conditions, eczema, asthma, conditions involving infiltration of T cells and
c inflammatory responses, atherosclerosis, leukocyte adhesion ncy, rheumatoid arthritis,
systemic lupus erythematosus (SLE), diabetes mellitus, multiple sclerosis, Reynaud’s syndrome,
mune thyroiditis, allergic encephalomyelitis, Sjorgen's syndrome, juvenile onset diabetes, immune
mediated by cytokines and "iliyinphooytes,
responses associated with acute and delayed hypersensitivity
WO 35740 PCT/U82012/031648
_ 73 _
tuberculosis, sarcoidosis, poiymyositis, granulotnaiosis, vasculitis, pernicious anemia (Addison’s disease),
diseases involving leukocyte dispedesis eentt’ai s system (CNS) inflammatory disorder, multiple
organ injury syndrome, hetnolytie anemia, myasthenia gravis, antigetnantihody compEex mediated
diseases, anti~glomerular basement membrane disease, antiphosphoiipid syndrome, ic neuritis,
Graves e, LambertEaton myasthenic syndrome, petnphigoid buElous petnphigus, autoimmune
polyendocrinopathies, Reiter’s disease, stiff—man syndrome, Behcet disease, giant cell arteritis, immune
complex nephritis, lgA nephropsthy, igM polyneuropathies, idiopathic thromboeytopenic purpura (Ill?)
and autoimmune throtnhocy‘topenia.
{@242} in some embodiments, the autoimmune or atory disease is ed from the group
consisting of: RA, inpus, immune thromhocytopenic purpurn, pure red ceiE aplasis, autoimmune anemia,
coid agglutinin disease, type B syndrome of severe n resistance, mixed cryoglobuEinermis,
henia gravis, Wegener's granulomntosis, microscopic polyangiitis (MFA) refractory pemphigus
vulget'is, dermatomyositis, Sjogren’s syndrome, active type—ii mixed cryogiobuiinetnia, petnphigus
Viligai‘is, mune neuropatliy, paraneopiastic opsocionusarnyoclonus syndrome, and, relapsing
remitting ntuitipies osi s (ERA/ESE
{(33243} tain embodiments the autoimmune disease or inflammatory diseaseiscltarecterized by
CD37 1n- eelis to which the CD37binding agent (eg.,antibody) binds,
{.6244} Ehe present invention provides Eor methods of treating autoimmune and intiannnatory
diseass sing adtninistetingaatherapeutically effective amount of a CD3'7—bihding agent to a
subject (tag, a suhject in need oE’treatment), in certain embodiments, the subject is a human.
{@245} The present invention further es methods for depleting B-cells, e,g., autorcuctive B»
cells, described herein. En CRttain embodiments, the method of .sittgth antibodies or other agent:
depleting B—ceiEs ses contacting a B~ceil with a CD37~hinding agent. (eta, dy) in vitro. For
example, a eeEl Eine that expresses CD37 is cultured in medium to which is added the antibody or other
agent to deplete the cells. in some ments, the ceEEs are isoiated from a patient sanmie such as, for
exatnpie, a tissue , pEeurai effusion, or blood sample and cultured in medium to which is added an
CD3 7~hinding agent to deplete the. ceils.
{@8246} in some etrthoditnents, the method of depleting B~eells, eg. autoretetive 3-ct.lls comprises
contacting the cells with the C3E337~hinding agent (cg, antibody) in viva, in certain embodiments,
contacting a red with 3 {i337binding agent is undertaken in an animal model For e, CD37-
binding agents can be administered to xenografts expressing one or more CD375 that have been grown in
immunocompromised mice (e.g. NOD/SCID mice). In some embodiments, cells are isolated from a
patient sample such as, for e, a tissue biopsy, pleural effusion, or blood sample and injected into
immunocompromised mice that are then administered a CD37—binding agent to deplete B-cells. In some
embodiments, the CD3 7-binding agent is administered at the same time or shortly after introduction of
W0 2012/135740 PCT/U82012/031648
_ 74 _
cells into the animal. In further examples, CD37 binding agents can be administered in vivo to mice
expressing one or more CD37 antigens. In some embodiments, these mice can be engineered to express
human CD37 in on to, or instead of, murine CD37. In some embodiments, these mice are disease
models, e.g. models for autoimmune e. In some embodiments, administering a CD37 binding agent
depletes B—cells in vivo. In some embodiments, a CD37 binding agent prevents T—cell stimulation. In
some embodiments, administering a CD37 binding agent prevents or alleviates an autoimmune disease.
[00247; in n embodiments, the B~celis press CD37, in ether ments, the B-ceils do
not press CD37. In some ments, the B—cells are not cancer cells. in some ments, the
IRS—cells are not turner ceiis In some embodiments, the B-cells are not cancerous cells.
The present invention further provides pharmaceutical compositions comprising one or more
of the CD37-binding agents described herein. In certain embodiments, the ceutical compositions
r comprise a pharmaceutically acceptable vehicle. These ceutical compositions find use in
treating autoimmune and inflammatory disease in human patients.
In certain embodiments, formulations are prepared for storage and use by combining a
purified antibody or agent of the present invention with a pharmaceutically acceptable vehicle (e.g.
carrier, excipient) (Remington, The Science and Practice of Pharmacy 20th Edition Mack Publishing,
2000). Suitable pharmaceutically acceptable vehicles include, but are not limited to, nontoxic buffers
such as phosphate, citrate, and other organic acids; salts such as sodium chloride; idants including
ascorbic acid and methionine; preservatives (e.g. octadecyldimethylbenzyl ammonium chloride;
hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl
alcohol; alkyl parabens, such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol;
and m-cresol); low molecular weight polypeptides (e.g. less than about 10 amino acid residues); proteins
such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone',
amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; carboEydrates such as
monosacchandes, disaccharides, glucose, mannose, or dextrins; chelating agents such as EDTA; sugars
such as e, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal
complexes (e.g. tein complexes); and non—ionic surfactants such as TWEEN or polyethylene glycol
(PEG).
The pharmaceutical itions of the present invention can be administered in any number
of ways for either local or systemic treatment. Administration can be l (such as to mucous
membranes including vaginal and rectal delivery) such as transdermal patches, ointments, lotions, creams,
gels, drops, suppositories, , liquids and powders; pulmonary (e.g., by inhalation or insufflation of
powders or aerosols, including by nebulizer; racheal, intranasal, epidermal and transdermal); oral; or
parenteral including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or
infusion; or intracranial (e.g., intrathecal or intraventricular) administration,
-75..
An antibody or immunoconjugate of the invention can be combined in a pharmaceutical
combination formulation, or dosing regimen as combination therapy, with a second compound having
anti-autoimmune or inflammatory properties. The second compound of the pharmaceutical combination
formulation or dosing regimen can have complementary activities to CD37—binding agent of the
combination such that they do not ely affect each other. Pharmaceutical compositions comprising
the CD37—binding agent and the second agent are also provided. For example, CD3 7-binding agents can
be administered in combination with CD20-binding agents, such as Rituximab. In other embodiments,
CD37—binding agents can be administered in ation with salicylate‘, nonsteroidal nflammatory
drugs such as indomethacin, phenylbutazone, phenylacetic acid derivatives (e.g., ibuprofen and
fenoprofen), naphthalene acetic acids (naproxen), ealkanoic acid (tometin), indoleacetic acids
(sulindac), halogenated anthranilic acid (meclofenamate sodium), piroxicam, zomepirac and diflunisal;
antimalarials such as chloroquine; gold salts; llamine; or immunosuppressive agents such as
methotrexate or corticosteroids. In some embodiments, the inding agent is administered in
combination with a second therapeutic selected from the group consisting of methotrexate, an anti-CD20
therapeutic, an L—6 receptor therapeutic, an anti—IL-12/23p40 therapeutic, a chemotherapeutic, an
suppressant, an anti-interferon beta-1a therapeutic, glatirareer acetate, an anti—a4-integrin
therapeutic, fingolimod, an Lys therapeutic, CTLA-Fc, or an anti-TNF therapeutic. In some
embodiments, the CD37—binding agent is administered in combination with a second therapeutic that is an
antibody ed against an antigen selected from a group consisting of CD3, CD14, CD19, CD20,
CD22, CD25, CD28, CD30, CD33, CD36, CD38, CD40, CD44, CD52, CD55, CD59, CD56, CD70,
CD79, CD80, CD103, CD134, CD137, CD138, and CD152. In some embodiments, the inding
agent is administered in combination with a second thereapeutic that is an antibody directed t a
target selected from the group consisting of IL-2, IL—6, IL-12, IL-23, IL-12/23 p40, IL-17, IFNy, TNFOL,
IFNOL, IL—15, IL-21, IL—la, IL-lb, IL—18, IL—8, IL-4, GM—CSF, IL—3, and IL—5. In some embodiments, the
CD3 ing agents are administered in ation with methotrexate.
For the treatment of the disease, the appropriate dosage of an antibody or agent of the t
invention depends on the type of disease to be treated, the severity and course of the disease, the
responsiveness of the disease, Whether the antibody or agent is administered for therapeutic or
preventative purposes, previous therapy, patient’s clinical history, and so on all at the discretion of the
treating physician. The antibody or agent can be administered one time or over a series of treatments
lasting from l days to several months, or until a cure is affected or a diminution of the disease state
is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the
body of the patient and will vary depending on the relative potency of an individual antibody or agent.
The administering physician can easily ine optimum dosages, dosing methodologies and repetition
rates. In certain embodiments, dosage is from 0.01 pg to 100 mg per kg of body weight, and can be given
W0 2012/135740 PCT/U82012/031648
-76—
once or more daily, weekly, monthiy or yearly, in certain embodiments, the dy or ether CD3?—
binding agent is given once every two weeks or once every three weeks. in certain ments, the
dosage of the antibody or other CD3 ibinding agent is from about 0.1 mg tc abcnt 20 mg per kg of body
weight. The treating physician can estimate repetiticn rates for dosing based on measured residence times
and concentrations of the drag in bodily fluids or tissues.
{9:325:23} The combination y can provide gy” and prove "synergistic”, ie. the effect
achieved when the active ingredients used together is greater than the sum of the effects that results from
using the compounds separately. A synergistic ef ect can be attained when the active ingredients are: (l)
comforniulatcd and administered er red simultaneousiy in a combined, unit desage formulation; (2')
delivered by alternation or in parallei as separate formulations; or (3) by some other regimen. When
delivered in alternation therapy, a synergistic effect can be attained when the cempcnnds are administered
cr delivered sequentiaiiy, eug by ent injections in separate syringes. in general, during aiternation
therapy, an effective desage of each active ingredient is administered sequentially, i..e serially, whereas in
combination therapy, effective s of two or more active ingredients are administered together,
VI. Kits comprising CD37-binding agents
The present invention provides kits that comprise the antibodies, immunoconjugates or other
agents described herein and that can be used to perform the methods described herein. In certain
ments, a kit comprises at least one purified antibody against CD37 in one or more containers. In
some embodiments, the kits contain all of the components ary and/or sufficient to perform a
detection assay, including all ls, directions for performing assays, and any necessary software for
analysis and presentation of results. A label or indicator describing, or a set of ctions for use of, kit
components in a ligand detection method of the present invention, can also be included. The instructions
thereof. One
may be ated with a package insert and/or the packaging of the kit or the components
d in the art will readily ize that the disclosed antibodies, immunoconjugates or other agents of
the present invention can be readily incorporated into one of the established kit formats which are well
known in the art. Such kits can also include, for example, other compounds and/or compositions, a
device(s) for administering the compounds and/or compositions, and written instructions in a form
prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or
biological products.
Further provided are kits comprising a CD37-binding agent (e.g., a CD37-binding dy),
as well as a second agent. In certain embodiments, the second agent is rituximab. In certain
embodiments, the second agent is methotrexate.
* * *
Embodiments of the present sure can be further defined by reference to the following
non-limiting examples, which describe in detail preparation of certain dies of the present disclosure
W0 2012/135740
_ 77 _
and methods for using antibodies of the present disclosure. It will be apparent to those skilled in the art
that many modifications, both to materials and methods, can be ced without departing from the
scope of the present disclosure.
Examples
It is tood that the examples and embodiments bed herein are for illustz‘ative
purposes only and that various modifications or changes light thereof will be suggested to persons
skilled in the art and are to be ed within the spirit and purview of this application.
All publications, s, patent applications, et sites, and accession numbers/database
cited herein are hereby incorporated
sequences (including both polynucleotide and polypeptide sequences)
by reference in their entirety for all es to the same extent as if each individual publication, patent,
and individually
patent application, intemet site, or accession number/database sequence were specifically
indicated to be so incorporated by reference.
Example 1
CDstXUesswnInnomalhumanJlBMCs
The CD37 antigen was ed to be expressed on B-cells from the pre—B stage to the
eral mature B—cell stage, while being absent on B-cell progenitors and terminally differentiated
plasma cells. (Link et al., 1987, J Pathol. 152:12-21). In addition, the CD37 antigen is only weakly
expressed T—cells, myeloid cells and granulocytes (Schwartz-Albiez et al. 1988, J.
on Immunol,
140(3)905—914).
The ability of antibodies (including certain CD37 antibodies and immunoconguates
previously described in US. Published Application No. 2011/0256153, which is herein incorporated by
reference in its entirety) to bind to normal human B—cells was measured using flow cytometry assays with
fluorescently labeled antibodies. In addition, the commercially ble QuantiBRITE system from BD
Biosciences was used to estimate antigen density based on the number of antibodies bound to the cells
(ABC). The QuantiBRITE system from BD Biosciences utilizes the following reagents: anti-CDZO-PE
supplied at 100 ug/mL and QuantiBRITE PE supplied as lyophilized PE-labeled beads. In addition, the
huCD37-3 antibody was labeled with PE to obtain an antibody—PE conjugate with an AbzPE ratio of
approximately lzl.
Fresh buffy coats from healthy donors were ed from ch Blood Components
(Brighton, MA, US) as a source of normal blood cells. Buffy coats were prepared by fugation of a
unit of whole blood and collecting the interface between the plasma and the red blood cells. This
unpurified buffy coat contains PBMCs, neutrophils, platelets, red blood cells, and plasma and was used
_ 73 _
for experiments on the same day it was drawn. Peripheral blood mononuclear cells (PBMCs) were
prepared from buffy coats by standard density gradient centrifugation using Ficoll-Paque as follows.
Blood was diluted 1:3 with 1x HBSS containing 5mM EDTA and up to 30 mL were added to a 50 mL
conical tube. Ten mL of Ficoll-Paque (GE Healthcare) were slowly added to the bottom of each tube.
Samples were fuged at 500 x g with no brake at RT for 30 minutes to obtain a layer of PBMCs
below the plasma and to remove red blood cells and most granulocytes. The PBMCs were transferred to
new tubes and washed twice with 1x I-[BSS containing 5mM EDTA by centrifugation at 400 x g for
minutes at RT. Staining buffer (1x HBSS, 1% BSA, 0.1% sodium azide) was then used to resuspend the
PBMC pellets at 6.25 x 106 cells/mL. Eighty uL of cells were transferred to a round-bottom l plate
to achieve 5 x 105 cells/assay and 20 uL of human serum (Sigma H4522) were added to block Fc receptor-
mediated binding and incubated with cells on ice for 20 min in the dark. Fluorescently labeled antibodies
obtained from Miltenyi were used to identify PBMC populations: anti-CD3-allophycocyanin (APC) was
used to identify s, anti-CDl9-APC for B—cells, D56-APC for natural killer (NK) cells and
anti-CD14—APC for monocytes.
Cells were co-stained for CD37 expression using 20 uL of huCD37—3-PE for a final
concentration of approximately 10 ug/mL. Likewise, cells were co-stained for CD20 expression using 20
“L of anti-CD20—PE. As a control a non-binding PE-labeled hngGl isotype control dy was used at
ug/mL. Staining was carried out for 1 hour on ice in the dark. Samples were washed twice with
staining buffer and fixed in 200 uL of 1% formaldehyde in 1x PBS. s were stored at 4°C in the
dark until acquisition, which was performed within 4 days of sample preparation.
A fresh tube of QuantiBRITE beads was reconstituted in the supplied tube with 0.5 mL of
staining buffer just prior to sample acquisition. Samples were ed on a FACSCalibur flow cytometer
(BD Biosciences). Compensation controls were run with each assay to select appropriate ment
settings and at least 10,000 events were collected for each sample. Instrument settings for fluorescence
and sation were kept the same for both cell sample and bead sample acquisition to allow for an
accurate comparison. CellQuest (version 5.2.1, BD ences) was used for acquisition control and
analysis.
The QuantiBRITE analysis utilizes on a bead standard with 4 bead populations conjugated
with a known number of PE molecules. For data analysis, a G1 gate was drawn around the bead singlets
on an SSC—H scatter plot. This gated bead population was subsequently analyzed using a
histogram plot of FL2-H to evaluate the level of PE staining. te markers were drawn around the
peaks of the four bead populations (Ml—M4) and the geometric mean for FL2 of each bead population was
determined. The FL2 geometric mean of each bead was plotted against the lot specific d values in
a log—log plot. Linear regression was performed to obtain a standard curve using the following equation:
y = mx + c, with “m” equal to the slope and “0” equal to the y-intercept.
, 79 -
{00265} For PBMC sample analysis, a GI gate was drawn around the positive fluorescent cell
population of st on an SSQH/TL-él-ll dot plot. This gated eel! population was subsequently analyzed
using a histogram plot of FL2~H to evaluate the level of heled antibody staining. The FLQ geometric
well as
mean was determined for each blood ceil sample stained with anti—CDB7-PE or anti—CD20~PE, as
unstained control samples. All ric mean values for 3912 were d against the bead standard
curve and values for PE per cell were olated. Since both antibodyl’lfi eonjuga‘tes were at a PEzAb
ratio of approximately 1:1, the values for PE per cell correspond to the number of dies bound per
cell (ABC) value. Experiments were petitioned with duplicate samples for each assay. The mean and
standard deviation was determined from several assays for each blood cell population
CD37 expression was evaluated in normal blood cells from 4 ndent donors. Results
were compared to CD20 staining, unstained cells and a non-binding hngG—PE conjugate as controls.
example of a typical staining profile of normal B-cells is given in a rams in Figure l. The average
ABC values of 4 different experiments for CD37 and CD20 were calculated and listed in Table l.
Table 1: ABC values for CD37 and CD20 expression on human PBMC samples
N0 Ab hung-PE
CD37 ABC {1320 ABC
control control
CDl9+Bcells 7744094598 “80 76
CD3+ T cells 2,016 336 74 68
CD56+ NK cells 3,090 264 85 88
CD 1 4+ monocytes 5,244 794 180 215
The highest overall CD37 staining level was found in CDl9+ B—cells at approximately 77,000
ABC. In addition, CD37 staining was seen at low levels in other PBMC populations examined, with
CDl4+ monocytes g CD37 staining at approximately 5,000 ABC, CD56+ NK cells at 3,000 ABC,
and CD3+ T cells at 2,000 ABC. Staining with the non—binding hngG-PE control resulted in ABC values
of approximately 70 — 90 for B, T and NK cells and approximately 200 for monocytes. In the same 4
donors CD20 expression was evaluated in comparison to CD37. In accordance with published findings,
the CD20 staining was restricted mainly to CDl9+ B-cells with an ABC value of approximately 95,000
ABC. The CD20 expression level was just slightly higher than the CD37 expression level. Only minimal
CD20 staining was observed in other PBMC populations examined, with CDl4+ monocytes showing
CD20 staining at 794 ABC, CD56+ NK cells at 264 ABC and CD3+ T cells at 336 ABC.
This result demonstrates that high CD37 expression is mainly restricted to s in
peripheral blood samples with only minor expression on peripheral T cells, NK cells and monocytes. This
is consistent with published findings ((Moore et al. 1986, i l. l3‘7(9):30l3—8; Sehwartnhlhiez et
al, @833, J. l., l40l’3)905~9l4). in addition, we found that the (2937 expression levels on
PCT/U82012/031648
- 80 _
peripheral B-cells is similar to the level of CD20 expression. This expression pattern strongly suggest that
CD37 directed therapies may be a suitable for targeting s in diseases such as B-cell malignancies,
autoimmune es, inflammatory diseases or other disorders of the immune system analogous to the
use of CD20 ed therapies.
Example 2A
InvztroBgduleelenonusmreurlfiedl’BMCs
{99279} The ability of humanized antibodies to deplete B—eells was measured using in vine assays
with human PBMCS according to published studies performed with rlmxiinab {'V'ugmeyster et al.
Cytonietry A. 2003;52{2):ll}l~9 and Vuglneyster et al. int lmmunephannaeol. 2004;4(8):l l l7—i24}.
Alernlnznmab (Campatli) was used as appositive control, since it has been ed to efficiently deplete
lymphocytes in viva and in vim: (Hale, Blood. 1933 Oet;62(4)2873—82 and Waldmann, Fllllos Trans R Soc
Lond B Biol Sci. 2005 Sep 29;360(lZl-6l):l707-l E).
Fresh buffy coats from healthy donors were ed from Research Blood Components
(Brighton, MA, US) as a source of normal blood cells for all experiments within this study. Buffy coats
were prepared by centrifugation of a unit of whole blood and collecting the interface between the plasma
and the red blood cells. This unpurified buffy coat contains PBMCs, neutrophils, platelets, red blood
cells, and plasma and was used for experiments on the same day it was drawn. Peripheral blood
clear cells (PBMCs) were ed from buffy coats by standard density gradient centrifugation
using Ficoll-Paque as follows. Blood was diluted 1:3 with 1x HBSS containing SmM EDTA and up to
mL were added to a 50 mL conical tube. Ten mL of Ficoll—Paque (GE Healthcare) were slowly added
to the bottom of each tube. Samples were centrifiaged at 500 x g with no brake at RT for 30 minutes to
obtain a layer of PBMCs below the plasma and to remove red blood cells and most granulocytes. The
PBMCs were erred to new tubes and washed twice with 1x HBSS containing SmM EDTA by
fugation at 400 x g for 10 minutes at RT. Staining buffer (1x HBSS, 1% BSA, 0.1% sodium azide)
was then used to resuspend the PBMC pellets in the initial blood volume to achieve the original cell
EGBZ'FZ To assess: the effect ofhuCD37-3. linCDB'?~3~SMCC£§M l huCD37—50~Si\v’lCC—
, lnlCD37~50,
DMl, mab, alemtnznrna‘n (Carnpath), and “l‘RtHllé on PBMC depletion. 90 at of purified cells.
were added to l2 x 75 min polystyrene tubes and incubated with 10 tlL ofa 100 rig/mi, solution of each
sample or a ltnlgG lsotyne control antibody for l ltr at 37°C in a humidified 5% (302 incubator. The final
antibody (Ab) concentration was ill gig/ml, in a final volume of 100 llL in staining butler. Three
independent samples were prepared for each treatment.
} To identify tions of PBMCS, all samples were co~stalned immediately alter Ab
incubation with l0~20 llL of lluorescently labeled Abs ed from, for example. Bl) Biosciences or
W0 2012/135740 PCT/U82012/031648
_ 81 _
Miltenyi. Anti-CD3-PerCP—Cy5.5 was used to identify T cells, anti-CDl9—APC for B—cells, and anti-
CDl4—FITC for tes. ng was d out in a total of 150 uL for 30 min in the dark at RT.
CountBright Absolute Counting Beads (Invitrogen) were ed and added to each sample at 50 uL per
tube. For PBMC prep samples, cells were washed once with 1 mL staining buffer and centrifuged at 400 x
g for 3-5 min. Supernatant was removed with a 1 mL pipette and cells were resuspended in 500 [AL of 1%
formaldehyde in 1x PBS. Samples were stored at 4°C in the dark until acquisition, which was performed
within 4 days of sample preparation.
] TreeStar FlowJo software (version PC 7.5) was used for data analysis. A gate was drawn
around the right bead population on an FSC-H vs SSC—H dot plot to determine a total bead count
for the sample. To determine the total count for each PBMC population of st, a separate gate was
drawn around the positive fluorescent population on an SSC-H vs FL(x)—H dot plot, where x is the
channel of interest. Specifically, a total count for T cells in a sample was found by gating the positive
population on an SSC—H vs FL3-H dot plot; for B-cells, the positive population was found on an SSC-H
vs FL4-H dot plot; for NK cells, an SSC-H vs FL2-H dot plot was used; for monocytes, an SSC-H vs
FLl-H dot plot was used. The ratio of CD19+ cells for B—cells (CD3+ cells for T cells, CD56+ cells for
NK cells, or CDl4+ cells for monocytes) relative to beads was determined and multiplied by 100. Percent
depletion was then calculated by taking the ratio of the cell to bead ratio in treated samples relative to the
cell to bead ratio in isotype control treated samples, subtracting this from 1 and lying by 100. This
corresponds to the following formula: Percent Depletion = 100 x (1 -cell to bead ratio of treated sample/
cell to bead ratio of control sample). Data for all cell types was analyzed in the same manner.
For two donors tested, treatment of purified PBMC samples with huCD37-3, huCD37-3—
SMCC—DMl, huCD37-50 or huCD37-50—SMCC-DM1 ed in approximately 55-70% depletion of B—
cells (see Figure 2). There was less than 10% depletion of T cells or monocytes. The B—cell restricted
depletion effect indicates that this ty is linked to the high CD37 expression on B-cells. In
comparison, treatment with the anti-CD20 antibody rituximab resulted in approximately 30—40% depletion
of B-cells. Treatment with the anti-CD37 SMIPTM TRU-016 resulted in only 20—30% ion of B—cells.
Alemtuzumab ent resulted in depletion of 60—70% of B—cells, 55-65% of T cells and 40-65% of
monocytes.
Example 2B
Dpseressonseformvztro Brcell d6551€41.91!.HSiIlE.§Z§11£if1§§iRBMQ§
To evaluate the esponse of the antibodies and conjugates, purified PBMCs from 2
donors were incubated with a 5—fold sample dilution series. Each sample dilution was added at 10 uL per
tube to 90 uL of purified cells in triplicate and ted for 1 hour at 37°C in a humidified 5% C02
incubator. The final concentration ranged from 10 ug/mL to 0.13 ng/mL. The same amount of a non—
binding hngG Ab was used as an isotype control.
_ 82 _
For two donors tested, treatment of purified PBMC samples with huCD37SMCC-DM1
resulted in a clear dose-response for the B—cell depletion activity (see Figure 3A and B). Incubation with
-3—SMCC-DM1 caused in Vitro depletion of approximately 60% of B—cells with an ECSO of 40-75
ng/mL. For an additional donor tested, ent of purified PBMC samples with huCDE7-3, huCD37-38,
huCD37-50, and huCD37-56 antibodies also resulted in a clear dose—response for the B-cell ion
activity (see Figure 3C). Incubation with these antibodies caused in Vitro depletion of imately 60-
70% of B—cells with an EC50 of 20-30 ng/mL.
Example 2C
InvztroBcelld‘afletlonusmxwmlgblggd
The ability of zed antibodies to deplete B—cells was measured using in Vitro assays
with whole blood according to published studies performed with rituximab (Vugmeyster et al. Cytometry
A. 2003;52(2)2101-9 and Vugmeyster et al. Int Immunopharmacol. 2004;4(8):l 1 17-24).
Fresh buffs-'7 coats from healthy donors were obtained from Research Blood Components
(Brighton, MA, US) as a source of normal blood cells for all experiments within this study. To assess the
effect of huCD37-3, SMCC—DM1, mab, alemtuzumab (Campath), and TRU-Ol6 on
peripheral blood cells (PBCs) in a whole blood matrix, 90 pL of whole blood from a buffy coat were
incubated with Abs or isotype control as detailed above in a total volume of 100 pL. Three independent
samples were prepared for each Ab treatment.
To identify populations of blood cells, all samples were co-stained immediately after Ab
incubation with 10 - 20 pL of fluorescently labeled Abs obtained from, for example, BD Biosciences or
Miltenyi. Anti-CD3-PerCP-Cy5.5 was used to identify T cells, anti-CDl9-APC for B-cells, anti-CD56—
PE for NK cells, and anti-CDl4-FITC for monocytes. Staining was carried out in a total of 150 [1L for 30
min in the dark at RT. CountBright Absolute Counting Beads (Invitrogen #C36950) werepvortexed and
added to each sample at 50 pL per tube to allow standardization of cell counts.
] Following cell staining, 2 mL of BD FACS Lysing Solution (BD Biosciences, diluted 1:10 in
dH20 according to the manufacturer’s instructions) were added to each sample in order to lyse the RBCs
present. Samples were incubated at RT for 15—20 min in the dark, centrifuged at 400 X g for 3—5 min, and
resuspended in 500 [1L of 1% formaldehyde in lx PBS. Samples were stored at 4°C in the dark until
acquisition, which was performed within 4 days of sample ation. s were acquired on a BD
FACSCalibur. Compensation controls were run with each assay to confirm instrument settings. A total of
160,000 ungated events were acquired for each sample using BD CellQuest software on 5.2).
TreeStar FlowJo software on PC 7.5) was used for data analysis as described above.
For one donors tested, treatment of d PBMC samples with -3, huCD37
SMCC—DMl, huCD37-50 or —50—SMCC-DM1 resulted in approximately 40% depletion of B—
WO 35740 PCT/U82012/031648
_ 83 _
cells (see Figure 4). There was less than 10% depletion of T cells, 'NK cells or monocytes. As seen for
puréfied PBMCs, the in vitro depletion is cted to B-cells indicating that the activity is linked to the
high CD37 expression on B-cells. In comparison, ent with the anti—CD20 antibody rituximab or the
D37 SMIPTM TRU—016 ed in a less than 10% depletion of B-cells. Alemtuzumab treatment
resulted in depletion of 40% of B-cells, 80% of T cells, 15% ofNK cells and 20% of monocytes.
Example 2D
DovLQPOUNOEHVJWBLfilliltfiWflé—Lhfillfilfi..lllgfilél
3} To evaluate the dose—respense of the antibodies and conjugates? whole bleed from 2 dencrs
was incubated with a lG—t‘eld sample dilution . Each sample dilution was added at it? at. per tube to
90 til, 0f purified cells in cate and incubated for '1 hr at 37°C in a humidified 5% C703 incubator. The
final concentration ranged from 10 ngij t0 ill ngx’rnL The same amount cf 3 nen~hinding hulgG Ab
was used as an isotype central.
300284} Fer two sinners tested, treatment of whole bleed samples with huCD37-3 or huCl'RS7—3—
SMCGDMI resulted in a clear dese response for the B~cell depletion activity {see Figure 5A and B). ln
additlen, huCDBZLSlB was tested fer one (inner and also showed a similar dose response fer the B—cell
depletion activity (see Figure SB}. lncnbatioh with huCl‘Bil—E, buCD373~SMCC~DMl er huCD37-v50
caused a maximum response at in vitro depletion 0f appreximately 304595 of B~cells with an ECSG of
40420 ng/mL.
In addition to the in vitro experiment described above, the ty of CD37 antibodies to
deplete B cells in vivo can be tested in huCD37 expressing mice (described in Example 3) and, for
dies that crossreact with macaque CD37, in monkey.
Example 2E
.m,Mm93;itchiinstsl..e«ase studlesusmwhumanPBMCs
In vitro ne release was measured by t for IFN-y (Interferon), TNF—a (Tumor
Necrosis Factor) and lL-6 (interleukin-6) using peripheral blood mononuclear cells (PBMCs) from
healthy human donors incubated for 18-20 hours with compounds at a concentration of 2.5 ng/mL to 250
pg/mL. The ELISpot method is designed to measure the number of cells secreting cytokine by capturing
the cytokine onto the assay plate during the entire length of the tion. In all assays the ve
control anti—CD3 antibody CD3-2, as well as a negative non—binding isotype hngG control antibody was
included. Alemtuzumab (Campath®) and rituximab (Rituxan®) were used in comparison, since both have
been reported to induce cytokine release in patients (Wing. J Clin Invest. 98:2819 (1996) and Winkler,
Blood 94:2217—2224 (1999)). The assay conditions were chosen to reflect conditions that are relevant for
antibody therapeutics. The highest concentration of 250 pg/mL tested corresponds to the maximum
W0 2012/135740
_ 84 _
serum concentration of an antibody, such as for e the CDZO-directed rituximab, in patient plasma
after an infusion of 10 mg/kg of antibody.
As can be seen in Figures 6 and 7, the positive control anti—CD3 antibody induced release of
very high levels of IFN—y, TNF-a and IL-6 with PBMCs from two different donors. In the same assays,
alemtuzumab caused intermediate ne release, while rituximab caused moderate cytokine release
with PBMCs from two different donors. In contrast, huCD3 7-3, huCD37—50, huCD37SMCC-DM1 or
huCD37SMCC—DM1 did not cause significant cytokine e in our assays.
This underscores the utility of the described CD37-targeting antibodies or conjugates as
therapeutics as they combine potent activity, such as B-cell depletion, with a favorable safety profile with
respect to cytokine release.
Example 3
1.11_yi129._m9d9.1§.19.§xa1natit11§agixi§:.913.9123]..di:§§t§d_antihgdi§§_9r.,aniuaates
] B—cell depletion is known to ameliorate autoimmune diseases. In fact, rituximab has been
approved for rheumatoid arthritis treatment ds JC et al. Nat Rev Immunol. 6: 119 (2006)). In
animal models, B—cell depletion using antibodies against B—cell antigens such as CD20, CD19 and CD79
has been shown to inhibit or ameliorate l autoimmune diseases including systemic lupus
erythematosus (SLE), experimental autoimmune encephalomyelitis (EAE; mouse model of multiple
sis), type-l diabetes (TlD) and toid arthritis (RA). The CD37 antigen is expressed at high
levels in human s. Therefore, antibodies or immunoconjugates directed against the CD37 antigen
could potentially deplete B-cells and be ore useful to treat le autoimmune diseases.
To test the y of CD37 targeting antibodies and immunoconjugates to treat human
autoimmune diseases, the activity of such CD37 targeting dies and immunoconjugates can be
studied in mice using several murine autoimmune disease models.
For example, anti-murine CD37 antibodies can be generated using nock-out mice or
other species such as rat and hamster, and antibodies that deplete B-cell in viva effectively can be selected.
The therapeutic potential of anti-CD37 antibodies can be tested in mouse models representing human
autoimmune diseases, for example, a spontaneous TlD model in NOD mice, a myelin oligodendrocyte
rotein (MOG) peptide induced EAE model in wild type C57/Bl6 mice, a collagen induced
toid arthritis model in DBA/l mice or a spontaneous systemic lupus erythematosus (SLE) model in
MRL/lpr mice. Examples of murine CD37 antibodies and their eutic efficacy in various animal
models of autoimmune disease are provided below.
Alternatively, the therapeutic potential of anti-human CD37 antibodies and
immunoconjugates can also be tested in murine autoimmune disease models that have been engineered to
W0 2012/135740 PCT/U82012/031648
_ 85 _
express the human CD37 antigen. Such human CD37 (huCD37) expressing mice can be generated using
standard knock in (Kl) or enic (Tg) approaches. For example, to generate huCD37 KI mice, human
CD37 cDNA can be inserted into the murine CD37 locus in the C57/Bl6 embryonic stem (ES) cells. The
homozygous huCD37 KI mice will express human CD37 cDNA under the regulation of the endogenous
murine CD37 promoter, thus the expression pattern of the huCD37 would mimic that of the endogenous
muCD37. The different approach utilizes bacterial artificial chromosome (BAC) containing the human
CD37 gene that can be randomly inserted into the mouse genome. This transgenic approach has been used
successfully to generate huCDZO Tg mice resulting in B-cell specific high level expression of the antigen.
{(302193} The resulting huCD37 expressing mice based on the C57/Bl6 ound can be used to
r develop several autoimmune disease model. For examples, MOG peptide immunization in the
C57/Bl6 strain background can induces severe EAE in two weeks. In addition, introducing a FcyRIIB
knock out phenotype by breeding huCD37 expressing mice with C57/Bl6 FcyRIIB knock out mice should
yield a mouse model that spontaneously p SLE and develop RA upon zation with collagen
II antigen. Alternatively, backcrossing of the huCD37 expressing 6 mice into the NOE?) or
MRL/lpr background for 10 generations can provide spontaneous TlD and SLE models, respectively.
Example 4A
generatigugfamtianggugllflmgnmlgnal.an.tih9si§:;c_k>ne_2_§_2_:3_
To develop proof of concept that CD37 targeting antibody and immunoconjugate can inhibit
autoimmune disease, anti—murine CD37 (muCD37) monoclonal antibodies were generated by immunizing
CD37-knock-out C57Bl/6 mice with 300—19, a murine pre-B cell line that endogenously ses the
muCD37 antigen. The immunogen was injected subcutaneously at the dose of 5x106 cells per mouse
every 2 weeks for 5 times. Three days before being sacrificed for hybridoma generation, the immunized
mice ed intraperitoneal ion of another dose of antigen. The spleen cells were fused with
murine myeloma P3X63Ag8.653 cells (P3 cells) (J. F. y et al. 1979, JImmunol, 123: 1548-1550)
at ratio of 1 P3 cells: 3 spleen cells according to standard procedure. The fused cells were cultured in
RPMI-1640 selection medium ning nthine-aminopterin—thymidine (HAT) (Sigma Aldrich) in
% C02 tor at 37°C until hybridoma clones were ready for antibody screening.
Screening was done using flow cytometric binding assay with spleen cells from wild type
mice and CD37-knockout mice. Tie spleen cells were counterstained with anti—CD45R (8220) dy
to identify B cells that constitutively express CD37 antigen. The hybridomas producing antibody that
bound the wild type, but not CD37-knock-out, B cells were subcloned by ng dilution. One stable
subclone (clone 252-3) was obtained. The 252—3 oma was expanded in low IgG serum containing
media and the antibody was purified using standard methods with protein A/G chromatography.
PCT/U82012/031648
-86—
Example 4B
The purified 252-3 monoclonal antibody was identified as a mouse IgG2a with lsoStrip
mouse monoclonal antibody isotypirig kit (Roche Diagnostics Corporation, Indianapolis, IN). To
determine the binding affinity to the muCD37 antigen, various concentrations of 252-3 antibody were
incubated with 300-19 cells, a murine pre-B cell line that ses the muCD37 antigen, for 30 minutes
at 4°C. Cells were then washed and counterstained with anti PE conjugate (Jackson
Immunoresearch, West Grove, PA) for 30 minutes at 4°C. The cells were finally washed, fixed in
formalin and analyzed by flow cytometry using a FACSarray (BD ence, San Jose, CA). The flow
cytometry data were analyzed using FlowJo (Tree Star Inc., Ashland, OR) and the geometric mean
fluorescence intensity was plotted t the antibody concentration in a semi-log plot (Figure 8). A
esponse curve was generated by non-linear regression and the ECSO value of the curve, which
ponds to the apparent dissociation constant (Kd) of the dy, was calculated using GraphPad
Prism (GraphPad Software Inc., La Jolla, CA). It was found that the Kd of the 252—3 antibody was 14 nM.
In contrast, the 252-3 antibody did not bind to human tumor cells expressing the human CD37 antigen.
The 252-3 antibody was then used as a surrogate antibody in murine autoimmune disease models to
demonstrate the therapeutic ial of a CD37—targeting antibody for the ent of autoimmune
diseases (Examples 5-7).
Example 5
i ..»..<.‘....._
Experémental autoimmune encephalomyelitis (EAE) is an animal model of inflammatory
demyelinating disease of the central nervous system (CNS), including multiple sclerosis in human.
Murine EAE is commonly induced by immunization of spinal cord homogenates, brain extracts, or CNS
protein such as myelin protein or peptide, ed by injection of pertussis toxin to break down the
blood-brain barrier and allow immune cells access to the CNS tissue. This immunization leads to multiple
small disseminated lesions of demyelination in the brain and spinal cord, causing tail paralysis followed
by limb paralysis.
To test the activity of anti-muCD37 antibody in the EAE model, we first studied the capacity
of the 252—3 antibody to e B cells in viva. C57Bl/6 mice were injected intraperitoneally with 25
mg/kg of 252—3 antibody or onal muréne IgG (Jackson Immunoresearch, West Grove, PA) as a
control. Peripheral blood was collected at different time points and analyzed for B and T cell levels by
flow cytometry, Allophycocyanin (APC)—conjugated anti—mouse CD45R (B220) antibody (ebioscience,
- $7 ..
San Diego, CA) and fluorescein isothiocyanate (FITC)—conjugated anti CD38 antibody (ebioscience, San
Diego, CA) were used to stain B and T cell populations, respectively. B cell depletion was assessed by
calculating the ratio of B to T cells for each sample and the B/T ratio was normalized by setting the
average B/T ratio of murine IgG—treated s to 100%. The normalized B/T cell ratio was plotted
mngG control mice and 252-3 antibody treated mice (Figure 9A). The result show that the B cell level of
the mice treated with 252-3 antibody was rapidly reduced within a few hours after the antibody injection.
The B cell depletion reached ~70% at 3h and peaked at day 3 (> 95%). After day 3, the B cell level slowly
increased and reached ~60% of the normal level at day 14. This data ts that the 252—3 antibody can
rapidly and efficiently e eral blood B cells, and this effect was sustained for at least 7 days
after the dy injection.
] The second study tested the capacity of 252-3 antibody to inhibit EAE. In this study, EAE
was induced in C57Bl/6 mice by subcutaneous immunization of MOG35.55 peptide emulsified in complete
Freund’s adjuvant (EAE kit from Hooke Laboratories, Lawrence, MA) into the upper and lower back at
day 0 and two intraperitoneal injections of pertussis toxin at 21": and 24h after antigen immunization. Mice
were checked for EAE signs daily starting on day 7 after immunization. The disease severity was scored
on a scale of 0 to 5 using the following criteria:
al Observations
0 ENO obvious changes1n motor functions of the mouse in comparison to non--immunized mice
When picked up by the tail, the tail has tension and1s erect. Hind legs are usually spread apartE
Whenthe mouse is walklng, there1s no gait or head g
l Limp tail.
When the mouse is picked up by tail, instead of being erect, the whole tail drapes over your
3 finger.
2 Limp tail and weakness of hind legs.
When the mouse is picked up by tail, legs are not spread apart, but held closer together. When
the mouse is observed when walking, it has clearly apparent wobbly walk. i
E 3 Limp tail and complete paralysis of hind legs (most common)
E Limb tail with sis of one front and one hind leg.
OR, ALL of:
*8 Severe head tilting
8 Walking only along the edges of the cage
a g against the cage wall
1* Spinnmg when pickedupbythe tail
PCT/U82012/031648
a 88 _
4 Limp tail, complete hind leg and partial front leg paralysis.
Mouse is minimally moving around the cage but appears alert and feeding. Usually, euthanasia
is recommended after the mouse scores level 4 for 2 days. When the mouse is euthanized
because of severe paralysis, a score of 5 is entered for that mouse for the rest of the experiment.
“Massages,“_______.._...i.iiiiiiii..........v""
“bureau“......................................................................................................................
Complete hind and front leg paralysis, no movement around the cage.
3 OR, t
Mouse is spontaneously rolling in the cage. I
OR, :
Mouse is found dead due to paralysis. i
If mouse is alive, euthanize the mouse immediately if it scores 5. Once mouse scored 5, the
same score is entered for all the days for the rest ofthe experiment.
=iii‘dsiib‘‘1‘‘'1‘‘‘‘'"''Ali'iii{£5'é"é'i'e'fr'i'eifc'l'"iESEBB?‘v‘‘Ei;£,§ii“§ETf‘iiXiawwbethErT“13313“1‘3?£121};“é‘fiéFEiiiiii;EH"iiiiiiiii‘ri1221i}’cii’fK?
the disease onset, mice were randomized and the 252-3 antibody or polyclonal mulgG was injected once
intraperitoneally at a 25 mg/kg dose. A total of 10 mice were enrolled for each group. At the end of the
study (18 days after the disease onset), the data were onized based on the day of e onset for
each mouse. The disease progression plot (Figure 9B) shows that mice from both groups had relapsing-
remitting form of EAE. During the first wave of clinical symptoms, the control mice d the mean of
3 while the mice treated with 252-3 antibody had a mean of 2. The difference in disease severity n
these two groups was sustained for more than 2 weeks after the disease onset. Taken together, this data
suggests that the 252-2 antibody treatment rapidly depletes the B cell population and alleviates EAE.
Example 6
uQQ§.Z_m9n9919nraLanti.b9d§i__irthitzit§Eritreidiabe esmNODmlce
Type-l diabetes (TlD) or juvenile diabetes or n-dependent diabetes millitus (IDDM) is
caused by auto—immune reaction against n—producing pancreatic beta cells. Destruction of beta cells
reduces n production and increases glucose level that produces various clinical symptoms. TlD
incidence in Northern Europe and the US is between 8 and 17/ 100,000. Insulin ment is the most
common treatment of the disease.
Non-obese diabetic (NOD) mice spontaneously develop TlD and have been widely used to
model the human disease. In NOD mice, the e starts with leukocytic infiltration of the pancreatic
islets (called insulitis) as early as 4 weeks of age. The insulitis progresses rapidly, leading to destruction
of atic islets and diabetes starting at 12-15 weeks of age. B cell depletion using anti-CD20 antibody
in the early stage of insulitis has been reported to delay the disease onset (Hu et al., J Clin lnves. 117,
3857 (2007)), suggesting that B cells play a critical role in the disease pathogenesis in NOD mice.
W0 2012/135740 PCT/U82012/031648
To test the activity of anti-muCD37 antibody, the 252—3 antibody was injected into six female
NOD mice intraperitoneally at 25 mg/kg every 10 days for a total of 4 injections starting at 5 weeks of age
(n=6). The control mice (n=6) were injected with polyclonal murine IgG (Jackson Immunoresearch, West
Grove, PA). Three days after the last injection, the B and T cell levels in peripheral blood were examined
by flow cytometry. Allophycocyanin (APC)—conjugated anti—mouse CD45R (B220) antibody
(ebioscience, San Diego, CA) and fluorescein ocyanate -conjugated anti CD38 antibody
(ebioscience, San Diego, CA) were used to stain B and T cell populations, respectively. The B/T cell ratio
was normalized to murine IgG control treated samples as described above and the normalized B/T cell
ratio was plotted for mngG control mice and 252-3 dy treated mice (Figure 10A). The s show
that the B cell level of the mice treated with 252-3 antibody was significantly reduced as compared to the
control mice, suggesting that the 252-3 antibody efficiently depletes peripheral blood B cells in NOD
mice. To e the effect of B cell depletion by anti-muCD37 dy, blood glucose level was
ed weekly starting at 12 weeks of age. Mice with blood glucose level 2 250 mg/dL in two
consecutive weeks are considered diabetic. The data in Figure 10B shows that the control mice started to
develop diabetes on week 15 and 83% of the mice had diabetes on week 22. In contrast, the mice treated
with 252-3 antibody started to develop diabetes on week 17 and only 50% of the mice were diabetic on
week 27. This data shows that treatment of 252—3 antibody efficiently depletes B cells in NOD mice,
delays the onset of diabetes and significantly reduces the disease incidence.
Example 7
Collagen-induced arthritis (CIA) is an animal model of rheumatoid arthritis (RA) that is
widely used to investigate e pathogenesis and to te therapeutic targets. Arthritis is normally
induced in mice or rats by immunization with autologous or heterologous type II collagen in adjuvant.
This zation elicits a robust T- and B- cell response to the antigen leading to proliferative synovitis
with infiltration of rphonuclear and mononuclear cells, pannus formation, cartilage degradation,
bone erosion and fibrosis.
Since different mouse strains have different susceptibility to antibody-mediated B cell
depletion (Ahuja et al., J. Immunol, 179: 3351-3361 (2007)), to test the ty of anti—muCD37 antibody
in CIA model, we first studied the capacity of the 252-3 dy to deplete B cells in DBA/ 1 mice. Mice
were injected eritoneally with 25 mg/kg of 252-3 dy or polyclonal murine IgG (Jackson
Immunoresearch, West Grove, PA) as control. Peripheral blood was collected at different time points and
analyzed for B and T cell levels by flow cytometry. Allophycocyanin (APC)—conjugated anti-mouse
CD45R (B220) antibody (ebioscience, San Diego, CA) and fluorescein isothiocyanate (FITC)—conjugated
anti CD38 antibody cience, San Diego, CA) were used to stain B and T cell populations,
WO 35740 PCT/U82012/031648
_ 90 _
tively. The ized B/T cell ratio was was calculated as described above and compared between
the mngG control mice and 252—3 dy treated mice (Figure 11A). The result show that the 252—3
antibody significantly reduced the peripheral blood B cell level to ~20% and ~8% in l and 3 days after the
antibody injection, and this low B cell level was maintained at 7 days after the antibody injection. This
data suggests that the 252-3 antibody can rapidly and efficiently deplete peripheral blood B cells, and this
effect was sustained for at least 7 days after the antibody injection.
The second study tests the capacity of 252-3 antibody to inhibit CIA. In this study, CIA was
induced in DBA/1 mice by subcutaneous immunization of chicken collagen/CFA (complete Freund’s
adjuvant) on day 0 and chicken collagen/IFA (incomplete Freund’s adjuvant) on day 21 (Hooke
tories, Lawrence, MA). Mice were checked for CIA signs daily starting on day 21 after
immunization. The CIA severity was scored on a scale of 0 to 16 (based on a score of 0 to 4 for each paw)
using the following criteria:
Clinics“, servatlons
paw,“_
fiuOneto__e__ 1nflamed and swollen
More than one toe, butnot entirepaw, inflamed and swollen
Mild swelhnv ofentirepaw\
__________ ntirepaw1nflamedand swollen
4 Very inflamedandswollen paw or ankylosed paw.“Ifthepaw
1 isankylosedthemouse cannotgrip etopofthepage...“
At the onset of arthritis ms, mice were randomized into two groups and injected with
the 252—3 antibody or polyclonal mulgG intraperitoneally at 10 mg/kg dose at three consecutive days. A
total of 12 mice were enrolled for each group. At the end of the study (21 days after the disease onset), the
data were synchronized based on the day of disease onset for each mouse. The disease progression plot
(Figure 11B) shows that the disease ty in control mice increased y from mean score of 2 at day
1 to 9.5 at day 7. In contrast, the disease in mice treated with the 252—3 antibody progressed cantly
slower with mean score of 4.4 at day 7. Altogether, this data suggests that the 252-2 antibody treatment
significantly depletes the B cell population and alleviates CIA.
In conclusion, the above experiments using a surrogate anti—muCD37 antibody provide
evidence that a CD37—targeting antibody, or an conjugate that includes a CD37 antibody, can
inhibit autoimmune diseases in animal models.
****
It is to be appreciated that the Detailed Description section, and not the Abstract section, is
intended to be used to ret the claims. The Abstract Abstract may set forth one or more but not all
.. 9] ..
exemplary embodiments of the present invention as contemplated by the inventors, and thus, is not
intended to limit the present invention and the appended claims in any way.
The present invention has been described above with the aid of functional building blocks
rating the implementation of specified functions and relationships thereof The ries of these
functional building blocks have been arbitrarily defined herein for the convenience of the description.
Alternate boundaries can be defined so long as the specified functions and relationships thereof are
appropriately performed.
The foregoing description of the specific embodiments will so fully reveal the general nature
of the invention that others can, by applying knowledge within the skill of the art, readily modify and/or
adapt for varéous applications such specific embodiments, without undue experimentation, without
departing from the general concept of the present ion. Therefore, such adaptations and
modifications are intended to be within the g and range of equivalents of the disclosed
ments, based on the teaching and guidance presented herein. It is to be understood that the
phraseology or terminology herein is for the e of description and not of limitation, such that the
terminology or phraseology of the t specification is to be interpreted by the d artisan in light of
the teachings and guidance.
The breadth and scope of the present ion should not be limited by any of the above-
bed exemplary embodiments, but should be defined only in accordance with the following claims
and their equivalents.
All publications, patents, and patent applications mentioned in this specification are herein
incorporated by reference to the same extent as if each independent publication, patent, or patent
application was cally and individually indicated to be incorporated by reference.
Claims (58)
1. Use of a purified zed antibody or antigen-binding fragment thereof that ically binds to CD37 in the preparation of a medicament for treating a patient having an autoimmune or inflammatory disease, wherein said humanized antibody or fragment thereof retains the ability of at least its chimeric or murine parent antibody to induce apoptosis in vitro in the absence of a cross-linking agent.
2. Use of a purified humanized antibody or antigen-binding fragment thereof that specifically binds to CD37 in the preparation of a ment for depleting a B-cell in a tion of cells comprising a ncerous B-cell, wherein said humanized antibody or fragment thereof retains the ability of at least its chimeric or murine parent antibody to induce apoptosis in vitro in the e of a cross-linking agent.
3. The use according to claim 1, wherein the antibody is a resurfaced antibody.
4. The use according to claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds to the same CD37 e as an antibody selected from the group consisting of: (a) an antibody comprising the polypeptide of SEQ ID NO:57 and the polypeptide of SEQ ID NO:74; (b) an antibody comprising the ptide of SEQ ID NO:63 and the polypeptide of SEQ ID NO:79; (c) an antibody comprising the polypeptide of SEQ ID NO:65 and the ptide of SEQ ID NO:81; (d) an antibody comprising the polypeptide of SEQ ID NO:67 and the polypeptide of SEQ ID NO:83; (e) an antibody comprising the polypeptide of SEQ ID NO:69 and the polypeptide of SEQ ID NO:85; and (f) an antibody comprising the polypeptide of SEQ ID NO:71 and the polypeptide of SEQ ID NO:87.
5. The use according to claim 1, wherein the antibody or antigen-binding fragment thereof competitively inhibits the binding to CD37 of an antibody selected from the group consisting of: (a) an antibody sing the polypeptide of SEQ ID NO:57 and the ptide of SEQ ID NO:74; (b) an antibody comprising the polypeptide of SEQ ID NO:63 and the polypeptide of SEQ ID NO:79; (c) an antibody comprising the polypeptide of SEQ ID NO:65 and the polypeptide of SEQ ID NO:81; (d) an dy comprising the polypeptide of SEQ ID NO:67 and the polypeptide of SEQ ID NO:83; (e) an antibody comprising the polypeptide of SEQ ID NO:69 and the polypeptide of SEQ ID NO:85; and (f) an antibody comprising the polypeptide of SEQ ID NO:71 and the polypeptide of SEQ ID NO:87.
6. The use according to claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds to human CD37 and macaque CD37.
7. The use according to claim 2, n the antibody or antigen-binding fragment thereof specifically binds to human CD37 and macaque CD37.
8. The use according to claim 6, wherein the antibody or antigen-binding fragment thereof is an antibody produced by a hybridoma selected from the group consisting ATCC Deposit Designation PTA-10665, deposited with the ATCC on February 18, 2010, ATCC Deposit Designation PTA-10666, deposited with the ATCC on February 18, 2010, ATCC Deposit Designation PTA-10667 deposited with the ATCC on February 18, 2010, ATCC Deposit Designation PTA-10668, deposited with the ATCC on February 18, 2010, ATCC Deposit Designation PTA-10669, deposited with the ATCC on February 18, 2010, and ATCC t Designation PTA-10670, deposited with the ATCC on February 18, 2010 or is an antigen-binding fragment thereof.
9. The use according to claim 7, wherein the dy or antigen-binding fragment is an antibody produced by a oma selected from the group consisting of ATCC Deposit ation PTA-10665, deposited with the ATCC on February 18, 2010, ATCC Deposit Designation 666, deposited with the ATCC on February 18, 2010, ATCC Deposit Designation PTA-10667 ted with the ATCC on February 18, 2010, ATCC Deposit Designation PTA-10668, deposited with the ATCC on February 18, 2010, ATCC Deposit Designation PTA-10669, deposited with the ATCC on February 18, 2010, and ATCC Deposit Designation PTA-10670, deposited with the ATCC on February 18, 2010 or is an antigen binding fragment thereof.
10. The use according to claim 1, wherein said antibody ses polypeptide sequences selected from the group consisting of: (a) SEQ ID NOs: 4, 5, and 6 and SEQ ID NOs: 28, 29, and 30; (b) SEQ ID NOs: 10, 11, and 12 and SEQ ID NOs: 34, 35, and 36; (c) SEQ ID NOs: 13, 14, and 15 and SEQ ID NOs: 37, 40, and 39; (d) SEQ ID NOs: 16, 17, and 18 and SEQ ID NOs: 41, 42, and 43; (e) SEQ ID NOs: 19, 20, and 21 and SEQ ID NOs: 44, 47, and 46; (f) SEQ ID NOs: 22, 23, and 24 and SEQ ID NOs: 48, 51, and 50; and (g) SEQ ID NOs: 25, 26, and 27 and SEQ ID NOs: 52, 53, and 54.
11. The use according to claim 1, n the antibody or antigen-binding fragment thereof comprises polypeptide ces that are at least 90%, 95%, or 99% identical to polypeptide sequences selected from the group consisting of: (a) SEQ ID NO:57 and SEQ ID NO:74; (b) SEQ ID NO:58 and SEQ ID NO:74; (c) SEQ ID NO:63 and SEQ ID NO:79; (d) SEQ ID NO:65 and SEQ ID NO:81; (e) SEQ ID NO:67 and SEQ ID NO:83; (f) SEQ ID NO:69 and SEQ ID NO:85; and (g) SEQ ID NO:71 and SEQ ID NO:87.
12. Use of a purified humanized antibody or antigen-binding fragment thereof that specifically binds to CD37 in the preparation of a medicament for treating a patient having an autoimmune or inflammatory e, wherein the antibody or antigen-binding fragment thereof comprises polypeptide sequences selected from the group consisting of: (a) SEQ ID NO:57 and SEQ ID NO:74; (b) SEQ ID NO:58 and SEQ ID NO:74; (c) SEQ ID NO:63 and SEQ ID NO:79; (d) SEQ ID NO:65 and SEQ ID NO:81; (e) SEQ ID NO:67 and SEQ ID NO:83; (f) SEQ ID NO:69 and SEQ ID NO:85; and (g) SEQ ID NO:71 and SEQ ID NO:87.
13. Use of a purified humanized antibody or antigen-binding fragment thereof that specifically binds to CD37 in the preparation of a medicament for ing a B-cell in a population of cells comprising a non-cancerous , wherein the antibody or antigen-binding fragment thereof comprises polypeptide ces selected from the group consisting of: (a) SEQ ID NO:57 and SEQ ID NO:74; (b) SEQ ID NO:58 and SEQ ID NO:74; (c) SEQ ID NO:63 and SEQ ID NO:79; (d) SEQ ID NO:65 and SEQ ID NO:81; (e) SEQ ID NO:67 and SEQ ID NO:83; (f) SEQ ID NO:69 and SEQ ID NO:85; and (g) SEQ ID NO:71 and SEQ ID NO:87.
14. The use according to claim 1, wherein said humanized antibody or n binding fragment thereof is also capable of inducing antibody dependent cell mediated cytotoxicity (ADCC).
15. The use according to any one of claims 1-14, which is a full length antibody.
16. The use according to any one of claims 1-14, which is an antigen-binding fragment.
17. The use according to any one of claims 1-14, wherein said antibody or n-binding fragment thereof comprises a Fab, Fab', F(ab')2, Fd, single chain Fv or scFv, disulfide linked Fv, V-NAR domain, IgNar, intrabody, IgGΔCH2, minibody, F(ab')3, tetrabody, triabody, diabody, single-domain antibody, DVD-Ig, Fcab, mAb2, (scFv)2, or scFv-Fc.
18. The use according to any one of claims 1-14, wherein the dy or antigen-binding fragment thereof is linked via a linker (L) to a cytotoxic agent (C) to form an immunoconjugate.
19. The use according to claim 18, n the immunoconjugate further ses a second (C).
20. The use according to claim 18, wherein the immunoconjugate further comprises a third (C).
21. The use according to claim 18, wherein the immunoconjugate further comprises a fourth (C).
22. The use according to claim 18, wherein the immunoconjugate comprises two to six (C).
23. The use according to claim 18, wherein the immunoconjugate comprises three to four (C).
24. The use according to claim 18, wherein said linker is selected from the group consisting of a cleavable linker, a non-cleavable linker, a hydrophilic , and a dicarboxylic acid based linker.
25. The use according to claim 24, wherein said linker is selected from the group consisting of: N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP); N-succinimidyl 4-(2- pyridyldithio)butanoate (SPDB) or inimidyl 4-(2-pyridyldithio)sulfobutanoate (sulfo-SPDB); N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (SMCC); N- sulfosuccinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate (sulfoSMCC); N- succinimidyl(iodoacetyl)-aminobenzoate (SIAB); and N-succinimidyl-[(N- maleimidopropionamido)-tetraethyleneglycol] ester (NHS-PEG4-maleimide).
26. The use according to claim 25, wherein said linker is SMCC.
27. The use according to claim 18, wherein said cytotoxic agent is selected from the group ting of a maytansinoid, maytansinoid , doxorubicin, a modified doxorubicin, benzodiazepine, taxoid, CC-1065, CC-1065 , duocarmycin, duocarmycin , calicheamicin, dolastatin, dolastatin analog, auristatin, tomaymycin derivative, and leptomycin derivative or a prodrug of the agent.
28. The use according to claim 27, wherein said cytotoxic agent is a maytansinoid.
29. The use according to claim 28, wherein said cytotoxic agent is N(2')-deacetyl-N(2')-(3- tooxopropyl)-maytansine (DM1) or N(2')-deacetyl-N(2')-(4-mercaptomethyl- 1-oxopentyl)-maytansine (DM4).
30. The use according to claim 29, wherein the immunoconjugate ses 3 or 4 (C) per (A).
31. The use according to claim 18, wherein the antibody or antigen-binding fragment comprises the polypeptides of SEQ ID NOs: 4, 5, and 6 and SEQ ID NOs: 28, 29, and 30.
32. The use according to claim 31, wherein (L) is SMCC.
33. The use according to claim 31, wherein (C) is DM1 or DM4.
34. The use according to claim 32, wherein (C) is DM1 or DM4.
35. The use according to claim 34, wherein (C) is DM1.
36. The use according to claim 35, wherein the immunoconjugate comprises 3 or 4 (C) per (A).
37. The use according to claim 18, wherein the antibody or antigen-binding fragment comprises the ptide of SEQ ID NO:57 and the polypeptide of SEQ ID NO:74.
38. The use according to claim 37, n (L) is SMCC.
39. The use according to claim 37, wherein (C) is DM1 or DM4.
40. The use according to claim 38, wherein (C) is DM1 or DM4.
41. The use according to claim 40, wherein (C) is DM1.
42. The use according to claim 41, wherein the immunoconjugate comprises 3 or 4 (C) per (A).
43. The use ing to claim 18, wherein the antibody or antigen-binding fragment comprises the polypeptide of SEQ ID NOs: 13, 14, and 15 and SEQ ID NOs: 37, 40, and 39.
44. The use according to claim 43, wherein (L) is SMCC.
45. The use ing to claim 43, wherein (C) is DM1 or DM4.
46. The use according to claim 44, wherein (C) is DM1 or DM4.
47. The use according to claim 46, wherein (C) is DM1.
48. The use ing to claim 47, wherein the immunoconjugate ses 3 or 4 (C) per (A).
49. The use according to claim 18, wherein the dy or antigen-binding fragment comprises the polypeptide of SEQ ID NO:65 and the polypeptide of SEQ ID NO:81.
50. The use according to claim 49, wherein (L) is SMCC.
51. The use according to claim 49, wherein (C) is DM1 or DM4.
52. The use according to claim 50, wherein (C) is DM1 or DM4.
53. The use ing to claim 52, wherein (C) is DM1.
54. The use according to claim 53, wherein the immunoconjugate comprises 3 or 4 (C) per (A).
55. The use according to claim 18, wherein said autoimmune or inflammatory disease is selected from the group consisting of toid arthritis, multiple sclerosis, type I diabetes mellitus, idiopathic inflammatory myopathy, systemic lupus erythematosus (SLE), myasthenia gravis, Grave's disease, dermatomyositis, polymyositis, Crohn's disease, tive colitis, gastritis, Hashimoto's thyroiditis, asthma, psoriasis, psoriatic arthritis, dermatitis, systemic scleroderma and sclerosis, inflammatory bowel disease (IBD), respiratory ss syndrome, itis, encephalitis, uveitis, glomerulonephritis, eczema, atherosclerosis, leukocyte adhesion deficiency, Raynaud's syndrome, Sjögren's syndrome, Reiter's disease, Beheet's disease, immune complex nephritis, IgA nephropathy, IgM polyneuropathies, immune-mediated thrombocytopenias, acute idiopathic thrombocytopenic purpura, chronic idiopathic thrombocytopenic a, hemolytic anemia, myasthenia gravis, lupus nephritis, atopic dermatitis, pemphigus is, opsoclonus-myoclonus syndrome, pure red cell aplasia, mixed cryoglobulinemia, ankylosing spondylitis, hepatitis C-associated cryoglobulinemic vasculitis, chronic focal encephalitis, bullous pemphigoid, hemophilia A, membranoproliferative glomerulonephritis, adult and juvenile dermatomyositis, adult polymyositis, chronic urticaria, primary y cirrhosis, neuromyelitis optica, ' dysthyroid disease, bullous pemphigoid, membranoproliferative glomerulonephritis, Churg-Strauss syndrome, le onset diabetes, hemolytic anemia, atopic dermatitis, systemic sclerosis, Sjögren's syndrome and glomerulonephritis, dermatomyositis, anti-neutrophil cytoplasmic antibody (ANCA), aplastic , mune hemolytic anemia (AIHA), factor VIII deficiency, hemophilia A, autoimmune neutropenia, Castleman's syndrome, Goodpasture's syndrome, solid organ transplant ion, graft versus host disease (GVHD), autoimmune hepatitis, lymphoid interstitial pneumonitis, HIV, bronchiolitis obliterans ransplant), Guillain-Barre Syndrome, large vessel vasculitis, giant cell (Takayasu's) arteritis, medium vessel vasculitis, Kawasaki's Disease, polyarteritis nodosa, Wegener's granulomatosis, microscopic polyangiitis (MPA), Omenn's syndrome, chronic renal failure, acute infectious mononucleosis, HIV and herpes virus associated diseases.
56. The use according to claim 55, n said mune or inflammatory disease is multiple sclerosis.
57. The use according to claim 55, n said autoimmune or inflammatory disease is diabetes mellitus.
58. The use according to claim 55, n said autoimmune or inflammatory disease is rheumatoid arthritis. ImmunoGen, Inc. By the patent attorneys for the applicant CULLENS
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ710201A NZ710201B2 (en) | 2011-04-01 | 2012-03-30 | Cd37-binding molecules and immunoconjugates thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161470863P | 2011-04-01 | 2011-04-01 | |
US61/470,863 | 2011-04-01 | ||
PCT/US2012/031648 WO2012135740A2 (en) | 2011-04-01 | 2012-03-30 | Cd37-binding molecules and immunoconjugates thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ615735A NZ615735A (en) | 2015-08-28 |
NZ615735B2 true NZ615735B2 (en) | 2015-12-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200270361A1 (en) | Cd37-binding molecules and immunoconjugates thereof | |
JP6133340B2 (en) | CD37 binding molecule and immunoconjugate thereof | |
JP6039751B2 (en) | Folate receptor 1 antibody and immunoconjugate and use thereof | |
AU2014233685B2 (en) | Anti-CD52 antibodies | |
EP3821006A2 (en) | Antibodies specific to folate receptor alpha | |
NZ615735B2 (en) | Cd37-binding molecules and immunoconjugates thereof | |
US20100129361A1 (en) | Immunosuppression with antibody against itm2a | |
NZ710201B2 (en) | Cd37-binding molecules and immunoconjugates thereof |